US20160090569A1 - Scheduled Feed - Google Patents
Scheduled Feed Download PDFInfo
- Publication number
- US20160090569A1 US20160090569A1 US14/865,222 US201514865222A US2016090569A1 US 20160090569 A1 US20160090569 A1 US 20160090569A1 US 201514865222 A US201514865222 A US 201514865222A US 2016090569 A1 US2016090569 A1 US 2016090569A1
- Authority
- US
- United States
- Prior art keywords
- cells
- inlet
- schedule
- feeding
- cell expansion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
- C12M41/48—Automatic or computerized control
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M21/00—Bioreactors or fermenters specially adapted for specific uses
- C12M21/08—Bioreactors or fermenters specially adapted for specific uses for producing artificial tissue or for ex-vivo cultivation of tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
- C12M25/10—Hollow fibers or tubes
- C12M25/12—Hollow fibers or tubes the culture medium flowing outside the fiber or tube
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
- C12M29/16—Hollow fibers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
Definitions
- Cell Expansion Systems are used to expand and differentiate cells.
- Cell expansion systems may be used to expand, e.g., grow, stem cells, such as mesenchymal stem cells (MSCs).
- MSCs mesenchymal stem cells
- Cell expansion systems may also expand other types of cells, such as bone marrow cells, for example.
- Stem cells which are expanded from donor cells may be used to repair or replace damaged or defective tissues and have broad clinical applications for a wide range of diseases.
- Cells, of both adherent and non-adherent type may be grown in a bioreactor in a cell expansion system.
- Embodiments of the present disclosure generally relate to scheduled feeding systems and methods for a cell expansion system, in which schedules proactively and automatically increase or maintain inlet rates, e.g., intracapillary (IC) inlet rates or extracapillary (EC) inlet rates, into a circulation loop, e.g., IC circulation loop, in the cell expansion system.
- inlet rates e.g., intracapillary (IC) inlet rates or extracapillary (EC) inlet rates
- IC circulation loop e.g., IC circulation loop
- Such proactive and automatic feeding occurs according to the applicable schedule and regardless of metabolite levels during cell, e.g., MSC, expansions.
- media exchanges are also included as a part of such schedules, in which media is exchanged at a certain rate (and quantity) as defined by the schedule.
- feed methods for cell expansion systems rely on the regular, e.g., daily, monitoring of metabolites, e.g., glucose and lactate from glucose consumption and lactate generation by the cells, to determine if inlet rates, e.g., IC inlet rates, should be increased.
- regular, e.g., daily, measurements of metabolites to determine whether or not to increase media inlet rates, e.g., IC inlet rates may be optional or eliminated altogether, according to embodiments.
- Scheduled feeding and/or scheduled media exchanges may apply to the expansion of any type of cell.
- Embodiments of the present disclosure further relate to aggressive and conservative feed schedules, in which an aggressive feed schedule feeds the cells at a faster rate (with a larger quantity of media used) than a conservative feed schedule, for example.
- an aggressive feed schedule feeds the cells at a faster rate (with a larger quantity of media used) than a conservative feed schedule, for example.
- such schedule may maintain feeding rates at current levels and/or may increase feeding rates in a manner that is neither conservative nor aggressive but, instead, is a combination of the two, for example.
- other types of feeding schedules may be used.
- these feed schedules are used in a closed, automated system for cell expansion.
- multiple schedules are used to expand cells in a particular run.
- a single schedule is used for controlling the feeding of the cells during cell expansion in a particular run.
- a single schedule may be used to control inlet rates for feeding the cells and for media exchanges, in which a media exchange replaces a portion or all of the existing media in a disposable set with new media.
- one or more schedules may be used to control inlet rates for feeding the cells with one or more additional schedules used to control media exchanges.
- Embodiments of the present disclosure provide for implementing such schedule(s) through the use of one or more protocols or tasks for use with a cell expansion system.
- UI user interface
- GUI graphical user interface
- a custom or user-defined protocol or task for following a scheduled feed may be created.
- a task may comprise one or more steps.
- a pre-programmed, default, or otherwise previously saved task for following a scheduled feed may be selected.
- each of the expressions “at least one of A, B and C,” “at least one of A, B, or C,” “one or more of A, B, and C,” “one or more of A, B, or C” and “A, B, and/or C” means A alone, B alone, C alone, A and B together, A and C together, B and C together, or A, B and C together.
- FIG. 1A depicts an embodiment of a cell expansion system (CES).
- CES cell expansion system
- FIG. 1B illustrates a front elevation view of an embodiment of a bioreactor showing circulation paths through the bioreactor.
- FIG. 1C depicts a rocking device for moving a cell growth chamber rotationally or laterally during operation of a cell expansion system, according to embodiments of the present disclosure.
- FIG. 2 illustrates a perspective view of a cell expansion system with a premounted fluid conveyance device, in accordance with embodiments of the present disclosure.
- FIG. 3 depicts a perspective view of a housing of a cell expansion system, in accordance with embodiments of the present disclosure.
- FIG. 4 illustrates a perspective view of a premounted fluid conveyance device, in accordance with embodiments of the present disclosure
- FIG. 5 depicts a schematic of a cell expansion system, in accordance with an embodiment of the present disclosure.
- FIG. 6 illustrates a schematic of a cell expansion system, in accordance with another embodiment of the present disclosure.
- FIG. 7A depicts a flow diagram illustrating the operational characteristics of a process for implementing a feed schedule during a cell expansion, in accordance with embodiments of the present disclosure.
- FIG. 7B illustrates a flow diagram depicting the operational characteristics of a process for implementing a feed schedule during a cell expansion, in accordance with embodiments of the present disclosure.
- FIG. 8 depicts a flow diagram illustrating the operational characteristics of a process for implementing a task or protocol for a scheduled feeding of cells for use with a cell expansion system, in accordance with embodiments of the present disclosure.
- FIG. 9 illustrates an example processing system of a cell expansion system upon which embodiments of the present disclosure may be implemented.
- FIG. 10 depicts data of an example in accordance with an embodiment of the present disclosure.
- FIG. 11 illustrates data of an example in accordance with an embodiment of the present disclosure.
- FIG. 12 depicts data of an example in accordance with an embodiment of the present disclosure.
- FIG. 13 illustrates data of an example in accordance with an embodiment of the present disclosure.
- Embodiments of the present disclosure are generally directed to systems and methods for using scheduled media inlet rate increases or scheduled feeds, e.g., intracapillary (IC) inlet rate increases or extracapillary (EC) inlet rate increases, to expand cells in a cell expansion system.
- IC intracapillary
- EC extracapillary
- Such cell expansion system is a closed, automated system.
- Feed schedules may be used to proactively and automatically increase IC inlet rates regardless of metabolite levels during cell, e.g., MSC, expansions.
- Scheduled feedings and/or scheduled media exchanges may apply to the expansion of any type of cell.
- the schedule may provide for maintaining the inlet rate.
- inlet rates may be increased or maintained without manual manipulation.
- the inlet rates may increase and then level off or plateau, in which the schedule provides both for the increasing and the maintaining of the rates.
- a first schedule provides for the increasing of the inlet rates
- a second schedule provides for the maintaining of the inlet rates at a certain rate.
- the first schedule is different from the second schedule. Additional schedules, such as third, fourth, fifth, sixth, seventh, etc. schedules may be used according to yet further embodiments.
- Embodiments are directed to a cell expansion system, as noted above.
- such cell expansion system is closed, in which a closed cell expansion system comprises contents that are not directly exposed to the atmosphere.
- Such cell expansion system may be automated.
- cells of both adherent and non-adherent type, may be grown in a bioreactor in the cell expansion system.
- the cell expansion system may include base media or other type of media. Methods for replenishment of media are provided for cell growth occurring in a bioreactor of the closed cell expansion system.
- the bioreactor used with such systems is a hollow fiber bioreactor. Many types of bioreactors may be used in accordance with embodiments of the present disclosure.
- the system may include, in embodiments, a bioreactor that further includes a first fluid flow path having at least opposing ends, a first opposing end of the first fluid flow path fluidly associated with a first port of a hollow fiber membrane and a second end of the first fluid flow path fluidly associated with a second port of the hollow fiber membrane, in which the first fluid flow path comprises an intracapillary portion of the hollow fiber membrane.
- a hollow fiber membrane comprises a plurality of hollow fibers.
- the system may further include a fluid inlet path fluidly associated with the first fluid flow path, in which a plurality of cells are introduced into the first fluid flow path through a first fluid inlet path.
- a first pump for circulating fluid in the first fluid flow path of the bioreactor may also be included.
- the system includes a controller for controlling operation of the first pump.
- the controller is a computing system, including a processor, for example.
- the controller is configured, in embodiments, to control the pump to circulate a fluid at a first rate within the first fluid flow path.
- a second pump for transferring intracapillary inlet fluid from an intracapillary media bag to the first fluid flow path and a second controller for controlling operation of the second pump are included.
- the second controller controls the second pump to transfer cells from a cell inlet bag to the first fluid flow path, for example. Additional controllers, e.g., third controller, fourth controller, fifth controller, sixth controller, etc., may be used in accordance with embodiments.
- additional pumps e.g., third pump, fourth pump, fifth pump, sixth pump, etc.
- third pump e.g., fourth pump, fifth pump, sixth pump, etc.
- present disclosure may refer to a media bag, a cell inlet bag, etc.
- multiple bags e.g., a first media bag, a second media bag, a third media bag, a first cell inlet bag, a second cell inlet bag, a third cell inlet bag, etc., and/or other types of containers, may be used in embodiments.
- a single media bag, a single cell inlet bag, etc. may be used.
- additional or other fluid paths e.g., a second fluid flow path, a second fluid inlet path, etc., may be included in embodiments.
- the system is controlled by, for example: a processor coupled to the cell expansion system; a display device, in communication with the processor, and operable to display data; and a memory, in communication with and readable by the processor, and containing a series of instructions.
- the processor when the instructions are executed by the processor, the processor receives an instruction to coat the bioreactor, for example.
- the processor may execute a series of steps to coat the bioreactor and may next receive an instruction to load cells into the bioreactor, for example.
- the processor may execute a series of steps to load the cells from a cell inlet bag, for example, into the bioreactor.
- CES 10 includes first fluid circulation path 12 and second fluid circulation path 14 .
- First fluid flow path 16 has at least opposing ends 18 and 20 fluidly associated with a hollow fiber cell growth chamber 24 (also referred to herein as a “bioreactor”), according to embodiments.
- opposing end 18 may be fluidly associated with a first inlet 22 of cell growth chamber 24
- opposing end 20 may be fluidly associated with first outlet 28 of cell growth chamber 24 .
- Fluid in first circulation path 12 flows through the interior of hollow fibers 116 (see FIG. 1B ) of hollow fiber membrane 117 (see FIG.
- first fluid flow control device 30 may be operably connected to first fluid flow path 16 and may control the flow of fluid in first circulation path 12 .
- Second fluid circulation path 14 includes second fluid flow path 34 , cell growth chamber 24 , and a second fluid flow control device 32 .
- the second fluid flow path 34 has at least opposing ends 36 and 38 , according to embodiments. Opposing ends 36 and 38 of second fluid flow path 34 may be fluidly associated with inlet port 40 and outlet port 42 respectively of cell growth chamber 24 . Fluid flowing through cell growth chamber 24 may be in contact with the outside of hollow fiber membrane 117 (see FIG. 1B ) in the cell growth chamber 24 , in which a hollow fiber membrane comprises a plurality of hollow fibers.
- Second fluid circulation path 14 may be operably connected to second fluid flow control device 32 .
- First and second fluid circulation paths 12 and 14 may thus be separated in cell growth chamber 24 by a hollow fiber membrane 117 (see FIG. 1B ). Fluid in first fluid circulation path 12 flows through the intracapillary (“IC”) space of the hollow fibers in the cell growth chamber 24 . First circulation path 12 may be referred to as the “IC loop.” Fluid in second circulation path 14 flows through the extracapillary (“EC”) space in the cell growth chamber 24 . Second fluid circulation path 14 may be referred to as the “EC loop.” Fluid in first fluid circulation path 12 may flow in either a co-current or counter-current direction with respect to flow of fluid in second fluid circulation path 14 , according to embodiments.
- IC intracapillary
- EC extracapillary
- Fluid inlet path 44 may be fluidly associated with first fluid circulation path 12 . Fluid inlet path 44 allows fluid into first fluid circulation path 12 , while fluid outlet path 46 allows fluid to leave CES 10 .
- Third fluid flow control device 48 may be operably associated with fluid inlet path 44 . Alternatively, third fluid flow control device 48 may alternatively be associated with first outlet path 46 .
- Fluid flow control devices as used herein may comprise a pump, valve, clamp, or combination thereof, according to embodiments. Multiple pumps, valves, and clamps can be arranged in any combination.
- the fluid flow control device is or includes a peristaltic pump.
- fluid circulation paths, inlet ports, and outlet ports may be constructed of tubing of any material.
- operably associated refers to components that are linked together in operable fashion and encompasses embodiments in which components are linked directly, as well as embodiments in which additional components are placed between the two linked components.
- “Operably associated” components can be “fluidly associated.” “Fluidly associated” refers to components that are linked together such that fluid can be transported between them. “Fluidly associated” encompasses embodiments in which additional components are disposed between the two fluidly associated components, as well as components that are directly connected. Fluidly associated components can include components that do not contact fluid, but contact other components to manipulate the system (e.g., a peristaltic pump that pumps fluids through flexible tubing by compressing the exterior of the tube).
- any kind of fluid including buffers, protein containing fluid, and cell-containing fluid, for example, can flow through the various circulations paths, inlet paths, and outlet paths.
- fluid including buffers, protein containing fluid, and cell-containing fluid, for example, can flow through the various circulations paths, inlet paths, and outlet paths.
- fluid media
- fluid media are used interchangeably.
- FIG. 1B an example of a hollow fiber cell growth chamber 100 which may be used with the present disclosure is shown in front side elevation view.
- Cell growth chamber 100 has a longitudinal axis LA-LA and includes cell growth chamber housing 104 .
- cell growth chamber housing 104 includes four openings or ports: IC inlet port 108 , IC outlet port 120 , EC inlet port 128 , and EC outlet port 132 .
- fluid in a first circulation path enters cell growth chamber 100 through IC inlet port 108 at a first longitudinal end 112 of the cell growth chamber 100 , passes into and through the intracapillary side (referred to in various embodiments as the intracapillary (“IC”) side or “IC space” of a hollow fiber membrane) of a plurality of hollow fibers 116 comprising hollow fiber membrane 117 , and out of cell growth chamber 100 through IC outlet port 120 located at a second longitudinal end 124 of the cell growth chamber 100 .
- the fluid path between the IC inlet port 108 and the IC outlet port 120 defines the IC portion 126 of the cell growth chamber 100 .
- Fluid in a second circulation path flows in the cell growth chamber 100 through EC inlet port 128 , comes in contact with the extracapillary side or outside (referred to as the “EC side” or “EC space” of the membrane) of the hollow fibers 116 , and exits cell growth chamber 100 via EC outlet port 132 .
- the fluid path between the EC inlet port 128 and the EC outlet port 132 comprises the EC portion 136 of the cell growth chamber 100 . Fluid entering cell growth chamber 100 via the EC inlet port 128 may be in contact with the outside of the hollow fibers 116 .
- Small molecules may diffuse through the hollow fibers 116 from the interior or IC space of the hollow fiber to the exterior or EC space, or from the EC space to the IC space.
- Large molecular weight molecules, such as growth factors, are typically too large to pass through the hollow fiber membrane, and may remain in the IC space of the hollow fibers 116 .
- the media may be replaced as needed, in embodiments.
- Media may also be circulated through an oxygenator or gas transfer module to exchange gasses as needed.
- Cells may be contained within a first circulation path and/or a second circulation path, as described below, and may be on either the IC side and/or EC side of the membrane, according to embodiments.
- the material used to make the hollow fiber membrane 117 may be any biocompatible polymeric material which is capable of being made into hollow fibers.
- One material which may be used is a synthetic polysulfone-based material, according to an embodiment of the present disclosure.
- the surface may be modified in some way, either by coating at least the cell growth surface with a protein such as fibronectin or collagen, or by exposing the surface to radiation, according to embodiments.
- Gamma treating the membrane surface allows for attachment of adherent cells without additionally coating the membrane with fibronectin, cryoprecipitate, or the like. Bioreactors made of gamma treated membranes may be reused. Other coatings and/or treatments for cell attachment may be used in accordance with embodiments of the present disclosure.
- the CES may include a device configured to move or “rock” the cell growth chamber relative to other components of the cell expansion system by attaching it to a rotational and/or lateral rocking device.
- FIG. 1C shows one such device, in which a bioreactor 100 may be rotationally connected to two rotational rocking components and to a lateral rocking component, according to an embodiment.
- a first rotational rocking component 138 rotates the bioreactor 100 around central axis 142 of the bioreactor 100 .
- Rotational rocking component 138 may be rotationally associated with bioreactor 100 .
- bioreactor 100 may be rotated continuously in a single direction around central axis 142 in a clockwise or counterclockwise direction.
- bioreactor 100 may rotate in alternating fashion, first clockwise, then counterclockwise, for example, around central axis 142 , according to embodiments.
- the CES may also include a second rotational rocking component that rotates bioreactor 100 around rotational axis 144 .
- Rotational axis 144 may pass through the center point of bioreactor 100 and may be normal to central axis 142 .
- Bioreactor 100 may be rotated continuously in a single direction around rotational axis 144 in a clockwise or counterclockwise direction, in embodiments.
- bioreactor 100 may be rotated around rotational axis 144 in an alternating fashion, first clockwise, then counterclockwise, for example.
- bioreactor 100 may also be rotated around rotational axis 144 and positioned in a horizontal or vertical orientation relative to gravity.
- lateral rocking component 140 may be laterally associated with bioreactor 100 .
- the plane of lateral rocking component 140 moves laterally in the ⁇ x and ⁇ y directions, in embodiments.
- the settling of cells in the bioreactor may be reduced by movement of cell-containing media within the hollow fibers, according to embodiments.
- the rotational and/or lateral movement of a rocking device may reduce the settling of cells within the device and reduce the likelihood of cells becoming trapped within a portion of the bioreactor.
- the rate of cells settling in the cell growth chamber is proportional to the density difference between the cells and the suspension media, according to Stoke's Law.
- a 180 degree rotation (fast) with a pause (having a total combined time of 30 seconds, for example) repeated as described above keeps non-adherent red blood cells suspended.
- a minimum rotation of about 180 degrees would be preferred in an embodiment; however, one could use rotation of up to 360 degrees or greater.
- Different rocking components may be used separately, or may be combined in any combination.
- a rocking component that rotates bioreactor 100 around central axis 142 may be combined with the rocking component that rotates bioreactor 100 around axis 144 .
- clockwise and counterclockwise rotation around different axes may be performed independently in any combination.
- the CES 200 includes a cell expansion machine 202 that comprises a hatch or closable door 204 for engagement with a back portion 206 of the cell expansion machine 202 .
- An interior space 208 within the cell expansion machine 202 includes features adapted for receiving and engaging a premounted fluid conveyance assembly 210 .
- the premounted fluid conveyance assembly 210 is detachably-attachable to the cell expansion machine 202 to facilitate relatively quick exchange of a new or unused premounted fluid conveyance assembly 210 at a cell expansion machine 202 for a used premounted fluid conveyance assembly 210 at the same cell expansion machine 202 .
- a single cell expansion machine 202 may be operated to grow or expand a first set of cells using a first premounted fluid conveyance assembly 210 and, thereafter, may be used to grow or expand a second set of cells using a second premounted fluid conveyance assembly 210 without needing to be sanitized between interchanging the first premounted fluid conveyance assembly 210 for the second premounted fluid conveyance assembly 210 .
- the premounted fluid conveyance assembly 210 includes a bioreactor 100 and an oxygenator or gas transfer module 212 (also see FIG. 4 ).
- Tubing guide slots are shown as 214 for receiving various media tubing connected to premounted fluid conveyance assembly 210 , according to embodiments.
- FIG. 3 illustrates the back portion 206 of cell expansion machine 202 prior to detachably-attaching a premounted fluid conveyance assembly 210 ( FIG. 2 ), in accordance with embodiments of the present disclosure.
- the closable door 204 (shown in FIG. 2 ) is omitted from FIG. 3 .
- the back portion 206 of the cell expansion machine 202 includes a number of different structures for working in combination with elements of a premounted fluid conveyance assembly 210 .
- the back portion 206 of the cell expansion machine 202 includes a plurality of peristaltic pumps for cooperating with pump loops on the premounted fluid conveyance assembly 210 , including the IC circulation pump 218 , the EC circulation pump 220 , the IC inlet pump 222 , and the EC inlet pump 224 .
- the back portion 206 of the cell expansion machine 202 includes a plurality of valves, including the IC circulation valve 226 , the reagent valve 228 , the IC media valve 230 , the air removal valve 232 , the cell inlet valve 234 , the wash valve 236 , the distribution valve 238 , the EC media valve 240 , the IC waste valve 242 , the EC waste valve 244 , and the harvest valve 246 .
- Several sensors are also associated with the back portion 206 of the cell expansion machine 202 , including the IC outlet pressure sensor 248 , the combination IC inlet pressure and temperature sensors 250 , the combination EC inlet pressure and temperature sensors 252 , and the EC outlet pressure sensor 254 .
- an optical sensor 256 for an air removal chamber, according to an embodiment.
- a shaft or rocker control 258 for rotating the bioreactor 100 is shown.
- Shaft fitting 260 associated with the shaft or rocker control 258 allows for proper alignment of a shaft access aperture, see e.g., 424 ( FIG. 4 ) of a tubing-organizer, see e.g., 300 ( FIG. 4 ) of a premounted conveyance assembly 210 or 400 with the back portion 206 of the cell expansion machine 202 .
- Rotation of shaft or rocker control 258 imparts rotational movement to shaft fitting 260 and bioreactor 100 .
- the alignment is a relatively simple matter of properly orienting the shaft access aperture 424 ( FIG. 4 ) of the premounted fluid conveyance assembly 210 or 400 with the shaft fitting 260 .
- FIG. 4 a perspective view of a detachably-attachable premounted fluid conveyance assembly 400 is shown.
- the premounted fluid conveyance assembly 400 may be detachably-attachable to the cell expansion machine 202 ( FIGS. 2 and 3 ) to facilitate relatively quick exchange of a new or unused premounted fluid conveyance assembly 400 at a cell expansion machine 202 for a used premounted fluid conveyance assembly 400 at the same cell expansion machine 202 .
- the bioreactor 100 may be attached to a bioreactor coupling that includes a shaft fitting 402 .
- the shaft fitting 402 includes one or more shaft fastening mechanisms, such as a biased arm or spring member 404 for engaging a shaft, e.g., 258 (shown in FIG. 3 ), of the cell expansion machine 202 .
- the premounted fluid conveyance assembly 400 includes tubing 408 A, 408 B, 408 C, 408 D, 408 E, etc., and various tubing fittings to provide the fluid paths shown in FIGS. 5 and 6 , as discussed below.
- Pump loops 406 A and 406 B may also be provided for the pump(s).
- the premounted fluid conveyance assembly 400 may include sufficient tubing length to extend to the exterior of the cell expansion machine 202 and to enable welded connections to tubing associated with media bag(s) or container(s), according to embodiments.
- FIG. 5 illustrates a schematic of an embodiment of a cell expansion system 500
- FIG. 6 illustrates a schematic of another embodiment of a cell expansion system 600 .
- the cells are grown in the IC space.
- the disclosure is not limited to such examples and may in other embodiments provide for cells to be grown in the EC space.
- FIG. 5 illustrates a CES 500 , which includes first fluid circulation path 502 (also referred to as the “intracapillary loop” or “IC loop”) and second fluid circulation path 504 (also referred to as the “extracapillary loop” or “EC loop”), according to embodiments.
- First fluid flow path 506 may be fluidly associated with cell growth chamber 501 to form first fluid circulation path 502 . Fluid flows into cell growth chamber 501 through IC inlet port 501 A, through hollow fibers in cell growth chamber 501 , and exits via IC outlet port 501 B. Pressure gauge 510 measures the pressure of media leaving cell growth chamber 501 . Media flows through IC circulation pump 512 which may be used to control the rate of media flow.
- IC circulation pump 512 may pump the fluid in a first direction or second direction opposite the first direction. Exit port 501 B may be used as an inlet in the reverse direction. Media entering the IC loop may enter through valve 514 .
- additional valves, pressure gauges, pressure/temperature sensors, ports, and/or other devices may be placed at various locations to isolate and/or measure characteristics of the media along portions of the fluid paths. Accordingly, it is to be understood that the schematic shown represents one possible configuration for various elements of the CES 500 , and modifications to the schematic shown are within the scope of the one or more present embodiments.
- samples of media may be obtained from sample port 516 or sample coil 518 during operation.
- Pressure/temperature gauge 520 disposed in first fluid circulation path 502 allows detection of media pressure and temperature during operation.
- Media then returns to IC inlet port 501 A to complete fluid circulation path 502 .
- Cells grown/expanded in cell growth chamber 501 may be flushed out of cell growth chamber 501 into harvest bag 599 through valve 598 or redistributed within the hollow fibers for further growth.
- Fluid in second fluid circulation path 504 enters cell growth chamber 501 via EC inlet port 501 C, and leaves cell growth chamber 501 via EC outlet port 501 D.
- Media in the EC loop 504 may be in contact with the outside of the hollow fibers in the cell growth chamber 501 , thereby allowing diffusion of small molecules into and out of the hollow fibers.
- Pressure/temperature gauge 524 disposed in the second fluid circulation path 504 allows the pressure and temperature of media to be measured before the media enters the EC space of the cell growth chamber 501 , according to an embodiment.
- Pressure gauge 526 allows the pressure of media in the second fluid circulation path 504 to be measured after it leaves the cell growth chamber 501 .
- samples of media may be obtained from sample port 530 or a sample coil during operation.
- fluid in second fluid circulation path 504 passes through EC circulation pump 528 to oxygenator or gas transfer module 532 .
- EC circulation pump 528 may also pump the fluid in opposing directions.
- Second fluid flow path 522 may be fluidly associated with oxygenator or gas transfer module 532 via oxygenator inlet port 534 and oxygenator outlet port 536 .
- fluid media flows into oxygenator or gas transfer module 532 via oxygenator inlet port 534 , and exits oxygenator or gas transfer module 532 via oxygenator outlet port 536 .
- Oxygenator or gas transfer module 532 adds oxygen to, and removes bubbles from, media in the CES 500 , for example.
- media in second fluid circulation path 504 may be in equilibrium with gas entering oxygenator or gas transfer module 532 .
- the oxygenator or gas transfer module 532 may be any appropriately sized oxygenator or gas transfer device. Air or gas flows into oxygenator or gas transfer module 532 via filter 538 and out of oxygenator or gas transfer device 532 through filter 540 . Filters 538 and 540 reduce or prevent contamination of oxygenator or gas transfer module 532 and associated media. Air or gas purged from the CES 500 during portions of a priming sequence may vent to the atmosphere via the oxygenator or gas transfer module 532 .
- first fluid circulation path 502 and second fluid circulation path 504 flows through cell growth chamber 501 in the same direction (a co-current configuration).
- the CES 500 may also be configured to flow in a counter-current conformation.
- media including cells (from bag 562 ), and fluid media from bag 546 may be introduced to first fluid circulation path 502 via first fluid flow path 506 .
- Fluid container 562 e.g., Cell Inlet Bag or Saline Priming Fluid for priming air out of the system
- valve 564 may be fluidly associated with the first fluid flow path 506 and the first fluid circulation path 502 via valve 564 .
- Fluid containers, or media bags, 544 e.g., Reagent
- 546 e.g., IC Media
- First and second sterile sealable input priming paths 508 and 509 are also provided.
- An air removal chamber (ARC) 556 may be fluidly associated with first circulation path 502 .
- the air removal chamber 556 may include one or more ultrasonic sensors including an upper sensor and lower sensor to detect air, a lack of fluid, and/or a gas/fluid interface, e.g., an air/fluid interface, at certain measuring positions within the air removal chamber 556 .
- ultrasonic sensors may be used near the bottom and/or near the top of the air removal chamber 556 to detect air, fluid, and/or an air/fluid interface at these locations.
- Embodiments provide for the use of numerous other types of sensors without departing from the spirit and scope of the present disclosure.
- optical sensors may be used in accordance with embodiments of the present disclosure. Air or gas purged from the CES 500 during portions of the priming sequence or other protocols may vent to the atmosphere out air valve 560 via line 558 that may be fluidly associated with air removal chamber 556 .
- Fluid container 566 may be fluidly associated with valve 570 that may be fluidly associated with first fluid circulation path 502 via distribution valve 572 and first fluid inlet path 542 .
- fluid container 566 may be fluidly associated with second fluid circulation path 504 via second fluid inlet path 574 and EC inlet path 584 by opening valve 570 and closing distribution valve 572 .
- fluid container 568 may be fluidly associated with valve 576 that may be fluidly associated with first fluid circulation path 502 via first fluid inlet path 542 and distribution valve 572 .
- fluid container 568 may be fluidly associated with second fluid inlet path 574 by opening valve 576 and closing distribution valve 572 .
- An optional heat exchanger 552 may be provided for media reagent or wash solution introduction.
- fluid may be initially advanced by the IC inlet pump 554 .
- fluid may be initially advanced by the EC inlet pump 578 .
- An air detector 580 such as an ultrasonic sensor, may also be associated with the EC inlet path 584 .
- first and second fluid circulation paths 502 and 504 are connected to waste line 588 .
- IC media may flow through waste line 588 and to waste or outlet bag 586 .
- EC media may flow through waste line 588 to waste or outlet bag 586 .
- cells may be harvested via cell harvest path 596 .
- cells from cell growth chamber 501 may be harvested by pumping the IC media containing the cells through cell harvest path 596 and valve 598 to cell harvest bag 599 .
- Various components of the CES 500 may be contained or housed within a machine or housing, such as cell expansion machine 202 ( FIGS. 2 and 3 ), wherein the machine maintains cells and media, for example, at a predetermined temperature.
- a machine or housing such as cell expansion machine 202 ( FIGS. 2 and 3 ), wherein the machine maintains cells and media, for example, at a predetermined temperature.
- CES 600 includes a first fluid circulation path 602 (also referred to as the “intracapillary loop” or “IC loop”) and second fluid circulation path 604 (also referred to as the “extracapillary loop” or “EC loop”).
- First fluid flow path 606 may be fluidly associated with cell growth chamber 601 to form first fluid circulation path 602 .
- Fluid flows into cell growth chamber 601 through IC inlet port 601 A, through hollow fibers in cell growth chamber 601 , and exits via IC outlet port 601 B.
- Pressure sensor 610 measures the pressure of media leaving cell growth chamber 601 .
- sensor 610 may, in embodiments, also be a temperature sensor that detects the media pressure and temperature during operation.
- IC circulation pump 612 may pump the fluid in a first direction or second direction opposite the first direction.
- Exit port 601 B may be used as an inlet in the reverse direction.
- Media entering the IC loop may enter through valve 614 .
- additional valves, pressure gauges, pressure/temperature sensors, ports, and/or other devices may be placed at various locations to isolate and/or measure characteristics of the media along portions of the fluid paths. Accordingly, it is to be understood that the schematic shown represents one possible configuration for various elements of the CES 600 , and modifications to the schematic shown are within the scope of the one or more present embodiments.
- samples of media may be obtained from sample coil 618 during operation. Media then returns to IC inlet port 601 A to complete fluid circulation path 602 . Cells grown/expanded in cell growth chamber 601 may be flushed out of cell growth chamber 601 into harvest bag 699 through valve 698 and line 697 . Alternatively, when valve 698 is closed, the cells may be redistributed within chamber 601 for further growth.
- Fluid in second fluid circulation path 604 enters cell growth chamber 601 via EC inlet port 601 C and leaves cell growth chamber 601 via EC outlet port 601 D.
- Media in the EC loop may be in contact with the outside of the hollow fibers in the cell growth chamber 601 , thereby allowing diffusion of small molecules into and out of the hollow fibers that may be within chamber 601 , according to an embodiment.
- Pressure/temperature sensor 624 disposed in the second fluid circulation path 604 allows the pressure and temperature of media to be measured before the media enters the EC space of the cell growth chamber 601 .
- Sensor 626 allows the pressure and/or temperature of media in the second fluid circulation path 604 to be measured after it leaves the cell growth chamber 601 .
- samples of media may be obtained from sample port 630 or a sample coil during operation.
- Second fluid flow path 622 may be fluidly associated with oxygenator or gas transfer module 632 via an inlet port 632 A and an outlet port 632 B of oxygenator or gas transfer module 632 .
- fluid media flows into oxygenator or gas transfer module 632 via inlet port 632 A, and exits oxygenator or gas transfer module 632 via outlet port 632 B.
- Oxygenator or gas transfer module 632 adds oxygen to, and removes bubbles from, media in the CES 600 , for example.
- media in second fluid circulation path 604 may be in equilibrium with gas entering oxygenator or gas transfer module 632 .
- the oxygenator or gas transfer module 632 may be any appropriately sized device useful for oxygenation or gas transfer. Air or gas flows into oxygenator or gas transfer module 632 via filter 638 and out of oxygenator or gas transfer device 632 through filter 640 . Filters 638 and 640 reduce or prevent contamination of oxygenator or gas transfer module 632 and associated media. Air or gas purged from the CES 600 during portions of a priming sequence may vent to the atmosphere via the oxygenator or gas transfer module 632 .
- first fluid circulation path 602 and second fluid circulation path 604 flows through cell growth chamber 601 in the same direction (a co-current configuration).
- the CES 600 may also be configured to flow in a counter-current conformation, according to embodiments.
- media including cells (from a source such as a cell container, e.g., a bag) may be attached at attachment point 662 , and fluid media from a media source may be attached at attachment point 646 .
- the cells and media may be introduced into first fluid circulation path 602 via first fluid flow path 606 .
- Attachment point 662 may be fluidly associated with the first fluid flow path 606 via valve 664
- attachment point 646 may be fluidly associated with the first fluid flow path 606 via valve 650 .
- a reagent source may be fluidly connected to point 644 and be associated with fluid inlet path 642 via valve 648 , or second fluid inlet path 674 via valves 648 and 672 .
- Air removal chamber (ARC) 656 may be fluidly associated with first circulation path 602 .
- the air removal chamber 656 may include one or more sensors including an upper sensor and lower sensor to detect air, a lack of fluid, and/or a gas/fluid interface, e.g., an air/fluid interface, at certain measuring positions within the air removal chamber 656 .
- ultrasonic sensors may be used near the bottom and/or near the top of the air removal chamber 656 to detect air, fluid, and/or an air/fluid interface at these locations.
- Embodiments provide for the use of numerous other types of sensors without departing from the spirit and scope of the present disclosure.
- optical sensors may be used in accordance with embodiments of the present disclosure. Air or gas purged from the CES 600 during portions of a priming sequence or other protocol(s) may vent to the atmosphere out air valve 660 via line 658 that may be fluidly associated with air removal chamber 656 .
- Attachment point 666 may be fluidly associated with valve 670 that may be fluidly associated with first fluid circulation path 602 via valve 672 and first fluid inlet path 642 .
- attachment point 666 may be fluidly associated with second fluid circulation path 604 via second fluid inlet path 674 and second fluid flow path 684 by opening valve 670 and closing valve 672 .
- attachment point 668 may be fluidly associated with valve 676 that may be fluidly associated with first fluid circulation path 602 via first fluid inlet path 642 and valve 672 .
- fluid container 668 may be fluidly associated with second fluid inlet path 674 by opening valve 676 and closing distribution valve 672 .
- fluid may be initially advanced by the IC inlet pump 654 .
- fluid may be initially advanced by the EC inlet pump 678 .
- An air detector 680 such as an ultrasonic sensor, may also be associated with the EC inlet path 684 .
- first and second fluid circulation paths 602 and 604 are connected to waste line 688 .
- IC media may flow through waste line 688 and to waste or outlet bag 686 .
- EC media may flow to waste or outlet bag 686 .
- cells from cell growth chamber 601 may be harvested via cell harvest path 697 .
- cells from cell growth chamber 601 may be harvested by pumping the IC media containing the cells through cell harvest path 697 , with valve 698 open, into cell harvest bag 699 .
- CES 600 may be contained or housed within a machine or housing, such as cell expansion machine 202 ( FIGS. 2 and 3 ), wherein the machine maintains cells and media, for example, at a predetermined temperature. It is further noted that, in embodiments, components of CES 600 and CES 500 ( FIG. 5 ) may be combined. In other embodiments, a CES may include fewer or additional components than those shown in FIGS. 5 and 6 and still be within the scope of the present disclosure.
- An example of a cell expansion system that may incorporate features of the present disclosure is the Quantum® Cell Expansion System, manufactured by Terumo BCT, Inc. in Lakewood, Colo.
- FIG. 7A illustrates example operational steps 700 of a process for implementing a scheduled feed that may be used with a cell expansion system, such as CES 500 ( FIG. 5 ) or CES 600 ( FIG. 6 ), in accordance with embodiments of the present disclosure.
- a cell expansion system such as CES 500 ( FIG. 5 ) or CES 600 ( FIG. 6 )
- such schedule may provide for one or more scheduled media exchange(s).
- START operation 702 is initiated, and process 700 proceeds to load the disposable tubing set 704 onto the cell expansion system.
- the system may be primed 706 .
- a user or an operator may provide an instruction to the system to prime by selecting a task for priming, for example.
- such task for priming may be a pre-programmed task.
- Process 700 then proceeds to coat the bioreactor 708 , in which the bioreactor may be coated with a coating agent.
- a reagent may be loaded into an IC loop until a reagent container is empty. The reagent may be chased from an air removal chamber into the IC loop, and the reagent may then be circulated in the IC loop. Any coating reagent known to those of skill in the art may be used, such as fibronectin or cryoprecipitate, for example.
- the IC/EC Washout task may be performed 710 , in which fluid on the IC circulation loop and on the EC circulation loop is replaced. The replacement volume is determined by the number of IC Volumes and EC Volumes exchanged.
- condition media task 712 may be executed to allow the media to reach equilibrium with the provided gas supply before cells are loaded into the bioreactor. For example, rapid contact between the media and the gas supply provided by the gas transfer module or oxygenator is provided by using a high EC circulation rate. The system may then be maintained in a proper or desired state until a user or operator, for example, is ready to load cells into the bioreactor.
- Process 700 next proceeds to loading cells 714 into the bioreactor from a cell inlet bag, for example.
- the cells may be loaded into the bioreactor from the cell inlet bag until the bag is empty. Cells may then be chased from the air removal chamber to the bioreactor. In embodiments that utilize larger chase volumes, cells may be spread and move toward the IC outlet. The distribution of cells may be promoted across the membrane via IC circulation, such as through an IC circulation pump, with no IC inlet, for example. Further, the cells, e.g., adherent cells, may be allowed to attach 716 to the hollow fibers.
- process 700 proceeds to query 718 , in which it is determined whether it is desired to follow a scheduled feed. If a scheduled feed is desired, process 700 branches “yes” to query 720 to determine whether a conservative, aggressive, or other type of scheduled feed is desired.
- schedules may be created by a custom task(s) for the cell expansion system, in which a user or an operator enters the desired feeding information and other conditions, such as media exchange(s), for example, according to an embodiment.
- the schedule may be selected from a list of pre-programmed, default, or previously saved tasks.
- the task (e.g., custom, pre-programmed, default, etc.) also may define the bioreactor rotation, in which the bioreactor may be rotated at some point(s) during the attachment and expansion of the cells.
- the bioreactor may be rotated 180°, or another defined degree of rotation, at a particular time(s) or point(s) in the cell expansion.
- process 700 follows the “conservative” branch to initiate a conservative feed schedule 722 .
- the cells are then fed according to the conservative feed schedule 724 , in which the cells may be fed with media.
- the cells may be fed with complete media, according to an embodiment.
- Complete media may be any media source used for cell growth.
- complete media may comprise alpha-MEM ( ⁇ -MEM) and fetal bovine serum (FBS), for example. Any type of media known to those of skill in the art may be used.
- FIG. 7A and process 700 refer to a conservative feed schedule at step 722 , for example, embodiments provide for the use of a single or multiple conservative feed schedules. Thus, multiple conservative feed schedules may be initiated and followed for the feeding of the cells at steps 722 and 724 . In other embodiments, a single conservative feed schedule may be followed.
- a conservative feed schedule such as the following shown in Table 1, may be used:
- a range of inlet rates, or inlet flow rates may be used during a conservative feed schedule.
- the inlet rates may range from about 0.01 mL/min IC (or EC) inlet to about 10.0 mL/min IC (or EC) inlet, with increases at each consecutive time period or interval, e.g., day or about 24-hour period, about 12-hour period, about 36-hour period, about 48-hour period, etc.
- inlet rates may range from about 100 mL/min to about 1,000 mL/min; about 2,000 mL/min; about 3,000 mL/min, etc.
- any amounts for scheduled inlet rates, inlet rate increases (or decreases or maintenance amounts), and/or media exchanges may be used in accordance with embodiments of the present disclosure.
- the inlet rates may increase, for example, at each consecutive time period or interval, e.g., day or about 24-hour period, about 12-hour period, about 36-hour period, about 48-hour period, etc., according to a percentage of the previous time period's rate, e.g., an increase of about 1% to about 100% from the previous time period's rate.
- the inlet flow rate may be increased by a percentage equal to or greater than about 1%, equal to or greater than about 5%, equal to or greater than about 10%, equal to or greater than about 15%, equal to or greater than about 20%, equal to or greater than about 25%, equal to or greater than about 30%, equal to or greater than about 35%, equal to or greater than about 40%, and equal to or greater than about 50%, of the previous time period's rate.
- the inlet flow rate may be increased by a percentage less than or equal to about 55%, less than or equal to about 60%, less than or equal to about 65%, less than or equal to about 70%, less than or equal to about 75%, less than or equal to about 80%, less than or equal to about 85%, less than or equal to about 90%, and less than or equal to about 100%, of the previous time period's rate.
- the inlet rates may increase by the same or different percentages for particular periods or intervals of time in a linear or non-linear fashion.
- a conservative feed schedule may include the doubling, i.e., increasing of the inlet rate by about 100%, of the inlet rate at Day 1 (or other time period) to achieve the inlet rate at Day 2 (or other time period), according to an embodiment.
- the inlet rates may increase by a smaller percentage, such as about 50%, about 66.6%, about 60%, about 25%, about 20%, respectively, of the previous time period's rate for the remaining days, or time periods, until harvest, according to embodiments.
- a conservative feed schedule may provide for the increase, decrease, and/or maintenance of flow rates for different periods of time.
- the inlet rates or inlet flow rates may be increased at fractions of a day or other period of time, e.g., after a certain number of hours or minutes has passed.
- the inlet rates may be increased automatically at 12 hour intervals, 6 hour intervals, 3 hour intervals, 1 hour intervals, 30 minute increments, 15 minute increments, etc.
- the inlet rates may be increased at intervals or periods spanning multiple days. For example, the inlet rates may be increased automatically at 1.5 day intervals, 2 day intervals, 3 day intervals, 4 day intervals, etc.
- the feeding of cells per a conservative feed schedule(s) 724 may proceed according to the example operational steps 754 depicted in FIG. 7B of a process for implementing a scheduled feed that may be used with a cell expansion system, such as CES 500 ( FIG. 5 ) or CES 600 ( FIG. 6 ).
- a scheduled feed may provide for one or more scheduled media exchange(s).
- Process 754 may be performed as one or more steps in process 700 ( FIG. 7A ).
- process 754 may be performed as part of steps 724 , 730 , and/or 734 of process 700 ( FIG. 7A ). As shown in FIG. 7A , a number of steps may precede process 754 , in embodiments.
- process 700 may precede process 754 .
- additional, fewer, or different steps may be included in process 754 than those shown in FIG. 7B .
- additional steps may be performed following step 766 , according to embodiments.
- START operation 756 is initiated, and process 754 proceeds to feed the cells at a first inlet rate during a first time period or interval of time according to a schedule, e.g., conservative feed schedule, 758 , according to an embodiment.
- the first inlet rate may be increased, according to a schedule, by a first percentage of the first inlet rate to achieve a second inlet rate 760 .
- Process 754 then proceeds to feed the cells at the second inlet rate during a second time period 762 according to a schedule.
- the second inlet rate may then be increased, according to a schedule, by a second percentage of the second inlet rate to achieve a third inlet rate 764 .
- Process 754 then proceeds with feeding the cells, according to a schedule, at a third inlet rate during a third time period 766 .
- Process 754 then terminates at END operation 768 . While process 754 depicts a first time period, a second time period, and a third time period, there could be any number of time periods, e.g., a fourth time period, a fifth time period, a sixth time period, a seventh time period, etc., in embodiments.
- process 754 depicts a first inlet rate, a second inlet rate, and a third inlet rate
- process 754 depicts a first inlet rate, a second inlet rate, and a third inlet rate
- there could be any number of inlet rates e.g., a fourth inlet rate, a fifth inlet rate, a sixth inlet rate, a seventh inlet rate, etc., in embodiments.
- the cells are allowed to grow or expand 726 while the conservative feed schedule is followed.
- the cells are not limited to growing or expanding at step 726 , but, instead, the cells may also expand during the feeding step(s), for example.
- glucose and lactate measurements do not need to be monitored, and inlet rates do not need to be manually increased, while the feed schedule is followed.
- data may optionally be collected if it is desired to monitor conditions before, during, or after a feed schedule is initiated, for example.
- process 700 branches from query 720 to “aggressive” to initiate an aggressive feed schedule 728 .
- FIG. 7A and process 700 refer to an aggressive feed schedule at step 728
- embodiments provide for the use of a single or multiple aggressive feed schedules.
- multiple aggressive feed schedules may be initiated and followed for the feeding of the cells at steps 728 and 730 .
- a single aggressive feed schedule may be followed.
- Such schedule may be created by a custom task(s) or custom protocol(s) for the cell expansion system, in which a user or an operator enters the desired feeding information and other conditions, such as media exchange(s), for example, according to an embodiment.
- the schedule may be selected from a list of pre-programmed, default, or previously saved tasks.
- the task e.g., custom, pre-programmed, default, etc.
- the bioreactor rotation in which the bioreactor may be rotated at some point(s) during the attachment and expansion of the cells.
- the bioreactor may be rotated 180°, or another defined degree of rotation, at a particular time(s) or point(s) in the cell expansion.
- the cells may then be fed according to the aggressive feed schedule 730 , in which the cells may be fed with media.
- the cells may be fed with complete media, according to an embodiment.
- Complete media may be any media source used for cell growth.
- complete media may comprise alpha-MEM ( ⁇ -MEM) and fetal bovine serum (FBS), for example. Any type of media known to those of skill in the art may be used.
- an aggressive feed schedule such as the following shown in Table 2, may be used:
- a range of inlet rates, or inlet flow rates may be used during an aggressive feed schedule.
- the inlet rates may range from about 0.01 mL/min IC (or EC) inlet to about 12.0 mL/min IC (or EC) inlet, with increases at each consecutive time period or interval, e.g., day or about 24-hour period, about 12-hour period, about 36-hour period, about 48-hour period, etc.
- inlet rates may range from about 100 mL/min to about 1,000 mL/min; about 2,000 mL/min; about 3,000 mL/min; about 4,000 mL/min; about 5,000 mL/min, etc.
- any amounts for scheduled inlet rates, inlet rate increases (or decreases or maintenance amounts), and/or media exchanges may be used in accordance with embodiments of the present disclosure.
- the inlet rates may increase, for example, at each consecutive time period or interval, e.g., day or about 24-hour period, about 12-hour period, about 36-hour period, about 48-hour period, etc., according to a percentage of the previous time period's rate, e.g., an increase of about 1% to about 300% of the previous time period's rate.
- the inlet flow rate may be increased by a percentage of equal to or greater than about 1%, equal to or greater than about 5%, equal to or greater than about 10%, equal to or greater than about 15%, equal to or greater than about 20%, equal to or greater than about 25%, equal to or greater than about 30%, equal to or greater than about 35%, equal to or greater than about 40%, and equal to or greater than about 50%, of the previous time period's rate.
- the inlet flow rate may be increased by a percentage of less than or equal to about 55%, less than or equal to about 60%, less than or equal to about 65%, less than or equal to about 70%, less than or equal to about 75%, less than or equal to about 80%, less than or equal to about 85%, less than or equal to about 90%, less than or equal to about 100%, less than or equal to 125%, less than or equal to 150%, less than or equal to 175%, less than or equal to 200%, less than or equal to 225%, less than or equal to 250%, less than or equal to 275%, and less than or equal to 300%, of the previous time period's rate.
- the inlet rates may increase by the same or different percentages for particular periods or intervals of time in a linear or non-linear fashion.
- an aggressive feed schedule may provide for the doubling of the inlet rate, i.e., provide for increases in inlet rates of equal to or greater than about 100%, of the previous time period's inlet rate for several consecutive time periods, e.g., days or about 24-hour periods, according to an embodiment.
- an aggressive feed schedule may provide for increases in inlet rates of equal to or greater than about 100% of the previous time period's inlet rate for at least two consecutive time periods or intervals of time.
- the cells may be fed at a first inlet rate during a first time period.
- the cells may be fed at a second inlet rate, in which the second inlet rate comprises an amount that is equal to or greater than about 100%, for example, of the first inlet rate.
- the cells may be fed at a third inlet rate during a third time period, in which the third inlet rate comprises an amount that is equal to or greater than about 100%, for example, of the second inlet rate.
- the inlet rates may increase by a smaller percentage, such as about 50%, about 33.3%, about 25%, respectively, of the previous time period's rate for the remaining days, or time periods, until harvest, according to embodiments.
- an aggressive feed schedule may provide for the increase and/or the maintenance of flow rates for different periods of time.
- a feed schedule e.g., aggressive, conservative, or other, may provide for a decrease in net flow rate from the previous time period's flow rate.
- the inlet rates or inlet flow rates may be increased at fractions of a day or other period of time, e.g., after a certain number of hours or minutes has passed.
- the inlet rates may be increased automatically at 12 hour intervals, 6 hour intervals, 3 hour intervals, 1 hour interval, 30 minute increments, 15 minute increments, etc.
- the inlet rates may be increased at intervals spanning multiple days.
- the inlet rates may be increased automatically at about 1.5 day intervals, 2 day intervals, 3 day intervals, 4 day intervals, etc., according to embodiments.
- the feeding of cells per an aggressive feed schedule(s) 730 may proceed according to the example operational steps 754 depicted in FIG. 7B of a process for implementing a scheduled feed that may be used with a cell expansion system, such as CES 500 ( FIG. 5 ) or CES 600 ( FIG. 6 ).
- a cell expansion system such as CES 500 ( FIG. 5 ) or CES 600 ( FIG. 6 ).
- such schedule may provide for one or more scheduled media exchange(s).
- Process 754 may be performed as one or more steps in process 700 ( FIG. 7A ).
- process 754 may be performed as part of steps 724 , 730 , and/or 734 of process 700 ( FIG. 7A ). As shown in FIG. 7A , a number of steps may precede process 754 , in embodiments.
- process 700 may precede process 754 .
- additional, fewer, or different steps may be included in process 754 than those shown in FIG. 7B .
- additional steps may be performed following step 766 , according to embodiments.
- START operation 756 is initiated, and process 754 proceeds to feed the cells at a first inlet rate during a first time period or interval of time according to a schedule, e.g., aggressive feed schedule, 758 , according to an embodiment.
- the first inlet rate may be increased, according to a schedule, by a first percentage of the first inlet rate to achieve a second inlet rate 760 .
- Process 754 then proceeds to feed the cells at the second inlet rate during a second time period 762 according to a schedule.
- the second inlet rate may then be increased, according to a schedule, by a second percentage of the second inlet rate to achieve a third inlet rate 764 .
- Process 754 then proceeds with feeding the cells, according to a schedule, at a third inlet rate during a third time period 766 .
- Process 754 then terminates at END operation 768 . While process 754 depicts a first time period, a second time period, and a third time period, there could be any number of time periods, e.g., a fourth time period, a fifth time, period, a sixth time period, a seventh time period, etc., in embodiments.
- process 754 depicts a first inlet rate, a second inlet rate, and a third inlet rate
- process 754 depicts a first inlet rate, a second inlet rate, and a third inlet rate
- there could be any number of inlet rates e.g., a fourth inlet rate, a fifth inlet rate, a sixth inlet rate, a seventh inlet rate, etc., in embodiments.
- the cells are allowed to grow or expand 726 while the aggressive feed schedule is followed.
- the cells are not limited to growing or expanding at step 726 , but, instead, the cells may also expand during the feeding step(s), for example.
- glucose and lactate measurements do not need to be monitored, and inlet rates do not need to be manually increased, while the feed schedule is followed.
- data may optionally be collected if it is desired to monitor conditions before, during, or after a feed schedule is initiated, for example.
- process 700 branches from query 720 to “other” to initiate an “other” type of feed schedule 732 .
- schedule may maintain feeding rates at current levels, according to an embodiment.
- schedule may increase feeding rates in a manner that is neither conservative nor aggressive but, instead, is a combination of the two, for example.
- an aggressive feed schedule or multiple aggressive feed schedules may be followed for certain periods or intervals of time, while a conservative feed schedule or multiple conservative feed schedules may be followed for other periods or intervals of time, according to embodiments.
- a single feed schedule may be followed with such feed schedule being a combination of a conservative feed schedule and an aggressive feed schedule based on the inlet flow rate amounts.
- FIG. 7A and process 700 refer to an “other” schedule at step 732 , for example, embodiments provide for the use of a single or multiple “other” feed schedules. Thus, multiple “other” feed schedules may be initiated and followed for the feeding of the cells at steps 732 and 734 . In other embodiments, a single “other” feed schedule may be followed.
- Such “other” schedules may be created by a custom task(s) or custom protocol(s) for the cell expansion system, in which a user or operator, for example, may enter the desired feeding information, and other conditions, such as media exchanges, for example, according to an embodiment.
- the schedule may be selected from a list of pre-programmed, default, or previously saved tasks.
- the task e.g., custom, pre-programmed, default, etc.
- the bioreactor rotation in which the bioreactor may be rotated at some point(s) during the attachment and expansion of the cells. For example, the bioreactor may be rotated 180°, or another defined degree of rotation, at a particular time(s) or point(s) in the cell expansion.
- the cells may then be fed according to the “other” type of feed schedule 734 , in which the cells may be fed with media.
- the cells may be fed with complete media, according to an embodiment.
- Complete media may be any media source used for cell growth.
- complete media may comprise alpha-MEM ( ⁇ -MEM) and fetal bovine serum (FBS), for example. Any type of media known to those of skill in the art may be used.
- the feeding of cells per an “other” feed schedule(s) 734 may proceed according to the example operational steps 754 depicted in FIG. 7B of a process for implementing a scheduled feed that may be used with a cell expansion system, such as CES 500 ( FIG. 5 ) or CES 600 ( FIG. 6 ).
- Process 754 may be performed as one or more steps in process 700 ( FIG. 7A ).
- process 754 may be performed as part of steps 724 , 730 , and/or 734 of process 700 ( FIG. 7A ).
- a number of steps may precede process 754 , in embodiments.
- additional, fewer, or different steps than those illustrated in process 700 ( FIG. 7A ) may precede process 754 .
- additional, fewer, or different steps may be included in process 754 than those shown in FIG. 7B , in embodiments.
- additional steps may be performed following step 766 , according to embodiments.
- START operation 756 is initiated, and process 754 proceeds to feed the cells at a first inlet rate during a first time period or interval of time according to a schedule, e.g., “other” feed schedule, 758 , according to an embodiment.
- the first inlet rate may be increased, according to a schedule, by a first percentage of the first inlet rate to achieve a second inlet rate 760 .
- Process 754 then proceeds to feed the cells at the second inlet rate during a second time period 762 according to a schedule.
- the second inlet rate may then be increased, according to a schedule, by a second percentage of the second inlet rate to achieve a third inlet rate 764 .
- Process 754 then proceeds with feeding the cells, according to a schedule, at a third inlet rate during a third time period 766 .
- Process 754 then terminates at END operation 768 . While process 754 depicts a first time period, a second time period, and a third time period, there could be any number of time periods, e.g., a fourth time period, a fifth time, period, a sixth time period, a seventh time period, etc., in embodiments.
- process 754 depicts a first inlet rate, a second inlet rate, and a third inlet rate
- process 754 depicts a first inlet rate, a second inlet rate, and a third inlet rate
- there could be any number of inlet rates e.g., a fourth inlet rate, a fifth inlet rate, a sixth inlet rate, a seventh inlet rate, etc., in embodiments.
- the cells are allowed to grow or expand 726 while the “other” type of feed schedule is followed.
- glucose and lactate measurements do not need to be monitored, and inlet rates do not need to be manually increased, while the feed schedule is followed.
- data may optionally be collected if it is desired to monitor conditions before, during, or after a feed schedule is initiated, for example.
- process 700 proceeds “no” to initiate feeding cells 736 , in which the media from a media bag, for example, is added to the cells to feed them.
- glucose/lactate levels may be measured 738 , in which a user or operator, for example, may measure such levels on a regular basis, e.g., daily, to determine any adjustment(s) to make to the feed amounts of media 740 based on the consumption and production of these metabolites.
- glucose/lactate measurements may be taken at random time periods, depending on the user's or operator's preference, for example.
- glucose/lactate levels are measured by taking a sample from a sample coil or sample port, such as an EC sample port, of a cell expansion system. In other embodiments, such glucose/lactate levels are measured by taking a sample by splicing the IC loop of a cell expansion system using a sterile tubing welder, for example.
- the cells may be fed accordingly 740 in amounts that account for the glucose/lactate levels measured at step 738 .
- the IC inlet rate may be increased two-fold when the glucose value falls below 70 mg/dL, according to an embodiment.
- the cells are allowed to grow or expand 742 .
- the cells are not limited to growing or expanding at step 742 , but, instead, the cells may also expand during the feeding step(s), for example.
- query 744 determines whether it is desired to continue the monitoring of the glucose/lactate levels. If it is desired to continue such monitoring to allow for adjustments to the feeding rates, process 700 proceeds “yes” to measure glucose/lactate levels 738 , and process 700 proceeds again to the feeding of the cells accordingly 740 and the growing/expanding of the cells 742 . If it is not desired to continue the monitoring of such glucose/lactate levels, process 700 proceeds “no” from query 744 .
- attached cells may be released 746 from the membrane of the bioreactor and suspended in the IC loop, for example.
- an IC/EC washout task in preparation for adding a reagent to release the cells is performed as part of operation 746 .
- IC/EC media may be replaced with a phosphate buffered saline (PBS) to remove protein, calcium (Ca 2+ ), and magnesium (Mg 2+ ) in preparation for adding trypsin, or another chemical-releasing agent, to release any adherent cells.
- PBS phosphate buffered saline
- Mg 2+ magnesium
- a reagent may be loaded into the system until the reagent bag is empty.
- the reagent may be chased into the IC loop, and the reagent may be mixed within the IC loop.
- harvest operation 748 transfers the cells in suspension from the IC circulation loop, for example, including any cells remaining in the bioreactor, to a harvest bag(s) or container(s).
- the disposable set is unloaded 750 from the cell expansion system, and process 700 then terminates at END operation 752 .
- FIG. 8 illustrates example operational steps 800 of a process for implementing a task(s) or protocol(s) for a scheduled feeding of cells for use with a cell expansion system, such as CES 500 ( FIG. 5 ) or CES 600 ( FIG. 6 ), in accordance with embodiments of the present disclosure.
- a cell expansion system such as CES 500 ( FIG. 5 ) or CES 600 ( FIG. 6 )
- such scheduled feed may provide for one or more scheduled media exchange(s).
- START operation 802 is initiated, in which a disposable set may be loaded onto a cell expansion system, the set may be primed, a bioreactor may be coated, IC/EC washout may occur, media may be conditioned, cells may be loaded, and cells may be allowed to attach, for example.
- process 800 proceeds to query 804 to determine whether it is desired to follow a scheduled feed.
- process 800 branches “yes” to query 806 to determine whether a pre-programmed, default, or previously saved task is available for a scheduled feed. If such a task is available, process 800 proceeds “yes” to select, or receive the selection of, the pre-programmed task to initiate scheduled feeding 808 .
- the cells may then be fed according to the feed schedule defined in the pre-programmed, default, or previously saved task, in which the cells may be fed with media.
- the cells may be fed with complete media, according to an embodiment.
- Complete media may be any media source used for cell growth.
- complete media may comprise alpha-MEM ( ⁇ -MEM) and fetal bovine serum (FBS), for example.
- glucose and lactate measurements do not need to be monitored, and inlet rates do not need to be manually increased, while a feed schedule is followed.
- data may optionally be collected if it is desired to monitor conditions before, during, or after a feed schedule is initiated, for example.
- such pre-programmed, default, or previously saved task may include defined inlet rates, media exchanges, etc., and may include a defined stop condition(s).
- stop condition may be a time period, such as about 24 hours, 12 hours, 6 hours, 30 minutes, 36 hours, 48 hours, 72 hours, etc., according to embodiments.
- the pre-programmed, default, or previously saved task may also define the bioreactor rotation, in which the bioreactor may be rotated at some point(s) during the attachment and expansion of the cells.
- the bioreactor may be rotated 180°, or another defined degree of rotation, at a particular time(s) or point(s) in the cell expansion.
- the cells are allowed to grow or expand 810 .
- the cells are not limited to growing or expanding at step 810 , but, instead, the cells may also expand during the feeding step(s), for example.
- process 800 branches “no” from query 806 to create a custom task X for scheduled feeding 812 , in which a user or operator, for example, may customize a task(s) to provide for the scheduled feeding of cells.
- such custom task may include defined inlet rates, media exchanges, etc., and may include a defined stop condition(s).
- stop condition may be a time period, such as about 24 hours, 12 hours, 6 hours, 30 minutes, 36 hours, 48 hours, 72 hours, etc., according to embodiments.
- the custom task may also define the bioreactor rotation, in which the bioreactor may be rotated at some point(s) during the attachment and expansion of the cells. For example, the bioreactor may be rotated 180°, or another defined degree of rotation, at a particular time(s) or point(s) in the cell expansion.
- step 812 may provide for creating Custom Task 1 for Day 1 (or other time period) of a scheduled feed, while step 814 may determine whether additional tasks, such as Custom Task 2 for Day 2 (or other time period), Custom Task 3 for Day 3 (or other time period), etc., are desired.
- Each custom task may thus be part of an overall schedule for feeding the cells, according to embodiments, in which each custom task itself provides for a scheduled feeding of the cells for a particular segment or interval of the schedule, e.g., time period (depending on any stop condition(s), for example).
- a single custom task comprises multiple steps, or sub-tasks, to provide for each segment of a scheduled feeding, in which each step or sub-task comprises a defined inlet rate(s), stop condition(s), etc.
- a custom task is created by modifying a previously defined task, such as a Feed Cells task, and saving the modified Feed Cells task as a new custom task for a scheduled feed.
- a custom task may be created with new fields defined for the particular custom task desired.
- process 800 proceeds “yes” to create custom task X for scheduled feeding 812 . If no additional custom tasks are desired, process 800 proceeds “no” to select, or receive the selection of, the custom task X 815 .
- the custom task X for scheduled feeding is initiated 816 , in which a first custom task may be initiated and may run until an applicable stop condition is met.
- the cells may then be fed according to the feed schedule defined in the custom task(s), in which the cells may be fed with media.
- the cells may be fed with complete media, according to an embodiment. Complete media may be any media source used for cell growth.
- complete media may comprise alpha-MEM ( ⁇ -MEM) and fetal bovine serum (FBS), for example. Any type of media known to those of skill in the art may be used.
- ⁇ -MEM alpha-MEM
- FBS fetal bovine serum
- glucose and lactate measurements do not need to be monitored, and inlet rates do not need to be manually increased, while a feed schedule is followed.
- data may optionally be collected if it is desired to monitor conditions before, during, or after a feed schedule is initiated, for example. If additional custom tasks are present, such as a second custom task, third custom task, fourth custom task, etc., each successive custom task may start when the immediately prior custom task meets its stop condition.
- the cells are allowed to grow or expand 810 .
- the cells are not limited to growing or expanding at step 810 , but, instead, the cells may also expand during the feeding step(s), such as during the running of custom task X controlling inlet rates, etc., for example.
- IC/EC washout task in preparation for adding a reagent to release the cells is performed as part of operation 828 .
- IC/EC media may be replaced with a phosphate buffered saline (PBS) to remove protein, calcium (Ca 2+ ), and magnesium (Mg 2+ ) in preparation for adding trypsin, or another chemical-releasing agent to release any adherent cells.
- PBS phosphate buffered saline
- Mg 2+ magnesium
- a reagent may be loaded into the system until the reagent bag is empty. The reagent may be chased into the IC loop, and the reagent may be mixed within the IC loop.
- harvest operation 830 transfers the cells in suspension from the IC circulation loop, including any cells remaining in the bioreactor, to a harvest bag. Finally, the disposable set is unloaded 832 from the cell expansion system, and process 800 then terminates at END operation 834 .
- process 800 branches “no” to initiate the feeding of cells 818 , in which a default or pre-programmed task for feeding the cells, e.g., “Feed Cells,” may be followed or a user or an operator, for example, may manually enter the inlet rates and other conditions to initiate feeding, according to embodiments.
- a default or pre-programmed task for feeding the cells e.g., “Feed Cells”
- glucose/lactate levels may be measured 820 , in which a user or operator, for example, may measure such levels on a regular basis, e.g., daily, to determine adjustments 822 , if any, to make to the amounts of media used for feeding the cells based on metabolite consumption and production.
- glucose/lactate measurements may be taken at random time periods, depending on the user's or operator's preference, for example.
- glucose/lactate levels are measured by taking a sample from a sample coil or sample port, such as an EC sample port, of a cell expansion system.
- glucose/lactate levels may be measured by taking a sample by splicing the IC loop of a cell expansion system using a sterile tubing welder, for example.
- the cells may be fed accordingly 822 in amounts that account for the glucose/lactate levels measured at step 820 .
- the IC inlet rate may be increased two-fold when the glucose value falls below 70 mg/dL, according to an embodiment.
- the cells are allowed to grow or expand 824 .
- the cells are not limited to growing or expanding at step 824 , but, instead, the cells may also expand during the feeding step(s), for example.
- query 826 determines whether it is desired to continue the monitoring of the glucose/lactate levels.
- process 800 proceeds “yes” to measure glucose/lactate levels 820 , and process 800 proceeds again to adjust the feeding of the cells accordingly 822 and the growing/expanding of the cells 824 . If it is not desired to continue the monitoring of such glucose/lactate levels, process 800 proceeds “no” from query 826 .
- attached cells may be released 828 from the membrane of the bioreactor and suspended in the IC loop, for example.
- an IC/EC washout task in preparation for adding a reagent to release the cells is performed as part of operation 828 .
- IC/EC media may be replaced with a phosphate buffered saline (PBS) to remove protein, calcium (Ca 2+ ), and magnesium (Mg 2+ ) in preparation for adding trypsin, or another chemical-releasing agent, to release any adherent cells.
- PBS phosphate buffered saline
- Mg 2+ magnesium
- a reagent may be loaded into the system until the reagent bag is empty.
- the reagent may be chased into the IC loop, and the reagent may be mixed within the IC loop.
- harvest operation 830 transfers the cells in suspension from the IC circulation loop, including any cells remaining in the bioreactor, to a harvest bag. Finally, the disposable set is unloaded 832 from the cell expansion system, and process 800 then terminates at END operation 834 .
- steps depicted are offered for purposes of illustration and may be rearranged, combined into other steps, used in parallel with other steps, etc., according to embodiments of the present disclosure. Fewer or additional steps may be used in embodiments without departing from the spirit and scope of the present disclosure. Also, steps (and any sub-steps), such as priming, coating a bioreactor, loading cells, for example, may be performed automatically in some embodiments, such as by a processor executing pre-programmed tasks stored in memory, in which such steps are provided merely for illustrative purposes.
- FIG. 9 illustrates example components of a computing system 900 upon which embodiments of the present disclosure may be implemented.
- Computing system 900 may be used in embodiments, for example, where a cell expansion system uses a processor to execute tasks, such as custom tasks or pre-programmed tasks performed as part of processes such as processes 700 , 754 , and 800 described above.
- a pre-programmed task may include, for example, follow “Scheduled Feed” for feeding cells per a specific schedule, such as a conservative, aggressive, or other type of schedule.
- the computing system 900 may include a user interface 902 , a processing system 904 , and/or storage 906 .
- the user interface 902 may include output device(s) 908 , and/or input device(s) 910 as understood by a person of skill in the art.
- Output device(s) 908 may include one or more touch screens, in which the touch screen may comprise a display area for providing one or more application windows.
- the touch screen may also be an input device 910 that may receive and/or capture physical touch events from a user or operator, for example.
- the touch screen may comprise a liquid crystal display (LCD) having a capacitance structure that allows the processing system 904 to deduce the location(s) of touch event(s), as understood by those of skill in the art.
- LCD liquid crystal display
- the processing system 904 may then map the location of touch events to UI elements rendered in predetermined locations of an application window.
- the touch screen may also receive touch events through one or more other electronic structures, according to embodiments.
- Other output devices 908 may include a printer, speaker, etc.
- Other input devices 910 may include a keyboard, other touch input devices, mouse, voice input device, etc., as understood by a person of skill in the art.
- Processing system 904 may include a processing unit 912 and/or a memory 914 , according to embodiments of the present disclosure.
- the processing unit 912 may be a general purpose processor operable to execute instructions stored in memory 914 .
- Processing unit 912 may include a single processor or multiple processors, according to embodiments. Further, in embodiments, each processor may be a multi-core processor having one or more cores to read and execute separate instructions.
- the processors may include general purpose processors, application specific integrated circuits (ASICs), field programmable gate arrays (FPGAs), other integrated circuits, etc., as understood by a person of skill in the art.
- the memory 914 may include any short-term or long-term storage for data and/or processor executable instructions, according to embodiments.
- the memory 914 may include, for example, Random Access Memory (RAM), Read-Only Memory (ROM), or Electrically Erasable Programmable Read-Only Memory (EEPROM), as understood by a person of skill in the art.
- RAM Random Access Memory
- ROM Read-Only Memory
- EEPROM Electrically Erasable Programmable Read-Only Memory
- Other storage media may include, for example, CD-ROM, tape, digital versatile disks (DVD) or other optical storage, tape, magnetic disk storage, magnetic tape, other magnetic storage devices, etc., as understood by a person of skill in the art.
- Storage 906 may be any long-term data storage device or component. Storage 906 may include one or more of the systems described in conjunction with the memory 914 , according to embodiments. The storage 906 may be permanent or removable. In embodiments, storage 906 stores data generated or provided by the processing system 904 .
- CES 500 FIG. 5
- CES 600 FIG. 6
- Such examples provide for scheduled feeds, e.g., IC inlet rate increases according to a schedule, for the expansion of cells.
- Such examples provide for the expansion of MSCs.
- Other cell types may be used in other embodiments.
- example methods or protocols below are provided for illustrative purposes and are not intended to limit other embodiments, which may include different or additional steps, parameters, or other features.
- the example methods or protocols, including the steps (and any sub-steps) may be performed automatically in some embodiments, such as by a processor executing pre-programmed tasks stored in memory.
- the steps (and any sub-steps) may be performed through the combination of automated and manual execution of operations.
- the steps (and any sub-steps) are performed by an operator(s) or user(s) or through other manual means.
- This example relates to the Culture of Human Bone Marrow-Derived Mesenchymal Stem Cells on an Automated Cell Expansion System Using Scheduled IC Inlet Rate Increases.
- the protocol of Table 3 is used, and three different seeding densities are examined: 238 cells/cm 2 (5 million total load); 476 cells/cm 2 (10 million total load); and 952 cells/cm 2 (20 million total load).
- Table 3 shows an example protocol that may be used with a cell expansion system, such as CES 500 ( FIG. 5 ) or CES 600 ( FIG.
- example protocol is provided for illustrative purposes and is not intended to limit other embodiments, which may include different steps, parameters, or other features.
- the example protocol including the steps (and any sub-steps) of priming the set, coating the bioreactor, loading cells, for example, may be performed automatically in some embodiments, such as by a processor executing pre-programmed tasks stored in memory.
- a cell expansion set or disposable tubing set
- the cell expansion set is primed.
- Such priming may occur by selecting a task for priming, in an embodiment.
- Such task for priming may be a pre-programmed task, for example.
- the cell expansion system is primed with phosphate buffered saline (PBS).
- PBS phosphate buffered saline
- the bioreactor is coated with a coating agent, such as fibronectin or cryoprecipitate in PBS.
- an IC/EC Washout task is performed, in which fluid on the IC and EC circulation loops is replaced with complete media, for example.
- media comprising alpha-MEM ( ⁇ -MEM) and fetal bovine serum (FBS) is used.
- ⁇ -MEM alpha-MEM
- FBS fetal bovine serum
- the media is conditioned to maintain a desired gas concentration across the hollow fibers in the bioreactor membrane.
- cells are loaded into the bioreactor. For example, as shown in Table 3 below, the cells are loaded with uniform suspension.
- cells e.g., adherent cells, are allowed to attach to the hollow fibers.
- the cells are then fed according to the schedule shown in Table 4 below, “Example Feed Schedule.” See Table 4 below.
- Table 4 below includes both an “Aggressive” feed schedule and a “Control.”
- the “Control” provides for measuring metabolite, e.g., glucose, levels and adjusting the IC inlet amount based on such measurements. See Table 4.
- the cells are allowed to grow or expand.
- an IC/EC Washout is performed.
- IC media is replaced with phosphate buffered saline (PBS) in preparation for adding trypsin to release the cells.
- PBS phosphate buffered saline
- the attached cells are then released from a hollow fiber membrane of the bioreactor and suspended in the IC loop.
- the cells are harvested using complete media.
- the cell expansion set is then unloaded.
- N 2 for all runs except Day 5, Day 6, and 7 Controls and 5 M Cell Load Day 6 Scheduled Feed, where N is the number of machines used per load condition, e.g., number of cells loaded and harvest day, according to embodiments.
- FIG. 10 presents a graphical representation 1000 of the data (see Table 5) for “Doubling Times for a Control Feed versus an Aggressive Feed” based on following the Example Protocol in Table 3 with the parameters of Table 4.
- the y-axis 1002 of FIG. 10 displays the doubling time (dT) for cells in hours for the Control Feed 1004 and for the Aggressive Feed 1006 .
- the x-axis 1008 displays the Time in Culture in days for the Control Feed 1004 and for the Aggressive Feed 1006 .
- Such results are provided for cell loads of 5 million total load (5 M), 10 million total load (10 M), and 20 million total load (20 M), as indicated on the x-axis 1008 .
- results are provided for the Doubling Times for Control versus Aggressive Feed at 1010 (5 M, 6 Days); 1012 (5 M, 7 Days); 1014 (10 M, 5 Days); 1016 (10 M, 6 Days); 1018 (10 M, 7 Days); 1020 (20 M, 5 Days); 1022 (20 M, 6 Days); and 1024 (20 M, 7 Days).
- FIG. 11 shows a graphical representation 1100 of the data (see Table 5) for “Number of Cells Harvested for a Control Feed versus an Aggressive Feed” based on following the Example Protocol in Table 3 with the parameters of Table 4.
- the y-axis 1102 of FIG. 11 displays the Number of Cells Harvested (10 6 ) for the Control Feed 1104 and for the Aggressive Feed 1106 .
- the x-axis 1108 displays the Time in Culture in days for the Control Feed 1104 and for the Aggressive Feed 1106 .
- Such results are provided for cell loads of 5 million total load (5 M), 10 million total load (10 M), and 20 million total load (20 M), as indicated on the x-axis 1108 .
- results are provided for the Number of Cells Harvested for Control versus Aggressive Feed at 1110 (5 M, 6 Days); 1112 (5 M, 7 Days); 1114 (10 M, 5 Days); 1116 (10 M, 6 Days); 1118 (10 M, 7 Days); 1120 (20 M, 5 Days); 1122 (20 M, 6 Days); and 1124 (20 M, 7 Days).
- the aggressive feed schedule of Table 4 during a bone marrow-derived MSC expansion may result in higher cell harvest yield in some instances, according to an embodiment.
- the aggressive feed schedule may result in some instances in about a 20% increase in cell yield as compared to the control feed method, except for the 10 M and 20 M loads expanded for seven (7) days, according to an embodiment.
- the lower cell yields for the aggressive feed schedule as compared to the control feed method at 1118 (10 M, 7 Days) and 1124 (20 M, 7 Days) may be due to over-confluence. Media usage may also be more predictable.
- Flow cytometry results for the control and aggressive feed schedules indicate that the cells may maintain MSC phenotype (data not shown). In an embodiment, little or no aggregation may be observed in the harvest products with high viability (>97%). Morphological characterization of MSC may also be observed on representative harvest products, according to an embodiment.
- This example relates to the Culture of Human Bone Marrow-Derived Mesenchymal Stem Cells on an Automated Cell Expansion System Using Scheduled IC Inlet Rate Increases.
- the protocol of Table 6 is used, and three different seeding densities are examined: 238 cells/cm 2 (5 million total load), 476 cells/cm 2 (10 million total load), and 952 cells/cm 2 (20 million total load). While Table 6 shows an example protocol that may be used with a cell expansion system, such as CES 500 ( FIG. 5 ) or CES 600 ( FIG.
- example protocol is provided for illustrative purposes and is not intended to limit other embodiments, which may include different steps, parameters, or other features.
- the example protocol including the steps (and any sub-steps) of priming the set, coating the bioreactor, loading cells, for example, may be performed automatically in some embodiments, such as by a processor executing pre-programmed tasks stored in memory.
- a cell expansion set or disposable tubing set
- the cell expansion set is primed.
- Such priming may occur by selecting a task for priming.
- Such task for priming may be a pre-programmed task, for example.
- the cell expansion system is primed with phosphate buffered saline (PBS).
- PBS phosphate buffered saline
- the bioreactor is coated with a coating agent, such as fibronectin or cryoprecipitate in PBS.
- an IC/EC Washout task is performed, in which fluid on the IC and EC circulation loops is replaced with complete media, for example.
- the media is conditioned to maintain a desired gas concentration across the hollow fibers in the bioreactor membrane.
- cells are loaded into the bioreactor. For example, as shown in Table 6 below, the cells are loaded with uniform suspension.
- cells e.g., adherent cells, are allowed to attach to the hollow fibers.
- the cells are then fed according to the schedule shown in Table 7 below, “Example Feed Schedule.” See Table 7 below.
- Table 7 below includes both a “Conservative” feed schedule and a “Control.”
- the “Control” provides for measuring metabolite, e.g., glucose, levels and adjusting the IC inlet amount based on such measurements. See Table 7 below.
- the cells are allowed to grow or expand.
- an IC/EC Washout is performed.
- IC media is replaced with PBS in preparation for adding trypsin to release the cells.
- the attached cells are then released from a hollow fiber membrane of the bioreactor and suspended in the IC loop, for example.
- the cells are harvested using complete media. The cell expansion set is then unloaded.
- FIG. 12 presents a graphical representation 1200 of the data (see Table 8) for “Doubling Times for a Control Feed versus a Conservative Feed” based on following the Example Protocol in Table 6 with the parameters of Table 7.
- the y-axis 1202 of FIG. 12 displays the doubling time (dT) for cells in hours for the Control Feed 1204 and for the Conservative Feed 1206 .
- the x-axis 1208 displays the Time in Culture in days for the Control Feed 1204 and for the Conservative Feed 1206 .
- Such results are provided for cell loads of 5 million total load (5 M), 10 million total load (10 M), and 20 million total load (20 M), as indicated on the x-axis 1208 .
- results are provided for the Doubling Times for Control versus Conservative Feed at 1210 (5 M, 7 Days); 1212 (5 M, 8 Days); 1214 (10 M, 6 Days); and 1216 (20 M, 7 Days).
- FIG. 13 presents a graphical representation 1300 of the data (see Table 8) for “Number of Cells Harvested for Control versus Conservative Feed” based on following the Example Protocol in Table 6 with the parameters of Table 7.
- the y-axis 1302 of FIG. 13 displays the Number of Cells Harvested (10 6 ) for the Control Feed 1304 and for the Conservative Feed 1306 .
- the x-axis 1308 displays the Time in Culture in days for the Control Feed 1304 and for the Conservative Feed 1306 .
- Such results are provided for cell loads of 5 million total load (5 M), 10 million total load (10 M), and 20 million total load (20 M), as indicated on the x-axis 1308 .
- results are provided for the Number of Cells Harvested for Control versus Conservative Feed at 1310 (5 M, 7 Days); 1312 (5 M, 8 Days); 1314 (10 M, 6 Days); and 1316 (20 M, 7 Days).
- implementing the conservative feed schedule of Table 7 during a bone marrow-derived MSC expansion may result in a comparable cell harvest yield in some instances, according to an embodiment.
- the conservative feed schedule may yield somewhat similar harvest numbers as the control feed in some instances but without the need for daily monitoring, in an embodiment. Media usage may also be more predictable.
- Flow cytometry results for the control and conservative feed schedules indicate that the cells may maintain MSC phenotype (data not shown). In an embodiment, little or no aggregation may be observed in the harvest products with high viability (>97%). Morphological characterization of MSC may also be observed on representative harvest products, according to an embodiment.
- Example 2 in Table 8 may show the use of less media than the amount of media used in the aggressive feed schedule of Example 1.
Abstract
Description
- This application claims the benefit of U.S. Provisional Application Ser. No. 62/055,986, filed on Sep. 26, 2014, and entitled, “Scheduled Feed.” The disclosure of the above-identified application is hereby incorporated by reference in its entirety as if set forth herein in full for all that it teaches and for all purposes.
- Cell Expansion Systems (CESs) are used to expand and differentiate cells. Cell expansion systems may be used to expand, e.g., grow, stem cells, such as mesenchymal stem cells (MSCs). Cell expansion systems may also expand other types of cells, such as bone marrow cells, for example. Stem cells which are expanded from donor cells may be used to repair or replace damaged or defective tissues and have broad clinical applications for a wide range of diseases. Cells, of both adherent and non-adherent type, may be grown in a bioreactor in a cell expansion system.
- Embodiments of the present disclosure generally relate to scheduled feeding systems and methods for a cell expansion system, in which schedules proactively and automatically increase or maintain inlet rates, e.g., intracapillary (IC) inlet rates or extracapillary (EC) inlet rates, into a circulation loop, e.g., IC circulation loop, in the cell expansion system. Such proactive and automatic feeding occurs according to the applicable schedule and regardless of metabolite levels during cell, e.g., MSC, expansions. In embodiments, media exchanges are also included as a part of such schedules, in which media is exchanged at a certain rate (and quantity) as defined by the schedule. Other feeding methods for cell expansion systems rely on the regular, e.g., daily, monitoring of metabolites, e.g., glucose and lactate from glucose consumption and lactate generation by the cells, to determine if inlet rates, e.g., IC inlet rates, should be increased. By instead following feed schedules, the taking of regular, e.g., daily, measurements of metabolites to determine whether or not to increase media inlet rates, e.g., IC inlet rates, may be optional or eliminated altogether, according to embodiments. Scheduled feeding and/or scheduled media exchanges may apply to the expansion of any type of cell.
- Embodiments of the present disclosure further relate to aggressive and conservative feed schedules, in which an aggressive feed schedule feeds the cells at a faster rate (with a larger quantity of media used) than a conservative feed schedule, for example. In other embodiments, such schedule may maintain feeding rates at current levels and/or may increase feeding rates in a manner that is neither conservative nor aggressive but, instead, is a combination of the two, for example. In yet other embodiments, other types of feeding schedules may be used. In embodiments, these feed schedules are used in a closed, automated system for cell expansion.
- In an embodiment, multiple schedules are used to expand cells in a particular run. In another embodiment, a single schedule is used for controlling the feeding of the cells during cell expansion in a particular run. In further embodiments, a single schedule may be used to control inlet rates for feeding the cells and for media exchanges, in which a media exchange replaces a portion or all of the existing media in a disposable set with new media. In other embodiments, one or more schedules may be used to control inlet rates for feeding the cells with one or more additional schedules used to control media exchanges.
- Embodiments of the present disclosure provide for implementing such schedule(s) through the use of one or more protocols or tasks for use with a cell expansion system. Through a user interface (UI) and graphical user interface (GUI) elements, a custom or user-defined protocol or task for following a scheduled feed may be created. A task may comprise one or more steps. In other embodiments, a pre-programmed, default, or otherwise previously saved task for following a scheduled feed may be selected.
- As used herein, “at least one,” “one or more,” and “and/or” are open-ended expressions that are both conjunctive and disjunctive in operation. For example, each of the expressions “at least one of A, B and C,” “at least one of A, B, or C,” “one or more of A, B, and C,” “one or more of A, B, or C” and “A, B, and/or C” means A alone, B alone, C alone, A and B together, A and C together, B and C together, or A, B and C together.
- This Summary is included to provide a selection of concepts in a simplified form, in which such concepts are further described below in the Detailed Description. This Summary is not intended to be used in any way to limit the claimed subject matter's scope. Features, including equivalents and variations thereof, may be included in addition to those provided herein.
- Embodiments of the present disclosure may be described by referencing the accompanying figures. In the figures, like numerals refer to like items.
-
FIG. 1A depicts an embodiment of a cell expansion system (CES). -
FIG. 1B illustrates a front elevation view of an embodiment of a bioreactor showing circulation paths through the bioreactor. -
FIG. 1C depicts a rocking device for moving a cell growth chamber rotationally or laterally during operation of a cell expansion system, according to embodiments of the present disclosure. -
FIG. 2 illustrates a perspective view of a cell expansion system with a premounted fluid conveyance device, in accordance with embodiments of the present disclosure. -
FIG. 3 depicts a perspective view of a housing of a cell expansion system, in accordance with embodiments of the present disclosure. -
FIG. 4 illustrates a perspective view of a premounted fluid conveyance device, in accordance with embodiments of the present disclosure -
FIG. 5 depicts a schematic of a cell expansion system, in accordance with an embodiment of the present disclosure. -
FIG. 6 illustrates a schematic of a cell expansion system, in accordance with another embodiment of the present disclosure. -
FIG. 7A depicts a flow diagram illustrating the operational characteristics of a process for implementing a feed schedule during a cell expansion, in accordance with embodiments of the present disclosure. -
FIG. 7B illustrates a flow diagram depicting the operational characteristics of a process for implementing a feed schedule during a cell expansion, in accordance with embodiments of the present disclosure. -
FIG. 8 depicts a flow diagram illustrating the operational characteristics of a process for implementing a task or protocol for a scheduled feeding of cells for use with a cell expansion system, in accordance with embodiments of the present disclosure. -
FIG. 9 illustrates an example processing system of a cell expansion system upon which embodiments of the present disclosure may be implemented. -
FIG. 10 depicts data of an example in accordance with an embodiment of the present disclosure. -
FIG. 11 illustrates data of an example in accordance with an embodiment of the present disclosure. -
FIG. 12 depicts data of an example in accordance with an embodiment of the present disclosure. -
FIG. 13 illustrates data of an example in accordance with an embodiment of the present disclosure. - The following Detailed Description provides a discussion of illustrative embodiments with reference to the accompanying drawings. The inclusion of specific embodiments herein should not be construed as limiting or restricting the present disclosure. Further, while language specific to features, acts, and/or structures, for example, may be used in describing embodiments herein, the claims are not limited to the features, acts, and/or structures described. A person of skill in the art will appreciate that other embodiments, including improvements, are within the spirit and scope of the present disclosure. Further, any alternatives or additions, including any listed as separate embodiments, may be used or incorporated with any other embodiments herein described.
- Embodiments of the present disclosure are generally directed to systems and methods for using scheduled media inlet rate increases or scheduled feeds, e.g., intracapillary (IC) inlet rate increases or extracapillary (EC) inlet rate increases, to expand cells in a cell expansion system. In embodiments, such cell expansion system is a closed, automated system. Feed schedules may be used to proactively and automatically increase IC inlet rates regardless of metabolite levels during cell, e.g., MSC, expansions. Scheduled feedings and/or scheduled media exchanges may apply to the expansion of any type of cell. By following the schedules, the taking of regular, e.g., daily, measurements of metabolites to determine whether or not to increase IC inlet rates may be optional or eliminated altogether, according to embodiments. Media usage may also be more predictable in embodiments. According to yet other embodiments, the schedule may provide for maintaining the inlet rate. With scheduled feeding, inlet rates may be increased or maintained without manual manipulation. For example, the inlet rates may increase and then level off or plateau, in which the schedule provides both for the increasing and the maintaining of the rates. In other embodiments, a first schedule provides for the increasing of the inlet rates, and a second schedule provides for the maintaining of the inlet rates at a certain rate. In embodiments, the first schedule is different from the second schedule. Additional schedules, such as third, fourth, fifth, sixth, seventh, etc. schedules may be used according to yet further embodiments.
- Embodiments are directed to a cell expansion system, as noted above. In embodiments, such cell expansion system is closed, in which a closed cell expansion system comprises contents that are not directly exposed to the atmosphere. Such cell expansion system may be automated. In embodiments, cells, of both adherent and non-adherent type, may be grown in a bioreactor in the cell expansion system. According to embodiments, the cell expansion system may include base media or other type of media. Methods for replenishment of media are provided for cell growth occurring in a bioreactor of the closed cell expansion system. In embodiments, the bioreactor used with such systems is a hollow fiber bioreactor. Many types of bioreactors may be used in accordance with embodiments of the present disclosure.
- The system may include, in embodiments, a bioreactor that further includes a first fluid flow path having at least opposing ends, a first opposing end of the first fluid flow path fluidly associated with a first port of a hollow fiber membrane and a second end of the first fluid flow path fluidly associated with a second port of the hollow fiber membrane, in which the first fluid flow path comprises an intracapillary portion of the hollow fiber membrane. In embodiments, a hollow fiber membrane comprises a plurality of hollow fibers. The system may further include a fluid inlet path fluidly associated with the first fluid flow path, in which a plurality of cells are introduced into the first fluid flow path through a first fluid inlet path. A first pump for circulating fluid in the first fluid flow path of the bioreactor may also be included. In embodiments, the system includes a controller for controlling operation of the first pump. In an embodiment, the controller is a computing system, including a processor, for example. The controller is configured, in embodiments, to control the pump to circulate a fluid at a first rate within the first fluid flow path. In some embodiments, a second pump for transferring intracapillary inlet fluid from an intracapillary media bag to the first fluid flow path and a second controller for controlling operation of the second pump are included. The second controller, in embodiments, controls the second pump to transfer cells from a cell inlet bag to the first fluid flow path, for example. Additional controllers, e.g., third controller, fourth controller, fifth controller, sixth controller, etc., may be used in accordance with embodiments. Further, additional pumps, e.g., third pump, fourth pump, fifth pump, sixth pump, etc., may be used in accordance with embodiments of the present disclosure. In addition, while the present disclosure may refer to a media bag, a cell inlet bag, etc., multiple bags, e.g., a first media bag, a second media bag, a third media bag, a first cell inlet bag, a second cell inlet bag, a third cell inlet bag, etc., and/or other types of containers, may be used in embodiments. In other embodiments, a single media bag, a single cell inlet bag, etc., may be used. Further, additional or other fluid paths, e.g., a second fluid flow path, a second fluid inlet path, etc., may be included in embodiments.
- In other embodiments, the system is controlled by, for example: a processor coupled to the cell expansion system; a display device, in communication with the processor, and operable to display data; and a memory, in communication with and readable by the processor, and containing a series of instructions. In embodiments, when the instructions are executed by the processor, the processor receives an instruction to coat the bioreactor, for example. In response to the instruction to coat the bioreactor, the processor may execute a series of steps to coat the bioreactor and may next receive an instruction to load cells into the bioreactor, for example. In response to the instruction to load cells, the processor may execute a series of steps to load the cells from a cell inlet bag, for example, into the bioreactor.
- A schematic of an example cell expansion system (CES) is depicted in
FIG. 1A , in accordance with embodiments of the present disclosure.CES 10 includes firstfluid circulation path 12 and secondfluid circulation path 14. Firstfluid flow path 16 has at least opposing ends 18 and 20 fluidly associated with a hollow fiber cell growth chamber 24 (also referred to herein as a “bioreactor”), according to embodiments. Specifically, opposingend 18 may be fluidly associated with afirst inlet 22 ofcell growth chamber 24, and opposingend 20 may be fluidly associated withfirst outlet 28 ofcell growth chamber 24. Fluid infirst circulation path 12 flows through the interior of hollow fibers 116 (seeFIG. 1B ) of hollow fiber membrane 117 (seeFIG. 1B ) disposed in cell growth chamber 24 (cell growth chambers and hollow fiber membranes are described in more detail infra). Further, first fluidflow control device 30 may be operably connected to firstfluid flow path 16 and may control the flow of fluid infirst circulation path 12. - Second
fluid circulation path 14 includes secondfluid flow path 34,cell growth chamber 24, and a second fluidflow control device 32. The secondfluid flow path 34 has at least opposing ends 36 and 38, according to embodiments. Opposing ends 36 and 38 of secondfluid flow path 34 may be fluidly associated withinlet port 40 andoutlet port 42 respectively ofcell growth chamber 24. Fluid flowing throughcell growth chamber 24 may be in contact with the outside of hollow fiber membrane 117 (seeFIG. 1B ) in thecell growth chamber 24, in which a hollow fiber membrane comprises a plurality of hollow fibers. Secondfluid circulation path 14 may be operably connected to second fluidflow control device 32. - First and second
fluid circulation paths cell growth chamber 24 by a hollow fiber membrane 117 (seeFIG. 1B ). Fluid in firstfluid circulation path 12 flows through the intracapillary (“IC”) space of the hollow fibers in thecell growth chamber 24.First circulation path 12 may be referred to as the “IC loop.” Fluid insecond circulation path 14 flows through the extracapillary (“EC”) space in thecell growth chamber 24. Secondfluid circulation path 14 may be referred to as the “EC loop.” Fluid in firstfluid circulation path 12 may flow in either a co-current or counter-current direction with respect to flow of fluid in secondfluid circulation path 14, according to embodiments. -
Fluid inlet path 44 may be fluidly associated with firstfluid circulation path 12.Fluid inlet path 44 allows fluid into firstfluid circulation path 12, whilefluid outlet path 46 allows fluid to leaveCES 10. Third fluidflow control device 48 may be operably associated withfluid inlet path 44. Alternatively, third fluidflow control device 48 may alternatively be associated withfirst outlet path 46. - Fluid flow control devices as used herein may comprise a pump, valve, clamp, or combination thereof, according to embodiments. Multiple pumps, valves, and clamps can be arranged in any combination. In various embodiments, the fluid flow control device is or includes a peristaltic pump. In embodiments, fluid circulation paths, inlet ports, and outlet ports may be constructed of tubing of any material.
- Various components are referred to herein as “operably associated.” As used herein, “operably associated” refers to components that are linked together in operable fashion and encompasses embodiments in which components are linked directly, as well as embodiments in which additional components are placed between the two linked components. “Operably associated” components can be “fluidly associated.” “Fluidly associated” refers to components that are linked together such that fluid can be transported between them. “Fluidly associated” encompasses embodiments in which additional components are disposed between the two fluidly associated components, as well as components that are directly connected. Fluidly associated components can include components that do not contact fluid, but contact other components to manipulate the system (e.g., a peristaltic pump that pumps fluids through flexible tubing by compressing the exterior of the tube).
- Generally, any kind of fluid, including buffers, protein containing fluid, and cell-containing fluid, for example, can flow through the various circulations paths, inlet paths, and outlet paths. As used herein, “fluid,” “media,” and “fluid media” are used interchangeably.
- Turning to
FIG. 1B , an example of a hollow fibercell growth chamber 100 which may be used with the present disclosure is shown in front side elevation view.Cell growth chamber 100 has a longitudinal axis LA-LA and includes cellgrowth chamber housing 104. In at least one embodiment, cellgrowth chamber housing 104 includes four openings or ports:IC inlet port 108,IC outlet port 120,EC inlet port 128, andEC outlet port 132. - According to embodiments of the present disclosure, fluid in a first circulation path enters
cell growth chamber 100 throughIC inlet port 108 at a firstlongitudinal end 112 of thecell growth chamber 100, passes into and through the intracapillary side (referred to in various embodiments as the intracapillary (“IC”) side or “IC space” of a hollow fiber membrane) of a plurality ofhollow fibers 116 comprisinghollow fiber membrane 117, and out ofcell growth chamber 100 throughIC outlet port 120 located at a secondlongitudinal end 124 of thecell growth chamber 100. The fluid path between theIC inlet port 108 and theIC outlet port 120 defines theIC portion 126 of thecell growth chamber 100. Fluid in a second circulation path flows in thecell growth chamber 100 throughEC inlet port 128, comes in contact with the extracapillary side or outside (referred to as the “EC side” or “EC space” of the membrane) of thehollow fibers 116, and exitscell growth chamber 100 viaEC outlet port 132. The fluid path between theEC inlet port 128 and theEC outlet port 132 comprises theEC portion 136 of thecell growth chamber 100. Fluid enteringcell growth chamber 100 via theEC inlet port 128 may be in contact with the outside of thehollow fibers 116. Small molecules (e.g., ions, water, oxygen, lactate, etc.) may diffuse through thehollow fibers 116 from the interior or IC space of the hollow fiber to the exterior or EC space, or from the EC space to the IC space. Large molecular weight molecules, such as growth factors, are typically too large to pass through the hollow fiber membrane, and may remain in the IC space of thehollow fibers 116. The media may be replaced as needed, in embodiments. Media may also be circulated through an oxygenator or gas transfer module to exchange gasses as needed. Cells may be contained within a first circulation path and/or a second circulation path, as described below, and may be on either the IC side and/or EC side of the membrane, according to embodiments. - The material used to make the
hollow fiber membrane 117 may be any biocompatible polymeric material which is capable of being made into hollow fibers. One material which may be used is a synthetic polysulfone-based material, according to an embodiment of the present disclosure. In order for the cells to adhere to the surface of the hollow fibers, the surface may be modified in some way, either by coating at least the cell growth surface with a protein such as fibronectin or collagen, or by exposing the surface to radiation, according to embodiments. Gamma treating the membrane surface allows for attachment of adherent cells without additionally coating the membrane with fibronectin, cryoprecipitate, or the like. Bioreactors made of gamma treated membranes may be reused. Other coatings and/or treatments for cell attachment may be used in accordance with embodiments of the present disclosure. - In embodiments, the CES (such as CES 500 (see
FIG. 5 ) and/or CES 600 (seeFIG. 6 ), for example) may include a device configured to move or “rock” the cell growth chamber relative to other components of the cell expansion system by attaching it to a rotational and/or lateral rocking device.FIG. 1C shows one such device, in which abioreactor 100 may be rotationally connected to two rotational rocking components and to a lateral rocking component, according to an embodiment. - A first
rotational rocking component 138 rotates thebioreactor 100 aroundcentral axis 142 of thebioreactor 100.Rotational rocking component 138 may be rotationally associated withbioreactor 100. In embodiments,bioreactor 100 may be rotated continuously in a single direction aroundcentral axis 142 in a clockwise or counterclockwise direction. Alternatively,bioreactor 100 may rotate in alternating fashion, first clockwise, then counterclockwise, for example, aroundcentral axis 142, according to embodiments. - The CES may also include a second rotational rocking component that rotates
bioreactor 100 aroundrotational axis 144.Rotational axis 144 may pass through the center point ofbioreactor 100 and may be normal tocentral axis 142.Bioreactor 100 may be rotated continuously in a single direction aroundrotational axis 144 in a clockwise or counterclockwise direction, in embodiments. Alternatively,bioreactor 100 may be rotated aroundrotational axis 144 in an alternating fashion, first clockwise, then counterclockwise, for example. In various embodiments,bioreactor 100 may also be rotated aroundrotational axis 144 and positioned in a horizontal or vertical orientation relative to gravity. - In embodiments,
lateral rocking component 140 may be laterally associated withbioreactor 100. The plane oflateral rocking component 140 moves laterally in the −x and −y directions, in embodiments. The settling of cells in the bioreactor may be reduced by movement of cell-containing media within the hollow fibers, according to embodiments. - The rotational and/or lateral movement of a rocking device may reduce the settling of cells within the device and reduce the likelihood of cells becoming trapped within a portion of the bioreactor. The rate of cells settling in the cell growth chamber is proportional to the density difference between the cells and the suspension media, according to Stoke's Law. In certain embodiments, a 180 degree rotation (fast) with a pause (having a total combined time of 30 seconds, for example) repeated as described above keeps non-adherent red blood cells suspended. A minimum rotation of about 180 degrees would be preferred in an embodiment; however, one could use rotation of up to 360 degrees or greater. Different rocking components may be used separately, or may be combined in any combination. For example, a rocking component that rotates
bioreactor 100 aroundcentral axis 142 may be combined with the rocking component that rotatesbioreactor 100 aroundaxis 144. Likewise, clockwise and counterclockwise rotation around different axes may be performed independently in any combination. - Turning to
FIG. 2 , an embodiment of acell expansion system 200 with a premounted fluid conveyance assembly is shown in accordance with embodiments of the present disclosure. TheCES 200 includes acell expansion machine 202 that comprises a hatch orclosable door 204 for engagement with aback portion 206 of thecell expansion machine 202. Aninterior space 208 within thecell expansion machine 202 includes features adapted for receiving and engaging a premountedfluid conveyance assembly 210. The premountedfluid conveyance assembly 210 is detachably-attachable to thecell expansion machine 202 to facilitate relatively quick exchange of a new or unused premountedfluid conveyance assembly 210 at acell expansion machine 202 for a used premountedfluid conveyance assembly 210 at the samecell expansion machine 202. A singlecell expansion machine 202 may be operated to grow or expand a first set of cells using a first premountedfluid conveyance assembly 210 and, thereafter, may be used to grow or expand a second set of cells using a second premountedfluid conveyance assembly 210 without needing to be sanitized between interchanging the first premountedfluid conveyance assembly 210 for the second premountedfluid conveyance assembly 210. The premountedfluid conveyance assembly 210 includes abioreactor 100 and an oxygenator or gas transfer module 212 (also seeFIG. 4 ). Tubing guide slots are shown as 214 for receiving various media tubing connected to premountedfluid conveyance assembly 210, according to embodiments. - Next,
FIG. 3 illustrates theback portion 206 ofcell expansion machine 202 prior to detachably-attaching a premounted fluid conveyance assembly 210 (FIG. 2 ), in accordance with embodiments of the present disclosure. The closable door 204 (shown inFIG. 2 ) is omitted fromFIG. 3 . Theback portion 206 of thecell expansion machine 202 includes a number of different structures for working in combination with elements of a premountedfluid conveyance assembly 210. More particularly, theback portion 206 of thecell expansion machine 202 includes a plurality of peristaltic pumps for cooperating with pump loops on the premountedfluid conveyance assembly 210, including theIC circulation pump 218, theEC circulation pump 220, theIC inlet pump 222, and theEC inlet pump 224. In addition, theback portion 206 of thecell expansion machine 202 includes a plurality of valves, including theIC circulation valve 226, thereagent valve 228, theIC media valve 230, theair removal valve 232, thecell inlet valve 234, thewash valve 236, thedistribution valve 238, theEC media valve 240, theIC waste valve 242, theEC waste valve 244, and theharvest valve 246. Several sensors are also associated with theback portion 206 of thecell expansion machine 202, including the ICoutlet pressure sensor 248, the combination IC inlet pressure andtemperature sensors 250, the combination EC inlet pressure andtemperature sensors 252, and the ECoutlet pressure sensor 254. Also shown is anoptical sensor 256 for an air removal chamber, according to an embodiment. - In accordance with embodiments, a shaft or
rocker control 258 for rotating thebioreactor 100 is shown. Shaft fitting 260 associated with the shaft orrocker control 258 allows for proper alignment of a shaft access aperture, see e.g., 424 (FIG. 4 ) of a tubing-organizer, see e.g., 300 (FIG. 4 ) of apremounted conveyance assembly back portion 206 of thecell expansion machine 202. Rotation of shaft orrocker control 258 imparts rotational movement to shaft fitting 260 andbioreactor 100. Thus, when an operator or user of theCES 200 attaches a new or unused premounted fluid conveyance assembly 400 (FIG. 4 ) to thecell expansion machine 202, the alignment is a relatively simple matter of properly orienting the shaft access aperture 424 (FIG. 4 ) of the premountedfluid conveyance assembly shaft fitting 260. - Turning to
FIG. 4 , a perspective view of a detachably-attachable premountedfluid conveyance assembly 400 is shown. The premountedfluid conveyance assembly 400 may be detachably-attachable to the cell expansion machine 202 (FIGS. 2 and 3 ) to facilitate relatively quick exchange of a new or unused premountedfluid conveyance assembly 400 at acell expansion machine 202 for a used premountedfluid conveyance assembly 400 at the samecell expansion machine 202. As shown inFIG. 4 , thebioreactor 100 may be attached to a bioreactor coupling that includes ashaft fitting 402. The shaft fitting 402 includes one or more shaft fastening mechanisms, such as a biased arm orspring member 404 for engaging a shaft, e.g., 258 (shown inFIG. 3 ), of thecell expansion machine 202. - According to embodiments, the premounted
fluid conveyance assembly 400 includestubing FIGS. 5 and 6 , as discussed below.Pump loops cell expansion machine 202 is located, the premountedfluid conveyance assembly 400 may include sufficient tubing length to extend to the exterior of thecell expansion machine 202 and to enable welded connections to tubing associated with media bag(s) or container(s), according to embodiments. - Next,
FIG. 5 illustrates a schematic of an embodiment of acell expansion system 500, andFIG. 6 illustrates a schematic of another embodiment of acell expansion system 600. In the embodiments shown inFIGS. 5 and 6 , and as described below, the cells are grown in the IC space. However, the disclosure is not limited to such examples and may in other embodiments provide for cells to be grown in the EC space. -
FIG. 5 illustrates aCES 500, which includes first fluid circulation path 502 (also referred to as the “intracapillary loop” or “IC loop”) and second fluid circulation path 504 (also referred to as the “extracapillary loop” or “EC loop”), according to embodiments. Firstfluid flow path 506 may be fluidly associated withcell growth chamber 501 to form firstfluid circulation path 502. Fluid flows intocell growth chamber 501 throughIC inlet port 501A, through hollow fibers incell growth chamber 501, and exits viaIC outlet port 501B.Pressure gauge 510 measures the pressure of media leavingcell growth chamber 501. Media flows throughIC circulation pump 512 which may be used to control the rate of media flow.IC circulation pump 512 may pump the fluid in a first direction or second direction opposite the first direction.Exit port 501B may be used as an inlet in the reverse direction. Media entering the IC loop may enter throughvalve 514. As those skilled in the art will appreciate, additional valves, pressure gauges, pressure/temperature sensors, ports, and/or other devices may be placed at various locations to isolate and/or measure characteristics of the media along portions of the fluid paths. Accordingly, it is to be understood that the schematic shown represents one possible configuration for various elements of theCES 500, and modifications to the schematic shown are within the scope of the one or more present embodiments. - With regard to the
IC loop 502, samples of media may be obtained fromsample port 516 orsample coil 518 during operation. Pressure/temperature gauge 520 disposed in firstfluid circulation path 502 allows detection of media pressure and temperature during operation. Media then returns toIC inlet port 501A to completefluid circulation path 502. Cells grown/expanded incell growth chamber 501 may be flushed out ofcell growth chamber 501 intoharvest bag 599 throughvalve 598 or redistributed within the hollow fibers for further growth. - Fluid in second
fluid circulation path 504 enterscell growth chamber 501 viaEC inlet port 501C, and leavescell growth chamber 501 viaEC outlet port 501D. Media in theEC loop 504 may be in contact with the outside of the hollow fibers in thecell growth chamber 501, thereby allowing diffusion of small molecules into and out of the hollow fibers. - Pressure/
temperature gauge 524 disposed in the secondfluid circulation path 504 allows the pressure and temperature of media to be measured before the media enters the EC space of thecell growth chamber 501, according to an embodiment.Pressure gauge 526 allows the pressure of media in the secondfluid circulation path 504 to be measured after it leaves thecell growth chamber 501. With regard to the EC loop, samples of media may be obtained fromsample port 530 or a sample coil during operation. - In embodiments, after leaving
EC outlet port 501D ofcell growth chamber 501, fluid in secondfluid circulation path 504 passes throughEC circulation pump 528 to oxygenator orgas transfer module 532.EC circulation pump 528 may also pump the fluid in opposing directions. Secondfluid flow path 522 may be fluidly associated with oxygenator orgas transfer module 532 viaoxygenator inlet port 534 andoxygenator outlet port 536. In operation, fluid media flows into oxygenator orgas transfer module 532 viaoxygenator inlet port 534, and exits oxygenator orgas transfer module 532 viaoxygenator outlet port 536. Oxygenator orgas transfer module 532 adds oxygen to, and removes bubbles from, media in theCES 500, for example. In various embodiments, media in secondfluid circulation path 504 may be in equilibrium with gas entering oxygenator orgas transfer module 532. The oxygenator orgas transfer module 532 may be any appropriately sized oxygenator or gas transfer device. Air or gas flows into oxygenator orgas transfer module 532 viafilter 538 and out of oxygenator orgas transfer device 532 throughfilter 540.Filters gas transfer module 532 and associated media. Air or gas purged from theCES 500 during portions of a priming sequence may vent to the atmosphere via the oxygenator orgas transfer module 532. - In the configuration depicted for
CES 500, fluid media in firstfluid circulation path 502 and secondfluid circulation path 504 flows throughcell growth chamber 501 in the same direction (a co-current configuration). TheCES 500 may also be configured to flow in a counter-current conformation. - In accordance with at least one embodiment, media, including cells (from bag 562), and fluid media from
bag 546 may be introduced to firstfluid circulation path 502 via firstfluid flow path 506. Fluid container 562 (e.g., Cell Inlet Bag or Saline Priming Fluid for priming air out of the system) may be fluidly associated with the firstfluid flow path 506 and the firstfluid circulation path 502 viavalve 564. - Fluid containers, or media bags, 544 (e.g., Reagent) and 546 (e.g., IC Media) may be fluidly associated with either first
fluid inlet path 542 viavalves fluid inlet path 574 viavalves input priming paths first circulation path 502. Theair removal chamber 556 may include one or more ultrasonic sensors including an upper sensor and lower sensor to detect air, a lack of fluid, and/or a gas/fluid interface, e.g., an air/fluid interface, at certain measuring positions within theair removal chamber 556. For example, ultrasonic sensors may be used near the bottom and/or near the top of theair removal chamber 556 to detect air, fluid, and/or an air/fluid interface at these locations. Embodiments provide for the use of numerous other types of sensors without departing from the spirit and scope of the present disclosure. For example, optical sensors may be used in accordance with embodiments of the present disclosure. Air or gas purged from theCES 500 during portions of the priming sequence or other protocols may vent to the atmosphere outair valve 560 vialine 558 that may be fluidly associated withair removal chamber 556. - EC media (e.g., from bag 568) or wash solution (e.g., from bag 566) may be added to either the first or second fluid flow paths.
Fluid container 566 may be fluidly associated withvalve 570 that may be fluidly associated with firstfluid circulation path 502 viadistribution valve 572 and firstfluid inlet path 542. Alternatively,fluid container 566 may be fluidly associated with secondfluid circulation path 504 via secondfluid inlet path 574 andEC inlet path 584 by openingvalve 570 and closingdistribution valve 572. Likewise,fluid container 568 may be fluidly associated withvalve 576 that may be fluidly associated with firstfluid circulation path 502 via firstfluid inlet path 542 anddistribution valve 572. Alternatively,fluid container 568 may be fluidly associated with secondfluid inlet path 574 by openingvalve 576 and closingdistribution valve 572. - An
optional heat exchanger 552 may be provided for media reagent or wash solution introduction. - In the IC loop, fluid may be initially advanced by the
IC inlet pump 554. In the EC loop, fluid may be initially advanced by theEC inlet pump 578. Anair detector 580, such as an ultrasonic sensor, may also be associated with theEC inlet path 584. - In at least one embodiment, first and second
fluid circulation paths line 588. Whenvalve 590 is opened, IC media may flow throughwaste line 588 and to waste oroutlet bag 586. Likewise, whenvalve 582 is opened, EC media may flow throughwaste line 588 to waste oroutlet bag 586. - In embodiments, cells may be harvested via
cell harvest path 596. Here, cells fromcell growth chamber 501 may be harvested by pumping the IC media containing the cells throughcell harvest path 596 andvalve 598 tocell harvest bag 599. - Various components of the
CES 500 may be contained or housed within a machine or housing, such as cell expansion machine 202 (FIGS. 2 and 3 ), wherein the machine maintains cells and media, for example, at a predetermined temperature. - Turning to
FIG. 6 , a schematic of another embodiment of acell expansion system 600 is shown.CES 600 includes a first fluid circulation path 602 (also referred to as the “intracapillary loop” or “IC loop”) and second fluid circulation path 604 (also referred to as the “extracapillary loop” or “EC loop”). Firstfluid flow path 606 may be fluidly associated withcell growth chamber 601 to form firstfluid circulation path 602. Fluid flows intocell growth chamber 601 throughIC inlet port 601A, through hollow fibers incell growth chamber 601, and exits viaIC outlet port 601B.Pressure sensor 610 measures the pressure of media leavingcell growth chamber 601. In addition to pressure,sensor 610 may, in embodiments, also be a temperature sensor that detects the media pressure and temperature during operation. Media flows throughIC circulation pump 612 which may be used to control the rate of media flow.IC circulation pump 612 may pump the fluid in a first direction or second direction opposite the first direction.Exit port 601B may be used as an inlet in the reverse direction. Media entering the IC loop may enter throughvalve 614. As those skilled in the art will appreciate, additional valves, pressure gauges, pressure/temperature sensors, ports, and/or other devices may be placed at various locations to isolate and/or measure characteristics of the media along portions of the fluid paths. Accordingly, it is to be understood that the schematic shown represents one possible configuration for various elements of theCES 600, and modifications to the schematic shown are within the scope of the one or more present embodiments. - With regard to the IC loop, samples of media may be obtained from
sample coil 618 during operation. Media then returns toIC inlet port 601A to completefluid circulation path 602. Cells grown/expanded incell growth chamber 601 may be flushed out ofcell growth chamber 601 intoharvest bag 699 throughvalve 698 andline 697. Alternatively, whenvalve 698 is closed, the cells may be redistributed withinchamber 601 for further growth. - Fluid in second
fluid circulation path 604 enterscell growth chamber 601 viaEC inlet port 601C and leavescell growth chamber 601 viaEC outlet port 601D. Media in the EC loop may be in contact with the outside of the hollow fibers in thecell growth chamber 601, thereby allowing diffusion of small molecules into and out of the hollow fibers that may be withinchamber 601, according to an embodiment. - Pressure/
temperature sensor 624 disposed in the secondfluid circulation path 604 allows the pressure and temperature of media to be measured before the media enters the EC space of thecell growth chamber 601.Sensor 626 allows the pressure and/or temperature of media in the secondfluid circulation path 604 to be measured after it leaves thecell growth chamber 601. With regard to the EC loop, samples of media may be obtained fromsample port 630 or a sample coil during operation. - After leaving
EC outlet port 601D ofcell growth chamber 601, fluid in secondfluid circulation path 604 passes throughEC circulation pump 628 to oxygenator orgas transfer module 632.EC circulation pump 628 may also pump the fluid in opposing directions, according to embodiments. Secondfluid flow path 622 may be fluidly associated with oxygenator orgas transfer module 632 via aninlet port 632A and anoutlet port 632B of oxygenator orgas transfer module 632. In operation, fluid media flows into oxygenator orgas transfer module 632 viainlet port 632A, and exits oxygenator orgas transfer module 632 viaoutlet port 632B. Oxygenator orgas transfer module 632 adds oxygen to, and removes bubbles from, media in theCES 600, for example. In various embodiments, media in secondfluid circulation path 604 may be in equilibrium with gas entering oxygenator orgas transfer module 632. The oxygenator orgas transfer module 632 may be any appropriately sized device useful for oxygenation or gas transfer. Air or gas flows into oxygenator orgas transfer module 632 viafilter 638 and out of oxygenator orgas transfer device 632 throughfilter 640.Filters gas transfer module 632 and associated media. Air or gas purged from theCES 600 during portions of a priming sequence may vent to the atmosphere via the oxygenator orgas transfer module 632. - In the configuration depicted for
CES 600, fluid media in firstfluid circulation path 602 and secondfluid circulation path 604 flows throughcell growth chamber 601 in the same direction (a co-current configuration). TheCES 600 may also be configured to flow in a counter-current conformation, according to embodiments. - In accordance with at least one embodiment, media, including cells (from a source such as a cell container, e.g., a bag) may be attached at
attachment point 662, and fluid media from a media source may be attached atattachment point 646. The cells and media may be introduced into firstfluid circulation path 602 via firstfluid flow path 606.Attachment point 662 may be fluidly associated with the firstfluid flow path 606 viavalve 664, andattachment point 646 may be fluidly associated with the firstfluid flow path 606 viavalve 650. A reagent source may be fluidly connected to point 644 and be associated withfluid inlet path 642 viavalve 648, or secondfluid inlet path 674 viavalves - Air removal chamber (ARC) 656 may be fluidly associated with
first circulation path 602. Theair removal chamber 656 may include one or more sensors including an upper sensor and lower sensor to detect air, a lack of fluid, and/or a gas/fluid interface, e.g., an air/fluid interface, at certain measuring positions within theair removal chamber 656. For example, ultrasonic sensors may be used near the bottom and/or near the top of theair removal chamber 656 to detect air, fluid, and/or an air/fluid interface at these locations. Embodiments provide for the use of numerous other types of sensors without departing from the spirit and scope of the present disclosure. For example, optical sensors may be used in accordance with embodiments of the present disclosure. Air or gas purged from theCES 600 during portions of a priming sequence or other protocol(s) may vent to the atmosphere outair valve 660 vialine 658 that may be fluidly associated withair removal chamber 656. - An EC media source may be attached to EC
media attachment point 668, and a wash solution source may be attached to washsolution attachment point 666, to add EC media and/or wash solution to either the first or second fluid flow path.Attachment point 666 may be fluidly associated withvalve 670 that may be fluidly associated with firstfluid circulation path 602 viavalve 672 and firstfluid inlet path 642. Alternatively,attachment point 666 may be fluidly associated with secondfluid circulation path 604 via secondfluid inlet path 674 and secondfluid flow path 684 by openingvalve 670 and closingvalve 672. Likewise,attachment point 668 may be fluidly associated withvalve 676 that may be fluidly associated with firstfluid circulation path 602 via firstfluid inlet path 642 andvalve 672. Alternatively,fluid container 668 may be fluidly associated with secondfluid inlet path 674 by openingvalve 676 and closingdistribution valve 672. - In the IC loop, fluid may be initially advanced by the
IC inlet pump 654. In the EC loop, fluid may be initially advanced by theEC inlet pump 678. Anair detector 680, such as an ultrasonic sensor, may also be associated with theEC inlet path 684. - In at least one embodiment, first and second
fluid circulation paths line 688. Whenvalve 690 is opened, IC media may flow throughwaste line 688 and to waste oroutlet bag 686. Likewise, whenvalve 692 is opened, EC media may flow to waste oroutlet bag 686. - After cells have been grown in
cell growth chamber 601, they may be harvested viacell harvest path 697. Here, cells fromcell growth chamber 601 may be harvested by pumping the IC media containing the cells throughcell harvest path 697, withvalve 698 open, intocell harvest bag 699. - Various components of the
CES 600 may be contained or housed within a machine or housing, such as cell expansion machine 202 (FIGS. 2 and 3 ), wherein the machine maintains cells and media, for example, at a predetermined temperature. It is further noted that, in embodiments, components ofCES 600 and CES 500 (FIG. 5 ) may be combined. In other embodiments, a CES may include fewer or additional components than those shown inFIGS. 5 and 6 and still be within the scope of the present disclosure. An example of a cell expansion system that may incorporate features of the present disclosure is the Quantum® Cell Expansion System, manufactured by Terumo BCT, Inc. in Lakewood, Colo. - Examples and further description of cell expansion systems are provided in U.S. Pat. No. 8,309,347 (“Cell Expansion System and Methods of Use,” issued on Nov. 13, 2012), which is hereby incorporated by reference herein in its entirety for all that it teaches and for all purposes.
- While various example embodiments of a cell expansion system and methods associated therewith have been described,
FIG. 7A illustrates exampleoperational steps 700 of a process for implementing a scheduled feed that may be used with a cell expansion system, such as CES 500 (FIG. 5 ) or CES 600 (FIG. 6 ), in accordance with embodiments of the present disclosure. In embodiments, such schedule may provide for one or more scheduled media exchange(s).START operation 702 is initiated, andprocess 700 proceeds to load the disposable tubing set 704 onto the cell expansion system. Next, the system may be primed 706. In an embodiment, a user or an operator, for example, may provide an instruction to the system to prime by selecting a task for priming, for example. In an embodiment, such task for priming may be a pre-programmed task.Process 700 then proceeds to coat thebioreactor 708, in which the bioreactor may be coated with a coating agent. For example, in embodiments, a reagent may be loaded into an IC loop until a reagent container is empty. The reagent may be chased from an air removal chamber into the IC loop, and the reagent may then be circulated in the IC loop. Any coating reagent known to those of skill in the art may be used, such as fibronectin or cryoprecipitate, for example. Once the bioreactor is coated, the IC/EC Washout task may be performed 710, in which fluid on the IC circulation loop and on the EC circulation loop is replaced. The replacement volume is determined by the number of IC Volumes and EC Volumes exchanged. - Next, to maintain the proper or desired gas concentration across the fibers in the bioreactor membrane, the
condition media task 712 may be executed to allow the media to reach equilibrium with the provided gas supply before cells are loaded into the bioreactor. For example, rapid contact between the media and the gas supply provided by the gas transfer module or oxygenator is provided by using a high EC circulation rate. The system may then be maintained in a proper or desired state until a user or operator, for example, is ready to load cells into the bioreactor. -
Process 700 next proceeds to loadingcells 714 into the bioreactor from a cell inlet bag, for example. In an embodiment, the cells may be loaded into the bioreactor from the cell inlet bag until the bag is empty. Cells may then be chased from the air removal chamber to the bioreactor. In embodiments that utilize larger chase volumes, cells may be spread and move toward the IC outlet. The distribution of cells may be promoted across the membrane via IC circulation, such as through an IC circulation pump, with no IC inlet, for example. Further, the cells, e.g., adherent cells, may be allowed to attach 716 to the hollow fibers. - Next,
process 700 proceeds to query 718, in which it is determined whether it is desired to follow a scheduled feed. If a scheduled feed is desired, process 700 branches “yes” to query 720 to determine whether a conservative, aggressive, or other type of scheduled feed is desired. Such schedules may be created by a custom task(s) for the cell expansion system, in which a user or an operator enters the desired feeding information and other conditions, such as media exchange(s), for example, according to an embodiment. In another embodiment, the schedule may be selected from a list of pre-programmed, default, or previously saved tasks. In embodiments, the task (e.g., custom, pre-programmed, default, etc.) also may define the bioreactor rotation, in which the bioreactor may be rotated at some point(s) during the attachment and expansion of the cells. For example, the bioreactor may be rotated 180°, or another defined degree of rotation, at a particular time(s) or point(s) in the cell expansion. - Where a conservative feed schedule is desired,
process 700 follows the “conservative” branch to initiate aconservative feed schedule 722. The cells are then fed according to theconservative feed schedule 724, in which the cells may be fed with media. For example, the cells may be fed with complete media, according to an embodiment. Complete media may be any media source used for cell growth. In an embodiment, complete media may comprise alpha-MEM (α-MEM) and fetal bovine serum (FBS), for example. Any type of media known to those of skill in the art may be used. WhileFIG. 7A andprocess 700 refer to a conservative feed schedule atstep 722, for example, embodiments provide for the use of a single or multiple conservative feed schedules. Thus, multiple conservative feed schedules may be initiated and followed for the feeding of the cells atsteps - In an embodiment, a conservative feed schedule, such as the following shown in Table 1, may be used:
-
TABLE 1 Example Conservative Feed Schedule Day Conservative Day 0 (Attach Cells) 0.1 mL/min EC Inlet Day 1 (Feed Cells) 0.1 mL/min IC Inlet Day 2 (Feed Cells) 0.2 mL/min IC Inlet Day 3 (Feed Cells) 0.3 mL/min IC Inlet Day 4 (Feed Cells) 0.5 mL/min IC Inlet Day 5 (Feed Cells) 0.8 mL/min IC Inlet Day 6 (Feed Cells) 1.0 mL/min IC Inlet or Harvest Day 7 (Feed Cells or 1.2 mL/min IC Inlet Harvest) or Harvest Estimated Media 4.4 L Usage (Calculated based on a 7-day expansion starting on Day 0 Attach Cells toDay 7 Harvest) - In embodiments, a range of inlet rates, or inlet flow rates, may be used during a conservative feed schedule. For example, in embodiments such as shown in Table 1, the inlet rates may range from about 0.01 mL/min IC (or EC) inlet to about 10.0 mL/min IC (or EC) inlet, with increases at each consecutive time period or interval, e.g., day or about 24-hour period, about 12-hour period, about 36-hour period, about 48-hour period, etc. In other embodiments, such as those involving a larger volume or growth space for cell expansion, inlet rates may range from about 100 mL/min to about 1,000 mL/min; about 2,000 mL/min; about 3,000 mL/min, etc. In consideration of the volume or growth space for cell expansion, any amounts for scheduled inlet rates, inlet rate increases (or decreases or maintenance amounts), and/or media exchanges may be used in accordance with embodiments of the present disclosure.
- According to embodiments, the inlet rates may increase, for example, at each consecutive time period or interval, e.g., day or about 24-hour period, about 12-hour period, about 36-hour period, about 48-hour period, etc., according to a percentage of the previous time period's rate, e.g., an increase of about 1% to about 100% from the previous time period's rate. For example, the inlet flow rate may be increased by a percentage equal to or greater than about 1%, equal to or greater than about 5%, equal to or greater than about 10%, equal to or greater than about 15%, equal to or greater than about 20%, equal to or greater than about 25%, equal to or greater than about 30%, equal to or greater than about 35%, equal to or greater than about 40%, and equal to or greater than about 50%, of the previous time period's rate. In other embodiments, the inlet flow rate may be increased by a percentage less than or equal to about 55%, less than or equal to about 60%, less than or equal to about 65%, less than or equal to about 70%, less than or equal to about 75%, less than or equal to about 80%, less than or equal to about 85%, less than or equal to about 90%, and less than or equal to about 100%, of the previous time period's rate. In embodiments, the inlet rates may increase by the same or different percentages for particular periods or intervals of time in a linear or non-linear fashion. For example, as indicated in Table 1, a conservative feed schedule may include the doubling, i.e., increasing of the inlet rate by about 100%, of the inlet rate at Day 1 (or other time period) to achieve the inlet rate at Day 2 (or other time period), according to an embodiment. Next, the inlet rates may increase by a smaller percentage, such as about 50%, about 66.6%, about 60%, about 25%, about 20%, respectively, of the previous time period's rate for the remaining days, or time periods, until harvest, according to embodiments. In embodiments, a conservative feed schedule may provide for the increase, decrease, and/or maintenance of flow rates for different periods of time.
- In embodiments, the inlet rates or inlet flow rates may be increased at fractions of a day or other period of time, e.g., after a certain number of hours or minutes has passed. For example, the inlet rates may be increased automatically at 12 hour intervals, 6 hour intervals, 3 hour intervals, 1 hour intervals, 30 minute increments, 15 minute increments, etc. In other embodiments, the inlet rates may be increased at intervals or periods spanning multiple days. For example, the inlet rates may be increased automatically at 1.5 day intervals, 2 day intervals, 3 day intervals, 4 day intervals, etc.
- In an embodiment, the feeding of cells per a conservative feed schedule(s) 724 may proceed according to the example
operational steps 754 depicted inFIG. 7B of a process for implementing a scheduled feed that may be used with a cell expansion system, such as CES 500 (FIG. 5 ) or CES 600 (FIG. 6 ). In embodiments, such scheduled feed may provide for one or more scheduled media exchange(s).Process 754 may be performed as one or more steps in process 700 (FIG. 7A ). For example,process 754 may be performed as part ofsteps FIG. 7A ). As shown inFIG. 7A , a number of steps may precedeprocess 754, in embodiments. In other embodiments, additional, fewer, or different steps than those illustrated in process 700 (FIG. 7A ) may precedeprocess 754. Further, additional, fewer, or different steps may be included inprocess 754 than those shown inFIG. 7B . For example, additional steps may be performed followingstep 766, according to embodiments. - Turning to
FIG. 7B andprocess 754,START operation 756 is initiated, andprocess 754 proceeds to feed the cells at a first inlet rate during a first time period or interval of time according to a schedule, e.g., conservative feed schedule, 758, according to an embodiment. Next, the first inlet rate may be increased, according to a schedule, by a first percentage of the first inlet rate to achieve asecond inlet rate 760.Process 754 then proceeds to feed the cells at the second inlet rate during asecond time period 762 according to a schedule. The second inlet rate may then be increased, according to a schedule, by a second percentage of the second inlet rate to achieve athird inlet rate 764.Process 754 then proceeds with feeding the cells, according to a schedule, at a third inlet rate during athird time period 766.Process 754 then terminates atEND operation 768. Whileprocess 754 depicts a first time period, a second time period, and a third time period, there could be any number of time periods, e.g., a fourth time period, a fifth time period, a sixth time period, a seventh time period, etc., in embodiments. In addition, whileprocess 754 depicts a first inlet rate, a second inlet rate, and a third inlet rate, there could be any number of inlet rates, e.g., a fourth inlet rate, a fifth inlet rate, a sixth inlet rate, a seventh inlet rate, etc., in embodiments. - Returning to
FIG. 7A , the cells are allowed to grow or expand 726 while the conservative feed schedule is followed. The cells are not limited to growing or expanding atstep 726, but, instead, the cells may also expand during the feeding step(s), for example. According to embodiments, glucose and lactate measurements do not need to be monitored, and inlet rates do not need to be manually increased, while the feed schedule is followed. However, in embodiments, data may optionally be collected if it is desired to monitor conditions before, during, or after a feed schedule is initiated, for example. - Returning to query 720, if an aggressive scheduled feed is desired, process 700 branches from
query 720 to “aggressive” to initiate anaggressive feed schedule 728. WhileFIG. 7A andprocess 700 refer to an aggressive feed schedule atstep 728, for example, embodiments provide for the use of a single or multiple aggressive feed schedules. Thus, multiple aggressive feed schedules may be initiated and followed for the feeding of the cells atsteps - The cells may then be fed according to the
aggressive feed schedule 730, in which the cells may be fed with media. For example, the cells may be fed with complete media, according to an embodiment. Complete media may be any media source used for cell growth. In an embodiment, complete media may comprise alpha-MEM (α-MEM) and fetal bovine serum (FBS), for example. Any type of media known to those of skill in the art may be used. - In an embodiment, an aggressive feed schedule, such as the following shown in Table 2, may be used:
-
TABLE 2 Example Aggressive Feed Schedule Day Aggressive Day 0 (Attach Cells) 0.1 mL/min EC Inlet Day 1 (Feed Cells) 0.1 mL/min IC Inlet Day 2 (Feed Cells) 0.2 mL/min IC Inlet Day 3 (Feed Cells) 0.4 mL/min IC Inlet Day 4 (Feed Cells) 0.8 mL/min IC Inlet Day 5 (Feed Cells) 1.2 mL/min IC Inlet Day 6 (Feed Cells) 1.6 mL/min IC Inlet or Harvest Day 7 (Feed Cells or Harvest) 2.0 mL/min IC Inlet or Harvest Estimated Media 6.4 L Usage (Calculated based on a 7-day expansion starting on Day 0 Attach Cells toDay 7 Harvest) - In embodiments, a range of inlet rates, or inlet flow rates, may be used during an aggressive feed schedule. For example, in embodiments such as shown in Table 2, the inlet rates may range from about 0.01 mL/min IC (or EC) inlet to about 12.0 mL/min IC (or EC) inlet, with increases at each consecutive time period or interval, e.g., day or about 24-hour period, about 12-hour period, about 36-hour period, about 48-hour period, etc. In other embodiments, such as those involving a larger volume or growth space for cell expansion, inlet rates may range from about 100 mL/min to about 1,000 mL/min; about 2,000 mL/min; about 3,000 mL/min; about 4,000 mL/min; about 5,000 mL/min, etc. In consideration of the volume or growth space for cell expansion, any amounts for scheduled inlet rates, inlet rate increases (or decreases or maintenance amounts), and/or media exchanges may be used in accordance with embodiments of the present disclosure.
- According to embodiments, the inlet rates may increase, for example, at each consecutive time period or interval, e.g., day or about 24-hour period, about 12-hour period, about 36-hour period, about 48-hour period, etc., according to a percentage of the previous time period's rate, e.g., an increase of about 1% to about 300% of the previous time period's rate. For example, the inlet flow rate may be increased by a percentage of equal to or greater than about 1%, equal to or greater than about 5%, equal to or greater than about 10%, equal to or greater than about 15%, equal to or greater than about 20%, equal to or greater than about 25%, equal to or greater than about 30%, equal to or greater than about 35%, equal to or greater than about 40%, and equal to or greater than about 50%, of the previous time period's rate. In other embodiments, the inlet flow rate may be increased by a percentage of less than or equal to about 55%, less than or equal to about 60%, less than or equal to about 65%, less than or equal to about 70%, less than or equal to about 75%, less than or equal to about 80%, less than or equal to about 85%, less than or equal to about 90%, less than or equal to about 100%, less than or equal to 125%, less than or equal to 150%, less than or equal to 175%, less than or equal to 200%, less than or equal to 225%, less than or equal to 250%, less than or equal to 275%, and less than or equal to 300%, of the previous time period's rate.
- In embodiments, the inlet rates may increase by the same or different percentages for particular periods or intervals of time in a linear or non-linear fashion. For example, as indicated in Table 2, an aggressive feed schedule may provide for the doubling of the inlet rate, i.e., provide for increases in inlet rates of equal to or greater than about 100%, of the previous time period's inlet rate for several consecutive time periods, e.g., days or about 24-hour periods, according to an embodiment. For example, in an embodiment, an aggressive feed schedule may provide for increases in inlet rates of equal to or greater than about 100% of the previous time period's inlet rate for at least two consecutive time periods or intervals of time. For example, the cells may be fed at a first inlet rate during a first time period. During a second time period, the cells may be fed at a second inlet rate, in which the second inlet rate comprises an amount that is equal to or greater than about 100%, for example, of the first inlet rate. Next, the cells may be fed at a third inlet rate during a third time period, in which the third inlet rate comprises an amount that is equal to or greater than about 100%, for example, of the second inlet rate. After such feeding, the inlet rates may increase by a smaller percentage, such as about 50%, about 33.3%, about 25%, respectively, of the previous time period's rate for the remaining days, or time periods, until harvest, according to embodiments. In embodiments, an aggressive feed schedule may provide for the increase and/or the maintenance of flow rates for different periods of time. In further embodiments, a feed schedule, e.g., aggressive, conservative, or other, may provide for a decrease in net flow rate from the previous time period's flow rate.
- In embodiments, the inlet rates or inlet flow rates may be increased at fractions of a day or other period of time, e.g., after a certain number of hours or minutes has passed. For example, the inlet rates may be increased automatically at 12 hour intervals, 6 hour intervals, 3 hour intervals, 1 hour interval, 30 minute increments, 15 minute increments, etc. In other embodiments, the inlet rates may be increased at intervals spanning multiple days. For example, the inlet rates may be increased automatically at about 1.5 day intervals, 2 day intervals, 3 day intervals, 4 day intervals, etc., according to embodiments.
- In an embodiment, the feeding of cells per an aggressive feed schedule(s) 730 may proceed according to the example
operational steps 754 depicted inFIG. 7B of a process for implementing a scheduled feed that may be used with a cell expansion system, such as CES 500 (FIG. 5 ) or CES 600 (FIG. 6 ). In embodiments, such schedule may provide for one or more scheduled media exchange(s).Process 754 may be performed as one or more steps in process 700 (FIG. 7A ). For example,process 754 may be performed as part ofsteps FIG. 7A ). As shown inFIG. 7A , a number of steps may precedeprocess 754, in embodiments. In other embodiments, additional, fewer, or different steps than those illustrated in process 700 (FIG. 7A ) may precedeprocess 754. Further, additional, fewer, or different steps may be included inprocess 754 than those shown inFIG. 7B . For example, additional steps may be performed followingstep 766, according to embodiments. - Turning to
FIG. 7B andprocess 754,START operation 756 is initiated, andprocess 754 proceeds to feed the cells at a first inlet rate during a first time period or interval of time according to a schedule, e.g., aggressive feed schedule, 758, according to an embodiment. Next, the first inlet rate may be increased, according to a schedule, by a first percentage of the first inlet rate to achieve asecond inlet rate 760.Process 754 then proceeds to feed the cells at the second inlet rate during asecond time period 762 according to a schedule. The second inlet rate may then be increased, according to a schedule, by a second percentage of the second inlet rate to achieve athird inlet rate 764.Process 754 then proceeds with feeding the cells, according to a schedule, at a third inlet rate during athird time period 766.Process 754 then terminates atEND operation 768. Whileprocess 754 depicts a first time period, a second time period, and a third time period, there could be any number of time periods, e.g., a fourth time period, a fifth time, period, a sixth time period, a seventh time period, etc., in embodiments. In addition, whileprocess 754 depicts a first inlet rate, a second inlet rate, and a third inlet rate, there could be any number of inlet rates, e.g., a fourth inlet rate, a fifth inlet rate, a sixth inlet rate, a seventh inlet rate, etc., in embodiments. - Returning to process 700, the cells are allowed to grow or expand 726 while the aggressive feed schedule is followed. The cells are not limited to growing or expanding at
step 726, but, instead, the cells may also expand during the feeding step(s), for example. According to embodiments, glucose and lactate measurements do not need to be monitored, and inlet rates do not need to be manually increased, while the feed schedule is followed. However, in embodiments, data may optionally be collected if it is desired to monitor conditions before, during, or after a feed schedule is initiated, for example. - Returning to query 720, if another type of scheduled feed is desired, process 700 branches from
query 720 to “other” to initiate an “other” type offeed schedule 732. For example, such schedule may maintain feeding rates at current levels, according to an embodiment. In another embodiment, such schedule may increase feeding rates in a manner that is neither conservative nor aggressive but, instead, is a combination of the two, for example. For example, an aggressive feed schedule or multiple aggressive feed schedules may be followed for certain periods or intervals of time, while a conservative feed schedule or multiple conservative feed schedules may be followed for other periods or intervals of time, according to embodiments. In other embodiments, a single feed schedule may be followed with such feed schedule being a combination of a conservative feed schedule and an aggressive feed schedule based on the inlet flow rate amounts. In yet other embodiments, other types of feeding schedules may be used. WhileFIG. 7A andprocess 700 refer to an “other” schedule atstep 732, for example, embodiments provide for the use of a single or multiple “other” feed schedules. Thus, multiple “other” feed schedules may be initiated and followed for the feeding of the cells atsteps - Such “other” schedules may be created by a custom task(s) or custom protocol(s) for the cell expansion system, in which a user or operator, for example, may enter the desired feeding information, and other conditions, such as media exchanges, for example, according to an embodiment. In another embodiment, the schedule may be selected from a list of pre-programmed, default, or previously saved tasks. In embodiments, the task (e.g., custom, pre-programmed, default, etc.) may also define the bioreactor rotation, in which the bioreactor may be rotated at some point(s) during the attachment and expansion of the cells. For example, the bioreactor may be rotated 180°, or another defined degree of rotation, at a particular time(s) or point(s) in the cell expansion.
- The cells may then be fed according to the “other” type of
feed schedule 734, in which the cells may be fed with media. For example, the cells may be fed with complete media, according to an embodiment. Complete media may be any media source used for cell growth. In an embodiment, complete media may comprise alpha-MEM (α-MEM) and fetal bovine serum (FBS), for example. Any type of media known to those of skill in the art may be used. In an embodiment, the feeding of cells per an “other” feed schedule(s) 734 may proceed according to the exampleoperational steps 754 depicted inFIG. 7B of a process for implementing a scheduled feed that may be used with a cell expansion system, such as CES 500 (FIG. 5 ) or CES 600 (FIG. 6 ). In embodiments, such scheduled feed may provide for one or more scheduled media exchange(s).Process 754 may be performed as one or more steps in process 700 (FIG. 7A ). For example,process 754 may be performed as part ofsteps FIG. 7A ). As shown inFIG. 7A , a number of steps may precedeprocess 754, in embodiments. In other embodiments, additional, fewer, or different steps than those illustrated in process 700 (FIG. 7A ) may precedeprocess 754. Further, additional, fewer, or different steps may be included inprocess 754 than those shown inFIG. 7B , in embodiments. For example, additional steps may be performed followingstep 766, according to embodiments. - Turning to
FIG. 7B andprocess 754,START operation 756 is initiated, andprocess 754 proceeds to feed the cells at a first inlet rate during a first time period or interval of time according to a schedule, e.g., “other” feed schedule, 758, according to an embodiment. Next, the first inlet rate may be increased, according to a schedule, by a first percentage of the first inlet rate to achieve asecond inlet rate 760.Process 754 then proceeds to feed the cells at the second inlet rate during asecond time period 762 according to a schedule. The second inlet rate may then be increased, according to a schedule, by a second percentage of the second inlet rate to achieve athird inlet rate 764.Process 754 then proceeds with feeding the cells, according to a schedule, at a third inlet rate during athird time period 766.Process 754 then terminates atEND operation 768. Whileprocess 754 depicts a first time period, a second time period, and a third time period, there could be any number of time periods, e.g., a fourth time period, a fifth time, period, a sixth time period, a seventh time period, etc., in embodiments. In addition, whileprocess 754 depicts a first inlet rate, a second inlet rate, and a third inlet rate, there could be any number of inlet rates, e.g., a fourth inlet rate, a fifth inlet rate, a sixth inlet rate, a seventh inlet rate, etc., in embodiments. - Returning to
FIG. 7A , the cells are allowed to grow or expand 726 while the “other” type of feed schedule is followed. According to embodiments, glucose and lactate measurements do not need to be monitored, and inlet rates do not need to be manually increased, while the feed schedule is followed. However, in embodiments, data may optionally be collected if it is desired to monitor conditions before, during, or after a feed schedule is initiated, for example. - Returning to query 718, if it is not desired to follow a scheduled feed,
process 700 proceeds “no” to initiate feedingcells 736, in which the media from a media bag, for example, is added to the cells to feed them. Next, glucose/lactate levels may be measured 738, in which a user or operator, for example, may measure such levels on a regular basis, e.g., daily, to determine any adjustment(s) to make to the feed amounts ofmedia 740 based on the consumption and production of these metabolites. In another embodiment, such glucose/lactate measurements may be taken at random time periods, depending on the user's or operator's preference, for example. In embodiments, such glucose/lactate levels are measured by taking a sample from a sample coil or sample port, such as an EC sample port, of a cell expansion system. In other embodiments, such glucose/lactate levels are measured by taking a sample by splicing the IC loop of a cell expansion system using a sterile tubing welder, for example. The cells may be fed accordingly 740 in amounts that account for the glucose/lactate levels measured atstep 738. For example, the IC inlet rate may be increased two-fold when the glucose value falls below 70 mg/dL, according to an embodiment. The cells are allowed to grow or expand 742. The cells are not limited to growing or expanding atstep 742, but, instead, the cells may also expand during the feeding step(s), for example. Next,query 744 determines whether it is desired to continue the monitoring of the glucose/lactate levels. If it is desired to continue such monitoring to allow for adjustments to the feeding rates,process 700 proceeds “yes” to measure glucose/lactate levels 738, andprocess 700 proceeds again to the feeding of the cells accordingly 740 and the growing/expanding of thecells 742. If it is not desired to continue the monitoring of such glucose/lactate levels,process 700 proceeds “no” fromquery 744. - Following either from “no” at
query 744 or from the growth or expansion of thecells 726, attached cells may be released 746 from the membrane of the bioreactor and suspended in the IC loop, for example. In embodiments, an IC/EC washout task in preparation for adding a reagent to release the cells is performed as part ofoperation 746. For example, IC/EC media may be replaced with a phosphate buffered saline (PBS) to remove protein, calcium (Ca2+), and magnesium (Mg2+) in preparation for adding trypsin, or another chemical-releasing agent, to release any adherent cells. A reagent may be loaded into the system until the reagent bag is empty. The reagent may be chased into the IC loop, and the reagent may be mixed within the IC loop. Following the release of any adherent cells,harvest operation 748 transfers the cells in suspension from the IC circulation loop, for example, including any cells remaining in the bioreactor, to a harvest bag(s) or container(s). Finally, the disposable set is unloaded 750 from the cell expansion system, andprocess 700 then terminates atEND operation 752. - Next,
FIG. 8 illustrates example operational steps 800 of a process for implementing a task(s) or protocol(s) for a scheduled feeding of cells for use with a cell expansion system, such as CES 500 (FIG. 5 ) or CES 600 (FIG. 6 ), in accordance with embodiments of the present disclosure. In embodiments, such scheduled feed may provide for one or more scheduled media exchange(s).START operation 802 is initiated, in which a disposable set may be loaded onto a cell expansion system, the set may be primed, a bioreactor may be coated, IC/EC washout may occur, media may be conditioned, cells may be loaded, and cells may be allowed to attach, for example. Next, process 800 proceeds to query 804 to determine whether it is desired to follow a scheduled feed. If it is desired to follow a scheduled feed, process 800 branches “yes” to query 806 to determine whether a pre-programmed, default, or previously saved task is available for a scheduled feed. If such a task is available, process 800 proceeds “yes” to select, or receive the selection of, the pre-programmed task to initiate scheduledfeeding 808. The cells may then be fed according to the feed schedule defined in the pre-programmed, default, or previously saved task, in which the cells may be fed with media. For example, the cells may be fed with complete media, according to an embodiment. Complete media may be any media source used for cell growth. In an embodiment, complete media may comprise alpha-MEM (α-MEM) and fetal bovine serum (FBS), for example. Any type of media known to those of skill in the art may be used. According to embodiments, glucose and lactate measurements do not need to be monitored, and inlet rates do not need to be manually increased, while a feed schedule is followed. However, in embodiments, data may optionally be collected if it is desired to monitor conditions before, during, or after a feed schedule is initiated, for example. In embodiments, such pre-programmed, default, or previously saved task may include defined inlet rates, media exchanges, etc., and may include a defined stop condition(s). For example, such stop condition may be a time period, such as about 24 hours, 12 hours, 6 hours, 30 minutes, 36 hours, 48 hours, 72 hours, etc., according to embodiments. In an embodiment, the pre-programmed, default, or previously saved task may also define the bioreactor rotation, in which the bioreactor may be rotated at some point(s) during the attachment and expansion of the cells. For example, the bioreactor may be rotated 180°, or another defined degree of rotation, at a particular time(s) or point(s) in the cell expansion. The cells are allowed to grow or expand 810. The cells are not limited to growing or expanding atstep 810, but, instead, the cells may also expand during the feeding step(s), for example. - If a pre-programmed, default, or previously saved task is not available, process 800 branches “no” from
query 806 to create a custom task X for scheduled feeding 812, in which a user or operator, for example, may customize a task(s) to provide for the scheduled feeding of cells. In embodiments, such custom task may include defined inlet rates, media exchanges, etc., and may include a defined stop condition(s). For example, such stop condition may be a time period, such as about 24 hours, 12 hours, 6 hours, 30 minutes, 36 hours, 48 hours, 72 hours, etc., according to embodiments. In an embodiment, the custom task may also define the bioreactor rotation, in which the bioreactor may be rotated at some point(s) during the attachment and expansion of the cells. For example, the bioreactor may be rotated 180°, or another defined degree of rotation, at a particular time(s) or point(s) in the cell expansion. - Next,
query 814 determines whether any other or additional custom tasks are desired. For example, step 812 may provide for creating Custom Task 1 for Day 1 (or other time period) of a scheduled feed, whilestep 814 may determine whether additional tasks, such as Custom Task 2 for Day 2 (or other time period), Custom Task 3 for Day 3 (or other time period), etc., are desired. Each custom task may thus be part of an overall schedule for feeding the cells, according to embodiments, in which each custom task itself provides for a scheduled feeding of the cells for a particular segment or interval of the schedule, e.g., time period (depending on any stop condition(s), for example). In other embodiments, a single custom task comprises multiple steps, or sub-tasks, to provide for each segment of a scheduled feeding, in which each step or sub-task comprises a defined inlet rate(s), stop condition(s), etc. In an embodiment, a custom task is created by modifying a previously defined task, such as a Feed Cells task, and saving the modified Feed Cells task as a new custom task for a scheduled feed. In another embodiment, a custom task may be created with new fields defined for the particular custom task desired. - Returning to query 814, if an additional custom task(s) is desired, process 800 proceeds “yes” to create custom task X for scheduled feeding 812. If no additional custom tasks are desired, process 800 proceeds “no” to select, or receive the selection of, the
custom task X 815. Next, the custom task X for scheduled feeding is initiated 816, in which a first custom task may be initiated and may run until an applicable stop condition is met. The cells may then be fed according to the feed schedule defined in the custom task(s), in which the cells may be fed with media. For example, the cells may be fed with complete media, according to an embodiment. Complete media may be any media source used for cell growth. In an embodiment, complete media may comprise alpha-MEM (α-MEM) and fetal bovine serum (FBS), for example. Any type of media known to those of skill in the art may be used. According to embodiments, glucose and lactate measurements do not need to be monitored, and inlet rates do not need to be manually increased, while a feed schedule is followed. However, in embodiments, data may optionally be collected if it is desired to monitor conditions before, during, or after a feed schedule is initiated, for example. If additional custom tasks are present, such as a second custom task, third custom task, fourth custom task, etc., each successive custom task may start when the immediately prior custom task meets its stop condition. The cells are allowed to grow or expand 810. The cells are not limited to growing or expanding atstep 810, but, instead, the cells may also expand during the feeding step(s), such as during the running of custom task X controlling inlet rates, etc., for example. - Following the growth or expansion of the
cells 810, attached cells may be released 828 from the membrane of the bioreactor and suspended in the IC loop, for example. In embodiments, an IC/EC washout task in preparation for adding a reagent to release the cells is performed as part ofoperation 828. For example, IC/EC media may be replaced with a phosphate buffered saline (PBS) to remove protein, calcium (Ca2+), and magnesium (Mg2+) in preparation for adding trypsin, or another chemical-releasing agent to release any adherent cells. A reagent may be loaded into the system until the reagent bag is empty. The reagent may be chased into the IC loop, and the reagent may be mixed within the IC loop. Following the release of any adherent cells,harvest operation 830 transfers the cells in suspension from the IC circulation loop, including any cells remaining in the bioreactor, to a harvest bag. Finally, the disposable set is unloaded 832 from the cell expansion system, and process 800 then terminates atEND operation 834. - Returning to query 804, if it is not desired to follow a schedule for feeding the cells, process 800 branches “no” to initiate the feeding of
cells 818, in which a default or pre-programmed task for feeding the cells, e.g., “Feed Cells,” may be followed or a user or an operator, for example, may manually enter the inlet rates and other conditions to initiate feeding, according to embodiments. Next, glucose/lactate levels may be measured 820, in which a user or operator, for example, may measure such levels on a regular basis, e.g., daily, to determineadjustments 822, if any, to make to the amounts of media used for feeding the cells based on metabolite consumption and production. In embodiments, no adjustments may be desired, while in other embodiments, increases in inlet rates of media may be made in response to the measured glucose/lactate levels. In another embodiment, such glucose/lactate measurements may be taken at random time periods, depending on the user's or operator's preference, for example. In embodiments, such glucose/lactate levels are measured by taking a sample from a sample coil or sample port, such as an EC sample port, of a cell expansion system. In other embodiments, such glucose/lactate levels may be measured by taking a sample by splicing the IC loop of a cell expansion system using a sterile tubing welder, for example. Where adjustments to the inlet rates are desired, such adjustments may be made, and the cells may be fed accordingly 822 in amounts that account for the glucose/lactate levels measured atstep 820. For example, the IC inlet rate may be increased two-fold when the glucose value falls below 70 mg/dL, according to an embodiment. The cells are allowed to grow or expand 824. The cells are not limited to growing or expanding atstep 824, but, instead, the cells may also expand during the feeding step(s), for example. Next,query 826 determines whether it is desired to continue the monitoring of the glucose/lactate levels. If it is desired to continue such monitoring to allow for adjustments to the feeding rates, process 800 proceeds “yes” to measure glucose/lactate levels 820, and process 800 proceeds again to adjust the feeding of the cells accordingly 822 and the growing/expanding of thecells 824. If it is not desired to continue the monitoring of such glucose/lactate levels, process 800 proceeds “no” fromquery 826. - Next, attached cells may be released 828 from the membrane of the bioreactor and suspended in the IC loop, for example. In embodiments, an IC/EC washout task in preparation for adding a reagent to release the cells is performed as part of
operation 828. For example, IC/EC media may be replaced with a phosphate buffered saline (PBS) to remove protein, calcium (Ca2+), and magnesium (Mg2+) in preparation for adding trypsin, or another chemical-releasing agent, to release any adherent cells. A reagent may be loaded into the system until the reagent bag is empty. The reagent may be chased into the IC loop, and the reagent may be mixed within the IC loop. Following the release of any adherent cells,harvest operation 830 transfers the cells in suspension from the IC circulation loop, including any cells remaining in the bioreactor, to a harvest bag. Finally, the disposable set is unloaded 832 from the cell expansion system, and process 800 then terminates atEND operation 834. - With respect to the processes illustrated in
FIGS. 7A, 7B, and 8 , the operational steps depicted are offered for purposes of illustration and may be rearranged, combined into other steps, used in parallel with other steps, etc., according to embodiments of the present disclosure. Fewer or additional steps may be used in embodiments without departing from the spirit and scope of the present disclosure. Also, steps (and any sub-steps), such as priming, coating a bioreactor, loading cells, for example, may be performed automatically in some embodiments, such as by a processor executing pre-programmed tasks stored in memory, in which such steps are provided merely for illustrative purposes. - Examples and further description of tasks and protocols, including custom tasks and pre-programmed tasks, for use with a cell expansion system are provided in U.S. patent application Ser. No. 13/269,323 (“Configurable Methods and Systems of Growing and Harvesting Cells in a Hollow Fiber Bioreactor System,” filed Oct. 7, 2011) and U.S. patent application Ser. No. 13/269,351 (“Customizable Methods and Systems of Growing and Harvesting Cells in a Hollow Fiber Bioreactor System,” filed Oct. 7, 2011), which are hereby incorporated by reference herein in their entireties for all that they teach and for all purposes.
- Next,
FIG. 9 illustrates example components of acomputing system 900 upon which embodiments of the present disclosure may be implemented.Computing system 900 may be used in embodiments, for example, where a cell expansion system uses a processor to execute tasks, such as custom tasks or pre-programmed tasks performed as part of processes such asprocesses - The
computing system 900 may include auser interface 902, a processing system 904, and/orstorage 906. Theuser interface 902 may include output device(s) 908, and/or input device(s) 910 as understood by a person of skill in the art. Output device(s) 908 may include one or more touch screens, in which the touch screen may comprise a display area for providing one or more application windows. The touch screen may also be aninput device 910 that may receive and/or capture physical touch events from a user or operator, for example. The touch screen may comprise a liquid crystal display (LCD) having a capacitance structure that allows the processing system 904 to deduce the location(s) of touch event(s), as understood by those of skill in the art. The processing system 904 may then map the location of touch events to UI elements rendered in predetermined locations of an application window. The touch screen may also receive touch events through one or more other electronic structures, according to embodiments.Other output devices 908 may include a printer, speaker, etc.Other input devices 910 may include a keyboard, other touch input devices, mouse, voice input device, etc., as understood by a person of skill in the art. - Processing system 904 may include a
processing unit 912 and/or amemory 914, according to embodiments of the present disclosure. Theprocessing unit 912 may be a general purpose processor operable to execute instructions stored inmemory 914.Processing unit 912 may include a single processor or multiple processors, according to embodiments. Further, in embodiments, each processor may be a multi-core processor having one or more cores to read and execute separate instructions. The processors may include general purpose processors, application specific integrated circuits (ASICs), field programmable gate arrays (FPGAs), other integrated circuits, etc., as understood by a person of skill in the art. - The
memory 914 may include any short-term or long-term storage for data and/or processor executable instructions, according to embodiments. Thememory 914 may include, for example, Random Access Memory (RAM), Read-Only Memory (ROM), or Electrically Erasable Programmable Read-Only Memory (EEPROM), as understood by a person of skill in the art. Other storage media may include, for example, CD-ROM, tape, digital versatile disks (DVD) or other optical storage, tape, magnetic disk storage, magnetic tape, other magnetic storage devices, etc., as understood by a person of skill in the art. -
Storage 906 may be any long-term data storage device or component.Storage 906 may include one or more of the systems described in conjunction with thememory 914, according to embodiments. Thestorage 906 may be permanent or removable. In embodiments,storage 906 stores data generated or provided by the processing system 904. - Below are examples of methods or protocols that may be used with a cell expansion system, such as CES 500 (
FIG. 5 ) and/or CES 600 (FIG. 6 ), for example, that implements features of the present disclosure. Such examples provide for scheduled feeds, e.g., IC inlet rate increases according to a schedule, for the expansion of cells. Such examples provide for the expansion of MSCs. Other cell types may be used in other embodiments. - It is noted that the example methods or protocols below are provided for illustrative purposes and are not intended to limit other embodiments, which may include different or additional steps, parameters, or other features. The example methods or protocols, including the steps (and any sub-steps), may be performed automatically in some embodiments, such as by a processor executing pre-programmed tasks stored in memory. In other embodiments, the steps (and any sub-steps) may be performed through the combination of automated and manual execution of operations. In further embodiments, the steps (and any sub-steps) are performed by an operator(s) or user(s) or through other manual means.
- This example relates to the Culture of Human Bone Marrow-Derived Mesenchymal Stem Cells on an Automated Cell Expansion System Using Scheduled IC Inlet Rate Increases. In this example, the protocol of Table 3 is used, and three different seeding densities are examined: 238 cells/cm2 (5 million total load); 476 cells/cm2 (10 million total load); and 952 cells/cm2 (20 million total load). While Table 3 shows an example protocol that may be used with a cell expansion system, such as CES 500 (
FIG. 5 ) or CES 600 (FIG. 6 ), that implements features of the present disclosure, it is noted that the example protocol is provided for illustrative purposes and is not intended to limit other embodiments, which may include different steps, parameters, or other features. The example protocol, including the steps (and any sub-steps) of priming the set, coating the bioreactor, loading cells, for example, may be performed automatically in some embodiments, such as by a processor executing pre-programmed tasks stored in memory. - In this example embodiment, a cell expansion set, or disposable tubing set, is loaded onto a cell expansion system. Next, the cell expansion set is primed. Such priming may occur by selecting a task for priming, in an embodiment. Such task for priming may be a pre-programmed task, for example. In this example, as shown in Table 3 below, the cell expansion system is primed with phosphate buffered saline (PBS). Next, the bioreactor is coated with a coating agent, such as fibronectin or cryoprecipitate in PBS. After coating the bioreactor, an IC/EC Washout task is performed, in which fluid on the IC and EC circulation loops is replaced with complete media, for example. In this example, media comprising alpha-MEM (α-MEM) and fetal bovine serum (FBS) is used. Next, the media is conditioned to maintain a desired gas concentration across the hollow fibers in the bioreactor membrane. Following the conditioning of media, cells are loaded into the bioreactor. For example, as shown in Table 3 below, the cells are loaded with uniform suspension. Next, cells, e.g., adherent cells, are allowed to attach to the hollow fibers. The cells are then fed according to the schedule shown in Table 4 below, “Example Feed Schedule.” See Table 4 below. Table 4 below includes both an “Aggressive” feed schedule and a “Control.” As shown in Table 4, the “Control” provides for measuring metabolite, e.g., glucose, levels and adjusting the IC inlet amount based on such measurements. See Table 4. Returning to the example protocol shown in Table 3, the cells are allowed to grow or expand. Next, an IC/EC Washout is performed. As shown in Table 3 for this example embodiment, IC media is replaced with phosphate buffered saline (PBS) in preparation for adding trypsin to release the cells. The attached cells are then released from a hollow fiber membrane of the bioreactor and suspended in the IC loop. Next, the cells are harvested using complete media. The cell expansion set is then unloaded.
-
TABLE 3 Example Pre-Selected MSC Expansion Protocol Day Task Media −1 Load Cell Expansion Set None Prime Cell Expansion Set PBS Coat Bioreactor FN or CPPT in PBS 0 IC EC Washout IC Inlet: Complete Media EC Inlet: Complete Media Condition Media IC Inlet: None EC Inlet: Complete Media Load Cells With Uniform IC Inlet: Complete Media Suspension EC Inlet: None Attach Cells (at 180°) IC Inlet: None EC Inlet: Complete Media 1 - Harvest Feed Cells (refer to Table 4) IC Inlet: Complete Media EC Inlet: None Harvest Release Adherent Cells IC/EC Washout with PBS then Trypsin Harvest Cells IC Inlet: Complete Media EC Inlet: Complete Media Unload Cell Expansion Set None -
TABLE 4 Example Feed Schedule Day Control Aggressive Day 0 (Attach Cells) 0.1 mL/min EC Inlet 0.1 mL/min EC Inlet Day 1 (Feed Cells) 0.1 mL/min IC Inlet 0.1 mL/min IC Inlet Day 2 (Feed Cells) Double IC Inlet if 0.2 mL/min IC Inlet glucose below 70 mg/dL Day 3 (Feed Cells) Double IC Inlet if 0.4 mL/min IC Inlet glucose below 70 mg/dL Day 4 (Feed Cells) Double IC Inlet if 0.8 mL/min IC Inlet glucose below 70 mg/dL Day 5 (Feed Cells) Double IC Inlet if 1.2 mL/min IC Inlet glucose below 70 mg/dL Day 6 (Feed Cells) Double IC Inlet if 1.6 mL/min IC Inlet or glucose below 70 Harvest mg/dL Day 7 (Feed Cells or Double IC Inlet if 2.0 mL/min IC Inlet or Harvest) glucose below 70 Harvest mg/dL Estimated Media 1.5 L-4.8 L 6.4 L Usage (Calculated based on a 7-day expansion starting on Day 0 Attach Cells toDay 7 Harvest) - Results of following the Example Protocol in Table 3 and the Control Feed and Aggressive Feed Schedule of Table 4 are shown in Table 5 below, according to an embodiment. In Table 5, “Sch. Feed” refers to “Scheduled Feed.”
-
TABLE 5 Results for Control v. Aggressive Feed Schedule 5M Cell Load 10M Cell Load 20M Cell Load Harvest Doubling Doubling Doubling Day Number Times Number Number Times Number Number of Times Number Culture of Cells (dT) of of Cells (dT) of Cells (dT) of Condition Harvested (hours) Doublings Harvested (hours) Doublings Harvested (hours) Doublings Day 5 2.02E+08 26.6 4.3 2.34E+08 33.9 3.5 Control Day 5 2.38E+08 +/− 25.2 +/− 4.6 +/− 3.85E+08 +/− 28.1 +/− 4.3 +/− Sch. Feed 9.45E+06 0.3 0.1 2.81E+07 0.7 0.1 Day 62.03E+08 26.1 5.3 2.59E+08 29.7 4.7 4.07E+08 33.1 4.3 Control Day 6 2.50E+08 24.7 5.6 3.55E+08 +/− 27.1 +/− 5.1 +/− 5.78E+08 +/− 29.7 +/− 4.9 +/− Sch. Feed 3.33E+07 0.7 0.1 3.91E+07 0.6 0.1 Day 7Control 2.19E+08 29.9 5.5 3.72E+08 31.3 5.2 4.45E+08 37.5 4.5 Day 74.11E+08 +/− 25.7 +/− 6.4 +/− 2.84E+08 +/− 33.9 +/− 4.8 +/− 1.66E+08 +/− 55.6 +/− 3.1 +/− Sch. Feed 3.01E+07 0.4 0.1 3.37E+07 1.2 0.1 3.48E+07 5.6 0.4
N=2 for all runs exceptDay 5,Day Cell Load Day 6 Scheduled Feed, where N is the number of machines used per load condition, e.g., number of cells loaded and harvest day, according to embodiments. - Further,
FIG. 10 presents agraphical representation 1000 of the data (see Table 5) for “Doubling Times for a Control Feed versus an Aggressive Feed” based on following the Example Protocol in Table 3 with the parameters of Table 4. The y-axis 1002 ofFIG. 10 displays the doubling time (dT) for cells in hours for theControl Feed 1004 and for theAggressive Feed 1006. Thex-axis 1008 displays the Time in Culture in days for theControl Feed 1004 and for theAggressive Feed 1006. Such results are provided for cell loads of 5 million total load (5 M), 10 million total load (10 M), and 20 million total load (20 M), as indicated on thex-axis 1008. As shown in Table 5 andFIG. 10 , results are provided for the Doubling Times for Control versus Aggressive Feed at 1010 (5 M, 6 Days); 1012 (5 M, 7 Days); 1014 (10 M, 5 Days); 1016 (10 M, 6 Days); 1018 (10 M, 7 Days); 1020 (20 M, 5 Days); 1022 (20 M, 6 Days); and 1024 (20 M, 7 Days). - Next,
FIG. 11 shows agraphical representation 1100 of the data (see Table 5) for “Number of Cells Harvested for a Control Feed versus an Aggressive Feed” based on following the Example Protocol in Table 3 with the parameters of Table 4. The y-axis 1102 ofFIG. 11 displays the Number of Cells Harvested (106) for theControl Feed 1104 and for theAggressive Feed 1106. Thex-axis 1108 displays the Time in Culture in days for theControl Feed 1104 and for theAggressive Feed 1106. Such results are provided for cell loads of 5 million total load (5 M), 10 million total load (10 M), and 20 million total load (20 M), as indicated on thex-axis 1108. As shown in Table 5 andFIG. 11 , results are provided for the Number of Cells Harvested for Control versus Aggressive Feed at 1110 (5 M, 6 Days); 1112 (5 M, 7 Days); 1114 (10 M, 5 Days); 1116 (10 M, 6 Days); 1118 (10 M, 7 Days); 1120 (20 M, 5 Days); 1122 (20 M, 6 Days); and 1124 (20 M, 7 Days). - As shown in Table 5 and
FIGS. 10 and 11 , implementing the aggressive feed schedule of Table 4 during a bone marrow-derived MSC expansion may result in higher cell harvest yield in some instances, according to an embodiment. As shown, the aggressive feed schedule may result in some instances in about a 20% increase in cell yield as compared to the control feed method, except for the 10 M and 20 M loads expanded for seven (7) days, according to an embodiment. The lower cell yields for the aggressive feed schedule as compared to the control feed method at 1118 (10 M, 7 Days) and 1124 (20 M, 7 Days) may be due to over-confluence. Media usage may also be more predictable. Flow cytometry results for the control and aggressive feed schedules indicate that the cells may maintain MSC phenotype (data not shown). In an embodiment, little or no aggregation may be observed in the harvest products with high viability (>97%). Morphological characterization of MSC may also be observed on representative harvest products, according to an embodiment. - This example relates to the Culture of Human Bone Marrow-Derived Mesenchymal Stem Cells on an Automated Cell Expansion System Using Scheduled IC Inlet Rate Increases. In this example, the protocol of Table 6 is used, and three different seeding densities are examined: 238 cells/cm2 (5 million total load), 476 cells/cm2 (10 million total load), and 952 cells/cm2 (20 million total load). While Table 6 shows an example protocol that may be used with a cell expansion system, such as CES 500 (
FIG. 5 ) or CES 600 (FIG. 6 ), that implements features of this disclosure, it is noted that the example protocol is provided for illustrative purposes and is not intended to limit other embodiments, which may include different steps, parameters, or other features. The example protocol, including the steps (and any sub-steps) of priming the set, coating the bioreactor, loading cells, for example, may be performed automatically in some embodiments, such as by a processor executing pre-programmed tasks stored in memory. - In this example embodiment, a cell expansion set, or disposable tubing set, is loaded onto a cell expansion system. Next, the cell expansion set is primed. Such priming may occur by selecting a task for priming. Such task for priming may be a pre-programmed task, for example. In this example, as shown in Table 6 below, the cell expansion system is primed with phosphate buffered saline (PBS). Next, the bioreactor is coated with a coating agent, such as fibronectin or cryoprecipitate in PBS. After coating the bioreactor, an IC/EC Washout task is performed, in which fluid on the IC and EC circulation loops is replaced with complete media, for example. Next, the media is conditioned to maintain a desired gas concentration across the hollow fibers in the bioreactor membrane. Following the conditioning of media, cells are loaded into the bioreactor. For example, as shown in Table 6 below, the cells are loaded with uniform suspension. Next, cells, e.g., adherent cells, are allowed to attach to the hollow fibers. The cells are then fed according to the schedule shown in Table 7 below, “Example Feed Schedule.” See Table 7 below. Table 7 below includes both a “Conservative” feed schedule and a “Control.” As shown in Table 7, the “Control” provides for measuring metabolite, e.g., glucose, levels and adjusting the IC inlet amount based on such measurements. See Table 7 below. Returning to the example protocol shown in Table 6, the cells are allowed to grow or expand. Next, an IC/EC Washout is performed. As shown in Table 6 for this example embodiment, IC media is replaced with PBS in preparation for adding trypsin to release the cells. The attached cells are then released from a hollow fiber membrane of the bioreactor and suspended in the IC loop, for example. Next, the cells are harvested using complete media. The cell expansion set is then unloaded.
-
TABLE 6 Example Pre-Selected MSC Expansion Protocol Day Task Media −1 Load Cell Expansion Set None Prime Cell Expansion Set PBS Coat Bioreactor FN or CPPT in PBS 0 IC EC Washout IC Inlet: Complete Media EC Inlet: Complete Media Condition Media IC Inlet: None EC Inlet: Complete Media Load Cells With Uniform IC Inlet: Complete Media Suspension EC Inlet: None Attach Cells (at 180°) IC Inlet: None EC Inlet: Complete Media 1 - Harvest Feed Cells (refer to Table 2) IC Inlet: Complete Media EC Inlet: None Harvest Release Adherent Cells IC/EC Washout with PBS then Trypsin Harvest Cells IC Inlet: Complete Media EC Inlet: Complete Media Unload Cell Expansion Set None -
TABLE 7 Example Feed Schedule Day Control Conservative Day 0 (Attach Cells) 0.1 mL/min EC Inlet 0.1 mL/min EC Inlet Day 1 (Feed Cells) 0.1 mL/min IC Inlet 0.1 mL/min IC Inlet Day 2 (Feed Cells) Double IC Inlet if 0.2 mL/min IC Inlet glucose below 70 mg/dL Day 3 (Feed Cells) Double IC Inlet if 0.3 mL/min IC Inlet glucose below 70 mg/dL Day 4 (Feed Cells) Double IC Inlet if 0.5 mL/min IC Inlet glucose below 70 mg/dL Day 5 (Feed Cells) Double IC Inlet if 0.8 mL/min IC Inlet glucose below 70 mg/dL Day 6 (Feed Cells) Double IC Inlet if 1.0 mL/min IC Inlet glucose below 70 or Harvest mg/dL Day 7 (Feed Cells or Double IC Inlet if 1.2 mL/min IC Inlet Harvest) glucose below 70 or Harvest mg/dL Estimated Media 1.5 L-4.8 L 4.4 L Usage (Calculated based on a 7-day expansion starting on Day 0 Attach Cells toDay 7 Harvest) - Results of following the Example Protocol in Table 6 and the Control Feed and Conservative Feed Schedule of Table 7 are shown in Table 8 below, according to an embodiment. In Table 8, “Sch. Feed” refers to “Scheduled Feed.”
-
TABLE 8 Results for Control v. Conservative Feed Schedule 5M Cell Load 10M Cell Load 20M Cell Load Harvest Doubling Doubling Doubling Day Number Times Number Number Times Number Number of Times Number Culture of Cells (dT) of of Cells (dT) of Cells (dT) of Condition Harvested (hours) Doublings Harvested (hours) Doublings Harvested (hours) Doublings Day 6 2.42E+08 31.3 4.6 Control Day 6 2.15E+08 +/− 32.6 +/− 4.4 +/− Sch. Feed 2.01E+07 1.0 0.1 Day 72.76E+08 29.0 5.8 3.93E+08 38.5 4.3 Control Day 7 2.75E+08 +/− 29.1 +/− 5.8 +/− 3.90E+08 +/− 38.7 +/− 4.3 +/− Sch. Feed 7.28E+06 0.2 0.0 3.50E+07 1.1 0.1 Day 84.07E+08 26.5 6.3 Control Day 8 4.20E+08 +/− 26.3 +/− 6.4 +/− Sch. Feed 3.97E+07 0.6 0.1
N=1 for all control runs and N=2 for all scheduled feed runs where N is the number of machines used per load condition, e.g., number of cells loaded and harvest day, according to embodiments. - Further,
FIG. 12 presents agraphical representation 1200 of the data (see Table 8) for “Doubling Times for a Control Feed versus a Conservative Feed” based on following the Example Protocol in Table 6 with the parameters of Table 7. The y-axis 1202 ofFIG. 12 displays the doubling time (dT) for cells in hours for theControl Feed 1204 and for theConservative Feed 1206. Thex-axis 1208 displays the Time in Culture in days for theControl Feed 1204 and for theConservative Feed 1206. Such results are provided for cell loads of 5 million total load (5 M), 10 million total load (10 M), and 20 million total load (20 M), as indicated on thex-axis 1208. As shown in Table 8 andFIG. 12 , results are provided for the Doubling Times for Control versus Conservative Feed at 1210 (5 M, 7 Days); 1212 (5 M, 8 Days); 1214 (10 M, 6 Days); and 1216 (20 M, 7 Days). - Next,
FIG. 13 presents agraphical representation 1300 of the data (see Table 8) for “Number of Cells Harvested for Control versus Conservative Feed” based on following the Example Protocol in Table 6 with the parameters of Table 7. The y-axis 1302 ofFIG. 13 displays the Number of Cells Harvested (106) for theControl Feed 1304 and for theConservative Feed 1306. Thex-axis 1308 displays the Time in Culture in days for theControl Feed 1304 and for theConservative Feed 1306. Such results are provided for cell loads of 5 million total load (5 M), 10 million total load (10 M), and 20 million total load (20 M), as indicated on thex-axis 1308. As shown in Table 8 andFIG. 13 , results are provided for the Number of Cells Harvested for Control versus Conservative Feed at 1310 (5 M, 7 Days); 1312 (5 M, 8 Days); 1314 (10 M, 6 Days); and 1316 (20 M, 7 Days). - As shown in Table 8 and
FIGS. 12 and 13 , implementing the conservative feed schedule of Table 7 during a bone marrow-derived MSC expansion may result in a comparable cell harvest yield in some instances, according to an embodiment. As shown above, the conservative feed schedule may yield somewhat similar harvest numbers as the control feed in some instances but without the need for daily monitoring, in an embodiment. Media usage may also be more predictable. Flow cytometry results for the control and conservative feed schedules indicate that the cells may maintain MSC phenotype (data not shown). In an embodiment, little or no aggregation may be observed in the harvest products with high viability (>97%). Morphological characterization of MSC may also be observed on representative harvest products, according to an embodiment. - Further, in comparing Examples 1 and 2, the data for Example 2 in Table 8 may show the use of less media than the amount of media used in the aggressive feed schedule of Example 1.
- It will be apparent to those skilled in the art that various modifications may be made to the apparatus, systems, structure, methods, and protocols described herein. Thus, it should be understood that the embodiments are not limited to the specific examples given. Various modifications, changes, and variations apparent to those skilled in the art may be made in the arrangement, operation, and details of the methods and systems of the present disclosure without departing from the scope of the invention.
Claims (23)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/865,222 US20160090569A1 (en) | 2014-09-26 | 2015-09-25 | Scheduled Feed |
US16/941,057 US11667881B2 (en) | 2014-09-26 | 2020-07-28 | Scheduled feed |
US18/300,427 US20230250387A1 (en) | 2014-09-26 | 2023-04-14 | Scheduled Feed |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462055986P | 2014-09-26 | 2014-09-26 | |
US14/865,222 US20160090569A1 (en) | 2014-09-26 | 2015-09-25 | Scheduled Feed |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/941,057 Division US11667881B2 (en) | 2014-09-26 | 2020-07-28 | Scheduled feed |
Publications (1)
Publication Number | Publication Date |
---|---|
US20160090569A1 true US20160090569A1 (en) | 2016-03-31 |
Family
ID=54291649
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/865,222 Abandoned US20160090569A1 (en) | 2014-09-26 | 2015-09-25 | Scheduled Feed |
US16/941,057 Active 2036-09-18 US11667881B2 (en) | 2014-09-26 | 2020-07-28 | Scheduled feed |
US18/300,427 Pending US20230250387A1 (en) | 2014-09-26 | 2023-04-14 | Scheduled Feed |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/941,057 Active 2036-09-18 US11667881B2 (en) | 2014-09-26 | 2020-07-28 | Scheduled feed |
US18/300,427 Pending US20230250387A1 (en) | 2014-09-26 | 2023-04-14 | Scheduled Feed |
Country Status (5)
Country | Link |
---|---|
US (3) | US20160090569A1 (en) |
EP (1) | EP3198006B1 (en) |
JP (1) | JP6830059B2 (en) |
CN (1) | CN106715676A (en) |
WO (1) | WO2016049421A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170349869A1 (en) * | 2016-06-07 | 2017-12-07 | Terumo Bct, Inc. | Methods and Systems for Coating a Cell Growth Surface |
CN109153954A (en) * | 2016-05-05 | 2019-01-04 | 泰尔茂比司特公司 | Automated production and collection |
US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120086657A1 (en) * | 2010-10-08 | 2012-04-12 | Caridianbct, Inc. | Configurable Methods and Systems of Growing and Harvesting Cells in a Hollow Fiber Bioreactor System |
US8309347B2 (en) * | 2007-03-05 | 2012-11-13 | Terumo Bct, Inc. | Cell expansion system and methods of use |
US20120308531A1 (en) * | 2011-06-06 | 2012-12-06 | ReGenesys BVBA | Expansion of Stem Cells in Hollow Fiber Bioreactors |
US20130244322A1 (en) * | 2012-03-15 | 2013-09-19 | Cellprothera | Automated apparatus and method of cell culture |
Family Cites Families (1086)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3013435A (en) | 1959-04-06 | 1961-12-19 | Microchemical Specialties Co | Buret |
US2997077A (en) | 1959-04-06 | 1961-08-22 | Microchemical Specialties Co | Fraction collector |
US3067915A (en) | 1960-05-23 | 1962-12-11 | Microchemical Specialties Co | Liquid dispensing devices |
US3191807A (en) | 1961-11-13 | 1965-06-29 | Microchemical Specialties Co | Dispenser adapted for ultra-micro range |
US3283727A (en) | 1964-11-02 | 1966-11-08 | Microchemical Specialties Co | Liquid dispenser with automatic air purge |
FR2035725A5 (en) | 1969-02-26 | 1970-12-18 | Nunc As | |
BE793952A (en) | 1972-01-14 | 1973-05-02 | Nunc As | PROCESS FOR IMPROVING THE SURFACE PROPERTIES OF AN ARTICLE SHAPED FROM A PLASTIC MATERIAL |
US3821087A (en) | 1972-05-18 | 1974-06-28 | Dedrick R | Cell culture on semi-permeable tubular membranes |
US3896061A (en) | 1972-08-16 | 1975-07-22 | Toray Industries | Semi-permeable membranes, their preparation and their use |
US4173415A (en) | 1976-08-20 | 1979-11-06 | Science Spectrum, Inc. | Apparatus and process for rapidly characterizing and differentiating large organic cells |
DE2848529A1 (en) | 1978-11-09 | 1980-05-29 | Behringwerke Ag | METHOD FOR PRODUCING THE REFRIGERABLE GLOBULIN AND MEDICINAL PRODUCTS CONTAINING IT |
JPS5642584A (en) | 1979-09-18 | 1981-04-20 | Asahi Chem Ind Co Ltd | Cell cultivation method |
US4301118A (en) | 1980-03-06 | 1981-11-17 | Spectrum Medical Industries, Inc. | Protein concentrator |
US4301010A (en) | 1980-03-10 | 1981-11-17 | Spectrum Medical Industries, Inc. | Vacuum filter |
JPS5714640A (en) | 1980-07-02 | 1982-01-25 | Toray Ind Inc | Separating membrane of methyl methacrylate type |
US4486188A (en) | 1980-08-14 | 1984-12-04 | Applied Medical Devices, Inc. | Bone marrow transplant method and apparatus |
US4440853A (en) | 1980-08-21 | 1984-04-03 | Board Of Trustees Of The Leland Stanford Junior University | Microbiological methods using hollow fiber membrane reactor |
US4418691A (en) | 1981-10-26 | 1983-12-06 | Massachusetts Institute Of Technology | Method of promoting the regeneration of tissue at a wound |
US4629686A (en) | 1982-02-19 | 1986-12-16 | Endotronics, Inc. | Apparatus for delivering a controlled dosage of a chemical substance |
JPH0751511B2 (en) | 1982-03-15 | 1995-06-05 | 味の素株式会社 | Cancer therapeutic agent containing interleukin-2 |
US4412990A (en) | 1982-07-02 | 1983-11-01 | Cutter Laboratories, Inc. | Composition having enhanced opsonic activity |
US4439901A (en) | 1983-03-28 | 1984-04-03 | Spectrum Medical Industries, Inc. | Clamp |
US4618586A (en) | 1983-04-08 | 1986-10-21 | Endotronics, Inc. | Apparatus for administering a controlled dosage of a chemical substance having an improved culture chamber |
US4478829A (en) | 1983-04-28 | 1984-10-23 | Armour Pharmaceutical Company | Pharmaceutical preparation containing purified fibronectin |
US4585654A (en) | 1983-04-29 | 1986-04-29 | Armour Pharmaceutical Co. | Process for pasteurizing fibronectin |
US4509695A (en) | 1983-07-18 | 1985-04-09 | Spectrum Medical Industries, Inc. | Tissue pulverizer |
US4650766A (en) | 1984-10-09 | 1987-03-17 | Endotronics, Inc. | Culturing apparatus |
US4804628A (en) | 1984-10-09 | 1989-02-14 | Endotronics, Inc. | Hollow fiber cell culture device and method of operation |
JPS62500356A (en) | 1984-10-09 | 1987-02-19 | エンドトロニツクス インコ−ポレ−テツド | Hollow fiber culture device and operating method with improved nutrient perfusion and product concentration |
AT385658B (en) | 1985-03-28 | 1988-05-10 | Serotherapeutisches Inst Wien | METHOD FOR PRODUCING A FIBRONEKTIN SOLUTION SUITABLE FOR HUMAN USE |
JPS61257181A (en) | 1985-05-09 | 1986-11-14 | Teijin Ltd | Culture of animal cell |
US4647539A (en) | 1985-05-24 | 1987-03-03 | Endotronics, Inc. | Method and apparatus for growing cells in vitro |
EP0220650A3 (en) | 1985-10-21 | 1988-08-24 | Endotronics Inc. | Method and device for culturing cells |
US4722902A (en) | 1985-11-04 | 1988-02-02 | Endotronics, Inc. | Apparatus and method for culturing cells, removing waste and concentrating product |
US4897358A (en) | 1985-12-02 | 1990-01-30 | Carrasco Jose I | Tissue storage system |
US5902741A (en) | 1986-04-18 | 1999-05-11 | Advanced Tissue Sciences, Inc. | Three-dimensional cartilage cultures |
US5863531A (en) | 1986-04-18 | 1999-01-26 | Advanced Tissue Sciences, Inc. | In vitro preparation of tubular tissue structures by stromal cell culture on a three-dimensional framework |
JP2529321B2 (en) | 1986-04-28 | 1996-08-28 | エンドトロニックス インコーポレーテッド | How to culture white blood cells |
US4889812A (en) | 1986-05-12 | 1989-12-26 | C. D. Medical, Inc. | Bioreactor apparatus |
US4894342A (en) | 1986-05-12 | 1990-01-16 | C. D. Medical, Inc. | Bioreactor system |
US4918019A (en) | 1986-05-12 | 1990-04-17 | C. D. Medical, Incorporated | Bioreactor system with plasticizer removal |
WO1988001643A1 (en) | 1986-08-29 | 1988-03-10 | Endotronics, Inc. | Method of culturing cells |
US5593580A (en) | 1986-11-26 | 1997-01-14 | Kopf; Henry B. | Filtration cassette article, and filter comprising same |
US5868930A (en) | 1986-11-26 | 1999-02-09 | Kopf; Henry B. | Filtration cassette article and filter comprising same |
US4885087A (en) | 1986-11-26 | 1989-12-05 | Kopf Henry B | Apparatus for mass transfer involving biological/pharmaceutical media |
US6022742A (en) | 1986-11-26 | 2000-02-08 | Kopf; Henry B. | Culture device and method |
US5744347A (en) | 1987-01-16 | 1998-04-28 | Ohio University Edison Biotechnology Institute | Yolk sac stem cells and their uses |
US5476922A (en) | 1987-06-24 | 1995-12-19 | Arch Development Corporation | Methods and compositions for the preparation and use of autocrine growth factors |
KR890005273A (en) | 1987-09-09 | 1989-05-13 | 이정오 | Continuous production method of citric acid by double tube reactor |
US5192553A (en) | 1987-11-12 | 1993-03-09 | Biocyte Corporation | Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use |
US5158881A (en) | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
US5156844A (en) | 1987-11-17 | 1992-10-20 | Brown University Research Foundation | Neurological therapy system |
US5015585A (en) | 1988-02-23 | 1991-05-14 | Robinson James R | Method and apparatus for culturing and diffusively oxygenating cells on isotropic membranes |
US4828706A (en) | 1988-03-07 | 1989-05-09 | Spectrum Medical Industries | Process for performing a dialysis operation |
US5258494A (en) | 1988-04-08 | 1993-11-02 | Stryker Corporation | Osteogenic proteins |
EP1225225A3 (en) | 1988-04-08 | 2003-01-08 | Stryker Corporation | Osteogenic devices |
US5081035A (en) | 1988-04-18 | 1992-01-14 | The University Of Michigan | Bioreactor system |
US4973558A (en) | 1988-04-28 | 1990-11-27 | Endotronics, Inc. | Method of culturing cells using highly gas saturated media |
US5595909A (en) | 1988-05-23 | 1997-01-21 | Regents Of The University Of Minnesota | Filter device |
US5605835A (en) | 1988-05-23 | 1997-02-25 | Regents Of The University Of Minnesota | Bioreactor device with application as a bioartificial liver |
US5130141A (en) | 1988-05-24 | 1992-07-14 | Law Peter K | Compositions for and methods of treating muscle degeneration and weakness |
US4988623A (en) | 1988-06-30 | 1991-01-29 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Rotating bio-reactor cell culture apparatus |
US5240861A (en) | 1988-07-29 | 1993-08-31 | Spectrum Medical Industries, Inc. | Device and process for concentrating biologic specimens in liquid form |
US5079168A (en) | 1988-08-10 | 1992-01-07 | Endotronics, Inc. | Cell culture apparatus |
US5416022A (en) | 1988-08-10 | 1995-05-16 | Cellex Biosciences, Inc. | Cell culture apparatus |
WO1990002171A1 (en) | 1988-08-31 | 1990-03-08 | Cellco Advanced Bioreactors, Inc. | In vitro cell culture reactor |
JPH0347074A (en) | 1989-07-14 | 1991-02-28 | Hitachi Ltd | Method and device for culturing animal cell with lactic acid as indicator |
US5162225A (en) | 1989-03-17 | 1992-11-10 | The Dow Chemical Company | Growth of cells in hollow fibers in an agitated vessel |
JPH066053B2 (en) | 1989-03-17 | 1994-01-26 | タバイエスペック株式会社 | Cell culture device |
ATE92107T1 (en) | 1989-04-29 | 1993-08-15 | Delta Biotechnology Ltd | N-TERMINAL FRAGMENTS OF HUMAN SERUM ALBUMIN-CONTAINING FUSION PROTEINS. |
IL94611A (en) | 1989-06-05 | 1994-12-29 | Organogenesis Inc | Cell culture medium containing insulin or an insulin-like growth factor, transferrin or ferrous ion and triiodothyronine or thyroxin and a method for its use |
USH1509H (en) | 1989-06-09 | 1995-12-05 | Eran; Harutyun | Heparin enhanced process for separating antihemophilic factor (Factor VIII) and fibronectin from cryoprecipitate |
US5635386A (en) | 1989-06-15 | 1997-06-03 | The Regents Of The University Of Michigan | Methods for regulating the specific lineages of cells produced in a human hematopoietic cell culture |
US5437994A (en) | 1989-06-15 | 1995-08-01 | Regents Of The University Of Michigan | Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells |
US5763266A (en) | 1989-06-15 | 1998-06-09 | The Regents Of The University Of Michigan | Methods, compositions and devices for maintaining and growing human stem and/or hematopoietics cells |
US5605822A (en) | 1989-06-15 | 1997-02-25 | The Regents Of The University Of Michigan | Methods, compositions and devices for growing human hematopoietic cells |
US5399493A (en) | 1989-06-15 | 1995-03-21 | The Regents Of The University Of Michigan | Methods and compositions for the optimization of human hematopoietic progenitor cell cultures |
US4960521A (en) | 1989-06-16 | 1990-10-02 | Andreas Keller | Process for performing a dialysis operation using a magnetic weighted clamp |
CA1340565C (en) | 1989-06-29 | 1999-05-25 | Thomas B. Okarma | Device and process for cell capture and recovery |
EP0455757B1 (en) | 1989-08-04 | 1999-03-31 | GRANDICS, Peter | An integrated cell culture-protein purification system for the automated production and purification of cell culture products |
US5112745A (en) | 1989-09-29 | 1992-05-12 | Space Medical Systems, Inc. | Rapid identification of microbial organisms and determination of antibiotic sensitivity by infrared spectroscopy |
US5510257A (en) | 1989-10-04 | 1996-04-23 | Sirkar; Kamalesh K. | Hollow fiber immobilization with chopped microporous hollow fibers |
US6248319B1 (en) | 1989-10-16 | 2001-06-19 | Krisztina M. Zsebo | Method for increasing hematopoietic progenitor cells by stem cell factor polypeptides |
CA2072149A1 (en) | 1989-10-30 | 1991-05-01 | James E. Bailey | Enhancement of cell growth by expression of a cloned hemoglobin gene |
US5019054A (en) | 1989-11-06 | 1991-05-28 | Mectra Labs, Inc. | Medical device valving mechanism |
AU7787191A (en) | 1989-11-09 | 1991-06-13 | Bio-Metric Systems, Inc. | Improved bioreactor surfaces and methods of making same |
US5149544A (en) | 1989-11-13 | 1992-09-22 | Research Corporation Technologies, Inc. | Method of inhibiting progenitor cell proliferation |
US5215895A (en) | 1989-11-22 | 1993-06-01 | Genetics Institute, Inc. | Dna encoding a mammalian cytokine, interleukin-11 |
NO168721C (en) | 1989-12-20 | 1992-03-25 | Steinar Risa | APPLIANCES FOR AUTOMATIC SETTING OF BROWY STICKERS O.L. |
US5169930A (en) | 1990-01-05 | 1992-12-08 | La Jolla Cancer Research Foundation | Fibronectin receptor |
US5834312A (en) | 1990-01-29 | 1998-11-10 | Hy-Gene, Inc. | Process and media for the growth of human epithelia |
US5126238A (en) | 1990-02-15 | 1992-06-30 | Unisyn Fibertec Corporation | Hollow fiber cell propagation system and method |
US5656421A (en) | 1990-02-15 | 1997-08-12 | Unisyn Technologies, Inc. | Multi-bioreactor hollow fiber cell propagation system and method |
DE4007703A1 (en) | 1990-03-10 | 1991-09-12 | Helmut Pelzer | Purifying contaminated ground - by using multiple independent bio-reactors drawn in series or parallel over affected area |
US5061620A (en) | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
US5342752A (en) | 1990-04-16 | 1994-08-30 | Cryopharm Corporation | Method of inactivation of viral blood contaminants using acridine deriatives |
US5635387A (en) | 1990-04-23 | 1997-06-03 | Cellpro, Inc. | Methods and device for culturing human hematopoietic cells and their precursors |
US5840580A (en) | 1990-05-01 | 1998-11-24 | Becton Dickinson And Company | Phenotypic characterization of the hematopoietic stem cell |
US5612211A (en) | 1990-06-08 | 1997-03-18 | New York University | Stimulation, production and culturing of hematopoietic progenitor cells by fibroblast growth factors |
US6326198B1 (en) | 1990-06-14 | 2001-12-04 | Regents Of The University Of Michigan | Methods and compositions for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells |
EP0471947A1 (en) | 1990-06-29 | 1992-02-26 | Sekisui Chemical Co., Ltd. | Culture bag |
US5283058A (en) | 1990-08-30 | 1994-02-01 | The General Hospital Corporation | Methods for inhibiting rejection of transplanted tissue |
US5202254A (en) | 1990-10-11 | 1993-04-13 | Endotronics, Inc. | Process for improving mass transfer in a membrane bioreactor and providing a more homogeneous culture environment |
WO1992007243A1 (en) | 1990-10-18 | 1992-04-30 | Cellpro, Incorporated | An apparatus and method for separating particles using a pliable vessel |
US5733542A (en) | 1990-11-16 | 1998-03-31 | Haynesworth; Stephen E. | Enhancing bone marrow engraftment using MSCS |
US5811094A (en) | 1990-11-16 | 1998-09-22 | Osiris Therapeutics, Inc. | Connective tissue regeneration using human mesenchymal stem cell preparations |
US5837539A (en) | 1990-11-16 | 1998-11-17 | Osiris Therapeutics, Inc. | Monoclonal antibodies for human mesenchymal stem cells |
US5226914A (en) | 1990-11-16 | 1993-07-13 | Caplan Arnold I | Method for treating connective tissue disorders |
US6010696A (en) | 1990-11-16 | 2000-01-04 | Osiris Therapeutics, Inc. | Enhancing hematopoietic progenitor cell engraftment using mesenchymal stem cells |
US5486359A (en) | 1990-11-16 | 1996-01-23 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells |
US5197985A (en) | 1990-11-16 | 1993-03-30 | Caplan Arnold I | Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells |
US6197325B1 (en) | 1990-11-27 | 2001-03-06 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
US6559119B1 (en) | 1990-11-27 | 2003-05-06 | Loyola University Of Chicago | Method of preparing a tissue sealant-treated biomedical material |
AU650711B2 (en) | 1990-12-13 | 1994-06-30 | Cellco, Inc. | Sustained and continuous production of high titers of recombinant viral vectors and transduced target cells for use in gene therapy |
AU7213691A (en) | 1991-02-18 | 1992-09-15 | Computer Cell Culture Center S.A. | Cell culture medium and method for preparing such medium |
CA2363965C (en) | 1991-03-11 | 2010-05-18 | Curis, Inc. | Protein-induced morphogenesis |
CA2107553C (en) | 1991-04-05 | 2001-07-31 | Nancy Lin | Monoclonal antibodies to stem cell factor receptors |
US6069005A (en) | 1991-08-07 | 2000-05-30 | Albert Einstein College Of Medicine Of Yeshwa University | Hapatoblasts and method of isolating same |
US5837258A (en) | 1991-08-30 | 1998-11-17 | University Of South Florida | Induction of tissue, bone or cartilage formation using connective tissue growth factor |
US5330915A (en) | 1991-10-18 | 1994-07-19 | Endotronics, Inc. | Pressure control system for a bioreactor |
US5240856A (en) | 1991-10-23 | 1993-08-31 | Cellpro Incorporated | Apparatus for cell separation |
US5310676A (en) | 1991-11-15 | 1994-05-10 | A/S Nunc | Cell cultivating device |
US5527467A (en) | 1992-01-10 | 1996-06-18 | Baxter International Inc. | Rectifying dialyzer, bioreactor and membrane |
US5240614A (en) | 1992-01-10 | 1993-08-31 | Baxter International Inc. | Process for removing unwanted materials from fluids and for producing biological products |
US6231881B1 (en) | 1992-02-24 | 2001-05-15 | Anton-Lewis Usala | Medium and matrix for long-term proliferation of cells |
US5549674A (en) | 1992-03-02 | 1996-08-27 | The Regents Of The University Of Michigan | Methods and compositions of a bioartificial kidney suitable for use in vivo or ex vivo |
US6410320B1 (en) | 1992-03-02 | 2002-06-25 | The University Of Michigan | Method and compositions for isolation and growth of kidney tubule stem cells, in vitro kidney tubulogenesis and ex vivo construction of renal tubules |
US6060270A (en) | 1992-03-02 | 2000-05-09 | The University Of Michigan | Methods and compositions for isolation and growth of kidney tubule stem cells, in vitro kidney tubulogenesis and ex vivo construction of renal tubules |
US5507949A (en) | 1992-03-20 | 1996-04-16 | Monsanto Company | Supported liquid membrane and separation process employing same |
ATE170091T1 (en) | 1992-03-20 | 1998-09-15 | Monsanto Co | EXTRACTION OF ORGANIC COMPOUNDS FROM AQUEOUS SOLUTIONS |
US5252216A (en) | 1992-03-24 | 1993-10-12 | Smithkline Beecham Corporation | Protein purification |
US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
US5436151A (en) | 1992-04-03 | 1995-07-25 | Regents Of The University Of Minnesota | Method for culturing human hematopoietic stem cells in vitro |
US5460964A (en) | 1992-04-03 | 1995-10-24 | Regents Of The University Of Minnesota | Method for culturing hematopoietic cells |
WO1994000484A1 (en) | 1992-06-22 | 1994-01-06 | Young Henry E | Scar inhibitory factor and use thereof |
US5439757A (en) | 1992-10-14 | 1995-08-08 | National Power Plc | Electrochemical energy storage and/or power delivery cell with pH control |
US5496659A (en) | 1992-10-14 | 1996-03-05 | National Power Plc | Electrochemical apparatus for energy storage and/or power delivery comprising multi-compartment cells |
US5422197A (en) | 1992-10-14 | 1995-06-06 | National Power Plc | Electrochemical energy storage and power delivery process utilizing iron-sulfur couple |
US5545492A (en) | 1992-10-14 | 1996-08-13 | National Power Plc | Electrochemical apparatus for power delivery utilizing an air electrode |
US5478739A (en) | 1992-10-23 | 1995-12-26 | Advanced Tissue Sciences, Inc. | Three-dimensional stromal cell and tissue culture system |
CA2148715A1 (en) | 1992-11-16 | 1994-05-26 | John E. Wagner | Pluripotential quiescent stem cell population |
DE69333243T2 (en) | 1992-11-24 | 2004-08-19 | G.D. Searle & Co., Chicago | MUTTED INTERLEUKIN-3 (IL-3) POLYPEPTIDES |
US5654186A (en) | 1993-02-26 | 1997-08-05 | The Picower Institute For Medical Research | Blood-borne mesenchymal cells |
US6054121A (en) | 1993-02-26 | 2000-04-25 | The Picower Institute For Medical Research | Modulation of immune responses in blood-borne mesenchymal cells |
US5804446A (en) | 1993-02-26 | 1998-09-08 | The Picower Institute For Medical Research | Blood-borne mesenchymal cells |
GB9308271D0 (en) | 1993-04-21 | 1993-06-02 | Univ Edinburgh | Method of isolating and/or enriching and/or selectively propagating pluripotential animal cells and animals for use in said method |
IL106255A0 (en) | 1993-04-23 | 1993-11-15 | Baxter Int | Method for isolating human blood cells |
US5772994A (en) | 1993-05-28 | 1998-06-30 | The University Of Pittsburgh | Hematopoietic facilitatory cells and their uses |
US5324428A (en) | 1993-07-19 | 1994-06-28 | Spectrum Medical Industries, Inc. | Disposable dialysis apparatus |
AU7520894A (en) | 1993-08-06 | 1995-02-28 | Unisyn Technologies, Inc. | Hollow fiber bioreactor system with improved nutrient oxygenation |
AU691529B2 (en) | 1993-10-06 | 1998-05-21 | University Of Florida Research Foundation, Inc. | Stem cell proliferation factor |
US5866420A (en) | 1993-10-08 | 1999-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Artificial liver device |
US6686198B1 (en) | 1993-10-14 | 2004-02-03 | President And Fellows Of Harvard College | Method of inducing and maintaining neuronal cells |
US5599703A (en) | 1993-10-28 | 1997-02-04 | The United States Of America As Represented By The Secretary Of The Navy | In vitro amplification/expansion of CD34+ stem and progenitor cells |
ATE238410T1 (en) | 1993-10-29 | 2003-05-15 | Unisearch Ltd | CELL SEPARATION DEVICE |
IL107483A0 (en) | 1993-11-03 | 1994-02-27 | Yeda Res & Dev | Bone marrow transplantation |
US6432711B1 (en) | 1993-11-03 | 2002-08-13 | Diacrin, Inc. | Embryonic stem cells capable of differentiating into desired cell lines |
US6555324B1 (en) | 1993-11-04 | 2003-04-29 | Becton Dickinson & Company | Method to distinguish hematopoietic progenitor cells |
WO1995013088A1 (en) | 1993-11-12 | 1995-05-18 | Regents Of The University Of Minnesota | Stroma-derived stem cell growth factors |
US5591625A (en) | 1993-11-24 | 1997-01-07 | Case Western Reserve University | Transduced mesenchymal stem cells |
US6811773B1 (en) | 1993-12-22 | 2004-11-02 | Human Genome Sciences, Inc. | Human monocyte colony inhibitory factor (M-CIF) polypeptides |
US6488925B2 (en) | 1993-12-22 | 2002-12-03 | Human Genome Sciences, Inc. | Macrophage inflammatory protein-4 (MIP-4) polypeptides |
US6451562B1 (en) | 1993-12-22 | 2002-09-17 | Human Genome Sciences, Inc. | Polypeptides encoding myeloid progenitor inhibitory factor-1 (MPIF-1) polynucleotides |
US5622857A (en) | 1995-08-08 | 1997-04-22 | Genespan Corporation | High performance cell culture bioreactor and method |
US5882918A (en) | 1995-08-08 | 1999-03-16 | Genespan Corporation | Cell culture incubator |
JPH09511392A (en) | 1994-02-09 | 1997-11-18 | ユニシン・テクノロジーズ・インコーポレーテッド | High performance cell culture bioreactor and method |
US5607844A (en) | 1994-02-16 | 1997-03-04 | University Of Pittsburgh | Mammalian augmenter of liver regeneration and variants thereof |
US6495129B1 (en) | 1994-03-08 | 2002-12-17 | Human Genome Sciences, Inc. | Methods of inhibiting hematopoietic stem cells using human myeloid progenitor inhibitory factor-1 (MPIF-1) (Ckbeta-8/MIP-3) |
US5679340A (en) | 1994-03-31 | 1997-10-21 | Diacrin, Inc. | Cells with multiple altered epitopes on a surface antigen for use in transplantation |
WO1995027040A1 (en) | 1994-04-01 | 1995-10-12 | Unisyn Technologies, Inc. | Culture media additives for hollow fiber bioreactors |
GB9407048D0 (en) | 1994-04-08 | 1994-06-01 | Nat Power Plc | Method for the fabrication of an electrochemical cell |
ZA952384B (en) | 1994-04-13 | 1996-09-23 | Nat Power Plc | Cation exchange membranes and method for the preparation of such membranes |
DE4412794A1 (en) | 1994-04-14 | 1995-12-14 | Univ Ludwigs Albert | Process for producing dendritic cells, cells thus obtained and containers for carrying out this process |
US5543316A (en) | 1994-04-20 | 1996-08-06 | Diacrin, Inc. | Injectable culture medium for maintaining viability of myoblast cells |
US7033339B1 (en) | 1998-05-29 | 2006-04-25 | Becton Dickinson And Company (Part Interest) | Self sealing luer receiving stopcock |
US6703017B1 (en) | 1994-04-28 | 2004-03-09 | Ixion Biotechnology, Inc. | Reversal of insulin-dependent diabetes by islet-producing stem cells, islet progenitor cells and islet-like structures |
US6001647A (en) | 1994-04-28 | 1999-12-14 | Ixion Biotechnology, Inc. | In vitro growth of functional islets of Langerhans and in vivo uses thereof |
US5855608A (en) | 1994-05-13 | 1999-01-05 | Thm Biomedical, Inc. | Device and methods for in vivo culturing of diverse tissue cells |
US5906827A (en) | 1994-06-03 | 1999-05-25 | Creative Biomolecules, Inc. | Matrix for the manufacture of autogenous replacement body parts |
US6174333B1 (en) | 1994-06-06 | 2001-01-16 | Osiris Therapeutics, Inc. | Biomatrix for soft tissue regeneration using mesenchymal stem cells |
WO1995033421A1 (en) | 1994-06-06 | 1995-12-14 | Case Western Reserve University | Biomatrix for tissue regeneration |
GB9413029D0 (en) | 1994-06-29 | 1994-08-17 | Common Services Agency | Stem cell immobilisation |
US5935849A (en) | 1994-07-20 | 1999-08-10 | Cytotherapeutics, Inc. | Methods and compositions of growth control for cells encapsulated within bioartificial organs |
US6103522A (en) | 1994-07-20 | 2000-08-15 | Fred Hutchinson Cancer Research Center | Human marrow stromal cell lines which sustain hematopoiesis |
US5776747A (en) | 1994-07-20 | 1998-07-07 | Cytotherapeutics, Inc. | Method for controlling the distribution of cells within a bioartificial organ using polycthylene oxide-poly (dimethylsiloxane) copolymer |
US5972703A (en) | 1994-08-12 | 1999-10-26 | The Regents Of The University Of Michigan | Bone precursor cells: compositions and methods |
US5840502A (en) | 1994-08-31 | 1998-11-24 | Activated Cell Therapy, Inc. | Methods for enriching specific cell-types by density gradient centrifugation |
US6054433A (en) | 1994-11-03 | 2000-04-25 | The Regents Of The University Of California | Methods and compositions for stimulating tissue growth and epithelial moisturization |
DE69532679T2 (en) | 1994-11-08 | 2005-03-03 | Cellfactors Plc | METHOD FOR THE PRODUCTION OF A HUMAN NEURAL CELL LINE |
US5581687A (en) | 1994-11-10 | 1996-12-03 | Baxter International Inc. | Interactive control systems for medical processing devices |
US7001328B1 (en) | 1994-11-15 | 2006-02-21 | Kenton W. Gregory | Method for using tropoelastin and for producing tropoelastin biomaterials |
AU699479B2 (en) | 1994-11-16 | 1998-12-03 | Amgen, Inc. | Use of stem cell factor and soluble interleukin-6 receptor for the ex vivo expansion of hematopoietic multipotential cells |
US6472200B1 (en) | 1999-07-23 | 2002-10-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Device and method for performing a biological modification of a fluid |
US6558664B1 (en) | 1994-12-13 | 2003-05-06 | Cell Factors Plc | Chondrocyte cell-lines |
US5736396A (en) | 1995-01-24 | 1998-04-07 | Case Western Reserve University | Lineage-directed induction of human mesenchymal stem cell differentiation |
US7410773B2 (en) | 1995-02-02 | 2008-08-12 | Ghazi Jaswinder Dhoot | Method of preparing an undifferentiated cell |
US5643736A (en) | 1995-02-06 | 1997-07-01 | Osiris Therapeutics, Inc. | Monoclonal antibodies for human osteogenic cell surface antigens |
US5788851A (en) | 1995-02-13 | 1998-08-04 | Aksys, Ltd. | User interface and method for control of medical instruments, such as dialysis machines |
GB9503197D0 (en) | 1995-02-18 | 1995-04-05 | Atomic Energy Authority Uk | A bioreactor |
US7008634B2 (en) | 1995-03-03 | 2006-03-07 | Massachusetts Institute Of Technology | Cell growth substrates with tethered cell growth effector molecules |
US5906934A (en) | 1995-03-14 | 1999-05-25 | Morphogen Pharmaceuticals, Inc. | Mesenchymal stem cells for cartilage repair |
US7094564B1 (en) | 1995-03-15 | 2006-08-22 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor |
GB9505663D0 (en) | 1995-03-21 | 1995-05-10 | Stringer Bradley M J | Genetically modified neural cells |
US6653134B2 (en) | 1995-03-28 | 2003-11-25 | Cp Hahnemann University | Isolated stromal cells for use in the treatment of diseases of the central nervous system |
US5733541A (en) | 1995-04-21 | 1998-03-31 | The Regent Of The University Of Michigan | Hematopoietic cells: compositions and methods |
US7429646B1 (en) | 1995-06-05 | 2008-09-30 | Human Genome Sciences, Inc. | Antibodies to human tumor necrosis factor receptor-like 2 |
BE1009306A5 (en) | 1995-04-28 | 1997-02-04 | Baxter Int | Bioreactor. |
US5674750A (en) | 1995-05-19 | 1997-10-07 | T. Breeders | Continuous selective clonogenic expansion of relatively undifferentiated cells |
US5925567A (en) | 1995-05-19 | 1999-07-20 | T. Breeders, Inc. | Selective expansion of target cell populations |
US6495364B2 (en) | 1995-05-23 | 2002-12-17 | Neurotech, S.A. | Mx-1 conditionally immortalized cells |
DE19520188C2 (en) | 1995-06-01 | 1999-04-08 | Geesthacht Gkss Forschung | Process for the production of polymer hollow fiber membranes |
MY115206A (en) | 1995-06-04 | 2003-04-30 | Regenesys Tech Ltd | Method for the preparation of cation exchange membranes doped with insoluble metal salts |
US5908782A (en) | 1995-06-05 | 1999-06-01 | Osiris Therapeutics, Inc. | Chemically defined medium for human mesenchymal stem cells |
EP0838033A1 (en) | 1995-06-06 | 1998-04-29 | Stemcell Therapeutics L.L.C. | GLYCOPROTEIN gp105 ON BL3 HEMATOPOIETIC STEM CELLS |
AU706026B2 (en) | 1995-06-06 | 1999-06-10 | Case Western Reserve University | Myogenic differentiation of human mesenchymal stem cells |
US5728581A (en) | 1995-06-07 | 1998-03-17 | Systemix, Inc. | Method of expanding hematopoietic stem cells, reagents and bioreactors for use therein |
US5877149A (en) | 1995-06-07 | 1999-03-02 | Beaulieu; Andre | Deepithelialized skin diffusion cell system |
US6238908B1 (en) | 1995-06-07 | 2001-05-29 | Aastrom Biosciences, Inc. | Apparatus and method for maintaining and growth biological cells |
US6228635B1 (en) | 1995-06-07 | 2001-05-08 | Aastrom Bioscience, Inc. | Portable cell growth cassette for use in maintaining and growing biological cells |
US5655546A (en) | 1995-06-07 | 1997-08-12 | Halpern; Alan A. | Method for cartilage repair |
US5688687A (en) | 1995-06-07 | 1997-11-18 | Aastrom Biosciences, Inc. | Bioreactor for mammalian cell growth and maintenance |
US6096532A (en) | 1995-06-07 | 2000-08-01 | Aastrom Biosciences, Inc. | Processor apparatus for use in a system for maintaining and growing biological cells |
US5653887A (en) | 1995-06-07 | 1997-08-05 | Cobe Laboratories, Inc. | Apheresis blood processing method using pictorial displays |
US6187757B1 (en) | 1995-06-07 | 2001-02-13 | Ariad Pharmaceuticals, Inc. | Regulation of biological events using novel compounds |
US5985653A (en) | 1995-06-07 | 1999-11-16 | Aastrom Biosciences, Inc. | Incubator apparatus for use in a system for maintaining and growing biological cells |
US6015554A (en) | 1995-06-07 | 2000-01-18 | Systemix, Inc. | Method of reconstituting human lymphoid and dendritic cells |
US6306575B1 (en) | 1995-06-16 | 2001-10-23 | Stemcell Technologies, Inc. | Methods for preparing enriched human hematopoietic cell preparations |
US6117985A (en) | 1995-06-16 | 2000-09-12 | Stemcell Technologies Inc. | Antibody compositions for preparing enriched cell preparations |
ES2237760T3 (en) | 1995-06-30 | 2005-08-01 | Toray Industries, Inc. | MANUFACTURING PROCEDURE OF A SEMIPERMEABLE MEMBRANE OF POLISHULPHONE HOLLOW FIBERS. |
US5627070A (en) | 1995-07-26 | 1997-05-06 | Celltherapy, Inc. | Cell growing device for in vitro cell population expansion |
WO1997005826A1 (en) | 1995-08-08 | 1997-02-20 | Laser Centers Of America | System for extracting tissue samples in laparoscopy |
US5705534A (en) | 1995-09-22 | 1998-01-06 | National Power Plc | Method for the preparation of cation exchange membranes doped with insoluble metal salts |
US5780300A (en) | 1995-09-29 | 1998-07-14 | Yale University | Manipulation of non-terminally differentiated cells using the notch pathway |
US5855613A (en) | 1995-10-13 | 1999-01-05 | Islet Sheet Medical, Inc. | Retrievable bioartificial implants having dimensions allowing rapid diffusion of oxygen and rapid biological response to physiological change |
US5700289A (en) | 1995-10-20 | 1997-12-23 | North Shore University Hospital Research Corporation | Tissue-engineered bone repair using cultured periosteal cells |
WO1997016527A1 (en) | 1995-10-30 | 1997-05-09 | Cellex Biosciences, Inc. | Cultureware for bioartificial liver |
JP2000500337A (en) | 1995-11-13 | 2000-01-18 | コールター コーポレイション | Method and apparatus for bulk enrichment of a population or subpopulation of cells |
US5858782A (en) | 1995-11-13 | 1999-01-12 | Regents Of The University Of Michigan | Functional human hematopoietic cells |
AU1119397A (en) | 1995-11-14 | 1997-06-05 | Regents Of The University Of Minnesota | Ex vivo culture of stem cells |
EP0868505B1 (en) | 1995-11-16 | 2005-02-02 | Case Western Reserve University | In vitro chondrogenic induction of human mesenchymal stem cells |
IT1282207B1 (en) | 1995-11-20 | 1998-03-16 | Fidia Advanced Biopolymers Srl | HUMAN BONE MARROW STEM CELL CULTURE SYSTEMS IN THREE-DIMENSIONAL MATRIXES CONSISTING OF HYALURONIC ACID ESTERS |
US6482231B1 (en) | 1995-11-20 | 2002-11-19 | Giovanni Abatangelo | Biological material for the repair of connective tissue defects comprising mesenchymal stem cells and hyaluronic acid derivative |
US5658995A (en) | 1995-11-27 | 1997-08-19 | Rutgers, The State University | Copolymers of tyrosine-based polycarbonate and poly(alkylene oxide) |
GB9526577D0 (en) | 1995-12-28 | 1996-02-28 | Nat Power Plc | Method for the fabrication of electrochemical cells |
US6200606B1 (en) | 1996-01-16 | 2001-03-13 | Depuy Orthopaedics, Inc. | Isolation of precursor cells from hematopoietic and nonhematopoietic tissues and their use in vivo bone and cartilage regeneration |
US6322786B1 (en) | 1996-02-15 | 2001-11-27 | Kansas University Medical Center Research Institute, Inc. | Method of producing bone-inducing agent |
WO1997029792A1 (en) | 1996-02-20 | 1997-08-21 | Cohesion Corporation | Tissue sealant compositions and methods of use thereof |
US5842477A (en) | 1996-02-21 | 1998-12-01 | Advanced Tissue Sciences, Inc. | Method for repairing cartilage |
ATE295875T1 (en) | 1996-03-01 | 2005-06-15 | Isotis Nv | METHOD FOR PRODUCING BONE IN VITRO |
EP0891419A4 (en) | 1996-03-12 | 2000-03-01 | Life Technologies Inc | Hematopoietic cell culture nutrient supplement |
US6479254B2 (en) | 1996-03-22 | 2002-11-12 | Human Genome Sciences, Inc. | Apoptosis inducing molecule II |
US20010017188A1 (en) | 1996-04-10 | 2001-08-30 | Cooley Graham Edward | Process for the fabrication of electrochemical cell components |
AU2730497A (en) | 1996-04-17 | 1997-11-07 | Case Western Reserve University | Cryopreservation and extensive subculturing of human mesenchymal stem cells |
WO1997040137A1 (en) | 1996-04-19 | 1997-10-30 | Osiris Therapeutics, Inc. | Regeneration and augmentation of bone using mesenchymal stem cells |
JP2000508922A (en) | 1996-04-26 | 2000-07-18 | ケース ウエスターン リザーブ ユニバーシティ | Skin regeneration using mesenchymal stem cells |
US6455678B1 (en) | 1996-04-26 | 2002-09-24 | Amcell Corporation | Human hematopoietic stem and progenitor cell antigen |
US5843633A (en) | 1996-04-26 | 1998-12-01 | Amcell Corporation | Characterization of a human hematopoietic progenitor cell antigen |
US5753506A (en) | 1996-05-23 | 1998-05-19 | Cns Stem Cell Technology, Inc. | Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals |
US6165785A (en) | 1996-05-24 | 2000-12-26 | University Of Cincinnati | Bone marrow cultures for developing suppressor and stimulator cells for research and therapeutic applications |
CA2256400A1 (en) | 1996-05-28 | 1997-12-04 | Brown University Research Foundation | Hyaluronan based biodegradable scaffolds for tissue repair |
JP3754708B2 (en) | 1996-06-04 | 2006-03-15 | ツィマー ゲーエム ベーハー | Method for producing cartilage tissue and implant for repairing endochondral and osteochondral defects and arrangement for carrying out the method |
US5824084A (en) | 1996-07-03 | 1998-10-20 | The Cleveland Clinic Foundation | Method of preparing a composite bone graft |
US6145688A (en) | 1996-07-17 | 2000-11-14 | Smith; James C. | Closure device for containers |
US5827740A (en) | 1996-07-30 | 1998-10-27 | Osiris Therapeutics, Inc. | Adipogenic differentiation of human mesenchymal stem cells |
US6458585B1 (en) | 1996-08-14 | 2002-10-01 | Nexell Therapeutics Inc. | Cytokine-free culture of dendritic cells |
GB9617058D0 (en) | 1996-08-14 | 1996-09-25 | Sandoz Ltd | Organic compounds |
US6787355B1 (en) | 1996-08-26 | 2004-09-07 | Mcgill University | Multipotent neural stem cells from peripheral tissues and uses thereof |
US5989269A (en) | 1996-08-30 | 1999-11-23 | Vts Holdings L.L.C. | Method, instruments and kit for autologous transplantation |
US5667985A (en) | 1996-09-24 | 1997-09-16 | Becton Dickinson And Company | Tissue biopsy cell suspender for cell analysis |
US6150164A (en) | 1996-09-30 | 2000-11-21 | The Regents Of The University Of Michigan | Methods and compositions of a bioartificial kidney suitable for use in vivo or ex vivo |
US5945337A (en) | 1996-10-18 | 1999-08-31 | Quality Biological, Inc. | Method for culturing CD34+ cells in a serum-free medium |
US5980887A (en) | 1996-11-08 | 1999-11-09 | St. Elizabeth's Medical Center Of Boston | Methods for enhancing angiogenesis with endothelial progenitor cells |
DE69736526T2 (en) | 1996-11-13 | 2007-04-26 | Cold Spring Harbor Laboratory | THERAPEUTIC USE OF NITROGEN MONOXIDE INHIBITORS |
US6372796B1 (en) | 1996-11-13 | 2002-04-16 | Cold Spring Harbor Laboratory | Therapeutic uses for nitric oxide inhibitors |
EP0941027A4 (en) | 1996-11-15 | 2000-08-09 | Osiris Therapeutics Inc | MSC-megakaryocyte precursor composition and method of isolating MSCS associated with isolated megakaryocytes by isolating megakaryocytes |
US6029101A (en) | 1996-11-18 | 2000-02-22 | Scius Corporation | Process control system user interface |
US7732129B1 (en) | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
US5928945A (en) | 1996-11-20 | 1999-07-27 | Advanced Tissue Sciences, Inc. | Application of shear flow stress to chondrocytes or chondrocyte stem cells to produce cartilage |
US6331409B1 (en) | 1996-11-21 | 2001-12-18 | The Regents Of The University Of Michigan | Methods and compositions for wound healing |
US6120491A (en) | 1997-11-07 | 2000-09-19 | The State University Rutgers | Biodegradable, anionic polymers derived from the amino acid L-tyrosine |
US6084060A (en) | 1996-12-09 | 2000-07-04 | Imclone Systems Incorporated | Composition and method for preserving progenitor cells |
ES2263185T3 (en) | 1996-12-10 | 2006-12-01 | Purdue Research Foundation | BIOMATERIAL DERIVED FROM VERPABRADO HEPATIC FABRIC. |
AU5530198A (en) | 1996-12-16 | 1998-07-15 | Zymogenetics Inc. | Compositions and methods for stimulating pancreatic islet cell regeneration |
US5766944A (en) | 1996-12-31 | 1998-06-16 | Ruiz; Margaret Eileen | T cell differentiation of CD34+ stem cells in cultured thymic epithelial fragments |
ATE321855T1 (en) | 1997-01-14 | 2006-04-15 | Human Genome Sciences Inc | TUMOR NECROSIS FACTOR RECEPTOR 5 |
AU716137B2 (en) | 1997-01-16 | 2000-02-17 | Cohesion Corporation | Lyophilized collagen-based biomaterials, process of preparation and uses thereof |
US20020031757A1 (en) | 1997-01-24 | 2002-03-14 | Asahi Medical Co., Ltd. | Method of regenerating a tissue |
US6335195B1 (en) | 1997-01-28 | 2002-01-01 | Maret Corporation | Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation |
US6342363B1 (en) | 1997-01-28 | 2002-01-29 | Human Genome Sciences, Inc. | Death domain containing receptor 4 nucleic acids and methods |
CA2280931C (en) | 1997-02-07 | 2009-05-05 | Stryker Corporation | Matrix-free osteogenic devices, implants and methods of use thereof |
US6632425B1 (en) | 1997-03-20 | 2003-10-14 | Human Genome Sciences, Inc. | Chemokine compositions |
AU6869198A (en) | 1997-03-25 | 1998-10-20 | Morphogenesis, Inc. | Universal stem cells |
ES2285770T3 (en) | 1997-05-12 | 2007-11-16 | Metabolix, Inc. | POLYHYDROXIALCANOATE FOR LIVE APPLICATIONS. |
EP0989855A4 (en) | 1997-05-13 | 2002-06-12 | Osiris Therapeutics Inc | Osteoarthritis cartilage regeneration using human mesenchymal stem cells |
WO1998051785A1 (en) | 1997-05-14 | 1998-11-19 | The General Hospital Corporation | Co-cultivation of cells in a micropatterned configuration |
US5955353A (en) | 1997-05-22 | 1999-09-21 | Excorp Medical, Inc. | Hollow fiber bioreactor with an extrafilament flow plug |
US5853247A (en) | 1997-05-27 | 1998-12-29 | Shroyer; John Bruce | Sample bag container |
US5783075A (en) | 1997-06-23 | 1998-07-21 | Spectrum Medical Laboratories, Inc. | Disposable dialyzer apparatus |
US6310195B1 (en) | 1997-06-24 | 2001-10-30 | Imclone Systems Incorporated | Nucleic acid encoding a lectin-derived progenitor cell preservation factor |
US6979307B2 (en) | 1997-06-24 | 2005-12-27 | Cascade Medical Enterprises Llc | Systems and methods for preparing autologous fibrin glue |
US5913859A (en) | 1997-07-01 | 1999-06-22 | Shapira; Ira L. | Apparatus for extracting bone marrow |
AU8476698A (en) | 1997-07-03 | 1999-01-25 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells from peripheral blood |
US7514074B2 (en) | 1997-07-14 | 2009-04-07 | Osiris Therapeutics, Inc. | Cardiac muscle regeneration using mesenchymal stem cells |
CA2296704C (en) | 1997-07-14 | 2010-10-19 | Osiris Therapeutics, Inc. | Cardiac muscle regeneration using mesenchymal stem cells |
ES2178102T3 (en) | 1997-07-16 | 2002-12-16 | Isotis Nv | DEVICE FOR THE GENERATION OF OSEO TISSUE, WHICH INCLUDES A BIODEGRADABLE COPOLIESTER THERMOPLASTIC AND CULTIVATED CELLS. |
US6077708A (en) | 1997-07-18 | 2000-06-20 | Collins; Paul C. | Method of determining progenitor cell content of a hematopoietic cell culture |
TWI239352B (en) | 1997-07-23 | 2005-09-11 | Takara Bio Inc | Gene transfer method with the use of serum-free medium |
CN1272118A (en) | 1997-07-28 | 2000-11-01 | 弗勃鲁根股份有限公司 | Collagen type I and type III adhesive compositions |
US6001643A (en) | 1997-08-04 | 1999-12-14 | C-Med Inc. | Controlled hydrodynamic cell culture environment for three dimensional tissue growth |
US6511958B1 (en) | 1997-08-14 | 2003-01-28 | Sulzer Biologics, Inc. | Compositions for regeneration and repair of cartilage lesions |
EP0896825B1 (en) | 1997-08-14 | 2002-07-17 | Sulzer Innotec Ag | Composition and device for in vivo cartilage repair comprising nanocapsules with osteoinductive and/or chondroinductive factors |
US6908763B1 (en) | 1997-08-22 | 2005-06-21 | The Board Of Trustees Of The Leland Stanford Junior University | Mammalian common lymphoid progenitor cell |
EP1003847A4 (en) | 1997-09-04 | 2005-04-06 | Science Res Lab Inc | Cell separation using electric fields |
WO1999011287A1 (en) | 1997-09-04 | 1999-03-11 | Osiris Therapeutics, Inc. | Ligands that modulate differentiation of mesenchymal stem cells |
CA2302339A1 (en) | 1997-09-20 | 1999-04-01 | Osiris Therapeutics, Inc. | Antigen presenting mesenchymal stem cells |
US6440734B1 (en) | 1998-09-25 | 2002-08-27 | Cytomatrix, Llc | Methods and devices for the long-term culture of hematopoietic progenitor cells |
ES2285785T3 (en) | 1997-09-29 | 2007-11-16 | Point Therapeutics, Inc. | STIMULATION OF IN VITRO HEMATOPOYETIC CELLS. |
US6194168B1 (en) | 1997-09-30 | 2001-02-27 | Human Genome Sciences, Inc. | Expression control sequences |
US6429012B1 (en) | 1997-10-06 | 2002-08-06 | Viacell, Inc. | Cell population containing non-fetal hemangioblasts and method for producing same |
US5998184A (en) | 1997-10-08 | 1999-12-07 | Unisyn Technologies, Inc. | Basket-type bioreactor |
CA2307807C (en) | 1997-10-23 | 2008-09-02 | Andrea G. Bodnar | Methods and materials for the growth of primate-derived primordial stem cells in feeder-free culture |
US6649631B1 (en) | 1997-10-23 | 2003-11-18 | The Board Of Regents Of The University Of Texas System | Compositions and methods for treating bone deficit conditions |
AU1203999A (en) | 1997-10-31 | 1999-05-24 | Osiris Therapeutics, Inc. | Human slit polypeptide and polynucleotides encoding same |
ATE273341T1 (en) | 1997-11-07 | 2004-08-15 | Univ Rutgers | STRICTLY ALTERNATING POLY(ALKYLENE OXIDE) COPOLYMERS |
AU1453899A (en) | 1997-11-10 | 1999-05-31 | Regents Of The University Of Michigan, The | Human bone accessory cells |
US6001585A (en) | 1997-11-14 | 1999-12-14 | Cellex Biosciences, Inc. | Micro hollow fiber bioreactor |
US6475481B2 (en) | 1997-11-18 | 2002-11-05 | Canji Inc | Purging of stem cell products |
GB9724879D0 (en) | 1997-11-26 | 1998-01-21 | Univ London | Process for the production of protein and products thereof |
US6248587B1 (en) | 1997-11-26 | 2001-06-19 | University Of Southern Cailfornia | Method for promoting mesenchymal stem and lineage-specific cell proliferation |
JP2001525176A (en) | 1997-12-04 | 2001-12-11 | デューク・ユニバーシティー | Methods for isolating and using CD7 + CD34-LIN-hematopoietic cells |
US6082364A (en) | 1997-12-15 | 2000-07-04 | Musculoskeletal Development Enterprises, Llc | Pluripotential bone marrow cell line and methods of using the same |
ATE420355T1 (en) | 1997-12-16 | 2009-01-15 | Univ Zuerich | DIAGNOSTICS FOR TRANSMISSABLE SPONGIFORM ENCEPHALOPATHY |
US6171548B1 (en) | 1997-12-29 | 2001-01-09 | Spectrum Environmental Technologies, Inc. | Surface and air sterilization using ultraviolet light and ultrasonic waves |
WO1999033949A1 (en) | 1997-12-29 | 1999-07-08 | Monsanto Company | A membrane process for making enhanced flavor fluids |
US6074366A (en) | 1998-01-16 | 2000-06-13 | Tandem Medical Inc. | Medication delivery apparatus |
AU2469299A (en) | 1998-01-23 | 1999-08-09 | Cornell Research Foundation Inc. | Purified populations of stem cells |
US6653105B2 (en) | 1998-02-11 | 2003-11-25 | Vitagen, Inc. | Clonal cells and cell lines derived from C3A cells and methods of making and using them |
US6962698B1 (en) | 1998-02-17 | 2005-11-08 | Gamida Cell Ltd. | Methods of controlling proliferation and differentiation of stem and progenitor cells |
US20020034819A1 (en) | 1998-02-23 | 2002-03-21 | Alan K. Smith | Human lineage committed cell composition with enhanced proliferative potential, biological effector function, or both; methods for obtaining same; and their uses |
AU749675B2 (en) | 1998-03-13 | 2002-07-04 | Mesoblast International Sarl | Uses for human non-autologous mesenchymal stem cells |
AU755888B2 (en) | 1998-03-18 | 2003-01-02 | Mesoblast International Sarl | Mesenchymal stem cells for prevention and treatment of immune responses in transplantation |
US6368636B1 (en) | 1998-03-18 | 2002-04-09 | Osiris Therapeutics, Inc. | Mesenchymal stem cells for prevention and treatment of immune responses in transplantation |
ATE227338T1 (en) | 1998-03-18 | 2002-11-15 | Massachusetts Inst Technology | VASCULARIZED PERFUSED ARRANGEMENTS FOR MICRO TISSUES AND MICRO ORGANS |
EP1064356A2 (en) | 1998-03-23 | 2001-01-03 | ZymoGenetics, Inc. | Cardiac-derived stem cells |
US6143293A (en) | 1998-03-26 | 2000-11-07 | Carnegie Mellon | Assembled scaffolds for three dimensional cell culturing and tissue generation |
EP1066060B1 (en) | 1998-04-03 | 2003-08-13 | Osiris Therapeutics, Inc. | Mesenchymal stem cells as immunosuppressants |
US5882929A (en) | 1998-04-07 | 1999-03-16 | Tissue Engineering, Inc. | Methods and apparatus for the conditioning of cartilage replacement tissue |
US5882295A (en) | 1998-04-13 | 1999-03-16 | Spectrum Medical Industries, Inc. | Video camera drape |
US6071691A (en) | 1998-04-27 | 2000-06-06 | Oregon Health Science University | Materials and methods for modulating differentiation |
GB2337150B (en) | 1998-05-07 | 2000-09-27 | Nat Power Plc | Carbon based electrodes |
ES2246085T3 (en) | 1998-05-07 | 2006-02-01 | University Of South Florida | OSEA MEDULA CELLS AS A SOURCE OF NEURONS USEFUL TO REPAIR THE SPINAL MEDULA AND THE BRAIN. |
JP4601166B2 (en) | 1998-05-11 | 2010-12-22 | ミルテニィ バイオテック ゲーエムベーハー | Method for directly selecting antigen-specific T cells |
US6835377B2 (en) | 1998-05-13 | 2004-12-28 | Osiris Therapeutics, Inc. | Osteoarthritis cartilage regeneration |
AU4094099A (en) | 1998-05-22 | 1999-12-13 | Osiris Therapeutics, Inc. | Production of megakaryocytes by co-culturing human mesenchymal stem cells with cd34+ cells |
AU4219899A (en) | 1998-05-28 | 1999-12-13 | President And Fellows Of Harvard College | Methods and compositions relating to modulation of cartilage cell growth and/or differentiation by modulation of nfatp activity |
DE69936720T2 (en) | 1998-05-29 | 2008-04-30 | Osiris Therapeutics, Inc. | HUMAN CD45 + AND / OR FIBROBLASTES + MESENCHYMAL STEM CELLS |
US6586192B1 (en) | 1998-05-29 | 2003-07-01 | Thomas Jefferson University | Compositions and methods for use in affecting hematopoietic stem cell populations in mammals |
DE69937347T2 (en) | 1998-06-08 | 2008-09-04 | Osiris Therapeutics, Inc. | REGULATION OF HEMATOPOIETIC STEM CELL DIFFERENTIATION THROUGH THE USE OF HUMAN MESENCHYMAL STEM CELLS |
CA2329519A1 (en) | 1998-06-08 | 1999-12-16 | Osiris Therapeutics, Inc. | In vitro maintenance of hematopoietic stem cells |
RU2139085C1 (en) | 1998-06-23 | 1999-10-10 | Санкт-Петербургская общественная организация "Институт биорегуляции и геронтологии" | Agent stimulating reparative processes and method of its use |
US6414219B1 (en) | 1998-06-30 | 2002-07-02 | Rutgers, The State University Of New Jersey | Osteopontin knock-out mouse and methods of use thereof |
US20090047289A1 (en) | 1998-06-30 | 2009-02-19 | Denhardt David T | Osteopontin Specific Antibodies and Methods of Use Thereof |
US6129911A (en) | 1998-07-10 | 2000-10-10 | Rhode Island Hospital, A Lifespan Partner | Liver stem cell |
GB9815173D0 (en) | 1998-07-13 | 1998-09-09 | Nat Power Plc | Process for the removal of sulphate ions |
JP3686335B2 (en) | 1998-07-13 | 2005-08-24 | ユニヴァースティ オブ サザーン カリフォルニア | Methods for promoting bone and cartilage growth and repair |
DE19833476B4 (en) | 1998-07-24 | 2005-08-25 | Huss, Ralf, Dr. | Genetically modified CD34 negatives, adherently growing hematopoietic stem cells and their use in gene therapy |
IL125532A0 (en) | 1998-07-27 | 1999-03-12 | Yeda Res & Dev | Hematopoietic cell composition for use in transplantation |
US6677306B1 (en) | 1998-07-29 | 2004-01-13 | Northwestern University | Chondrogenic and osteogenic inducing molecule |
AU5671899A (en) | 1998-08-10 | 2000-03-06 | Fibrogen, Inc. | Collagen type i and type iii hemostatic compositions for use as a vascular sealant and wound dressing |
US20020015724A1 (en) | 1998-08-10 | 2002-02-07 | Chunlin Yang | Collagen type i and type iii hemostatic compositions for use as a vascular sealant and wound dressing |
US6703209B1 (en) | 1998-08-13 | 2004-03-09 | Biotransplant, Inc. | Porcine totipotent cells and method for long-term culture |
US6849255B2 (en) | 1998-08-18 | 2005-02-01 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods and compositions for enhancing cartilage repair |
US6894022B1 (en) | 1998-08-27 | 2005-05-17 | Eidgenossische Technische Hochschule Zurich | Growth factor modified protein matrices for tissue engineering |
US6767737B1 (en) | 1998-08-31 | 2004-07-27 | New York University | Stem cells bearing an FGF receptor on the cell surface |
AU766735B2 (en) | 1998-09-15 | 2003-10-23 | Isotis N.V. | Osteoinduction |
WO2000015679A1 (en) | 1998-09-15 | 2000-03-23 | National Power Plc | Water based grafting |
GB2341601B (en) | 1998-09-15 | 2000-07-26 | Nat Power Plc | Process for the preparation of reticulated copper or nickel sulfide |
US7338798B2 (en) | 1998-09-15 | 2008-03-04 | The Regents Of The University Of Michigan | System and method for forming a cardiac muscle construct |
GB9820109D0 (en) | 1998-09-15 | 1998-11-11 | Nat Power Plc | Vitrified carbon compositions |
US6569654B2 (en) | 1998-09-18 | 2003-05-27 | Massachusetts Institute Of Technology | Electroactive materials for stimulation of biological activity of stem cells |
WO2000017326A1 (en) | 1998-09-21 | 2000-03-30 | Musc Foundation For Research Development | Non-hematopoietic cells, including cardiomyocytes and skeletal muscle cells, derived from hematopoietic stem cells and methods of making and using them |
GB9821156D0 (en) | 1998-09-29 | 1998-11-25 | Nat Power Plc | Manufacturable electrochemical cell |
US6632934B1 (en) | 1998-09-30 | 2003-10-14 | Board Of Regents, The University Of Texas System | MORC gene compositions and methods of use |
JP2000106882A (en) | 1998-10-02 | 2000-04-18 | Chemo Sero Therapeut Res Inst | Enzyme producing plasma protein having tumor metastasis and proliferation inhibitory action and plasma protein fragmented by the same |
US20070166834A1 (en) | 1998-10-05 | 2007-07-19 | Biopath Automation, L.L.C. | Apparatus and method for harvesting and handling tissue samples for biopsy analysis |
US8026096B1 (en) | 1998-10-08 | 2011-09-27 | Protein Sciences Corporation | In vivo active erythropoietin produced in insect cells |
US6454811B1 (en) | 1998-10-12 | 2002-09-24 | Massachusetts Institute Of Technology | Composites for tissue regeneration and methods of manufacture thereof |
WO2000023799A1 (en) | 1998-10-21 | 2000-04-27 | Steven Jay Smith | Protein quantitation with cell imaging densitometry |
US7410798B2 (en) | 2001-01-10 | 2008-08-12 | Geron Corporation | Culture system for rapid expansion of human embryonic stem cells |
US6667176B1 (en) | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
JP2002529071A (en) | 1998-11-09 | 2002-09-10 | コンソルツィオ・ペール・ラ・ジェスティオーネ・デル・チェントロ・ディ・ビオテクノロジー・アヴァンツァテ | Serum-free medium for chondrocyte-like cells |
AU1478000A (en) | 1998-11-13 | 2000-06-05 | Osiris Therapeutics, Inc. | (in utero) transplantation of human mesenchymal stem cells |
WO2000029001A1 (en) | 1998-11-13 | 2000-05-25 | Osiris Therapeutics, Inc. | Uses of fibroblasts or supernatants from fibroblasts for the suppression of immune responses in transplantation |
US6761887B1 (en) | 1998-11-16 | 2004-07-13 | Osiris Therapeutics, Inc. | Alginate layer system for chondrogenic differentiation of human mesenchymal stem cells |
US6184035B1 (en) | 1998-11-18 | 2001-02-06 | California Institute Of Technology | Methods for isolation and activation of, and control of differentiation from, skeletal muscle stem or progenitor cells |
GB9826658D0 (en) | 1998-12-03 | 1999-01-27 | Univ London | Tissue repair |
US6328765B1 (en) | 1998-12-03 | 2001-12-11 | Gore Enterprise Holdings, Inc. | Methods and articles for regenerating living tissue |
EP1135465A2 (en) | 1998-12-04 | 2001-09-26 | Naval Medical Research Center | Human brain endothelial cells and growth medium and method for expansion of primitive cd34+cd38- bone marrow stem cells |
US6629003B1 (en) | 1998-12-04 | 2003-09-30 | Vector Corporation | Batch processing control system recipe management and batch information system |
GB2346006B (en) | 1999-01-20 | 2001-01-31 | Nat Power Plc | Method of carrying out electrochemical reactions |
ES2147163B1 (en) | 1999-01-25 | 2001-03-01 | Esp Farmaceuticas Centrum Sa | A PHARMACEUTICAL COMPOSITION WITH REGULATORY ACTIVITY OF THE EXPRESSION OF THE ADHESION MOLECULES. |
US6627191B1 (en) | 1999-01-25 | 2003-09-30 | Seattle Biomedical Research Institute | Anti-transforming growth factor Beta (TGF-β) treated stem cell composition and method |
EP1144595A2 (en) | 1999-02-04 | 2001-10-17 | McGILL UNIVERSITY | Platform for the differentiation of cells |
NZ513303A (en) | 1999-02-04 | 2003-03-28 | Technion Res & Dev Foundation | Three dimensional plug flow bioreactor, and its use for the maintenance and expansion of hemopoietic stem cells and/or progenitor cells |
EP1175487A2 (en) | 1999-02-10 | 2002-01-30 | Curis, Inc. | Pancreatic progenitor cells, methods and uses related thereto |
US6767738B1 (en) | 1999-02-11 | 2004-07-27 | The Salk Institute For Biological Studies | Method of isolating adult mammalian CNS-derived progenitor stem cells using density gradient centrifugation |
US6468794B1 (en) | 1999-02-12 | 2002-10-22 | Stemcells, Inc. | Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations |
US6376742B1 (en) | 1999-02-17 | 2002-04-23 | Richard J. Zdrahala | In vivo tissue engineering with biodegradable polymers |
WO2000052446A1 (en) | 1999-03-02 | 2000-09-08 | Qualigen, Inc. | Methods and apparatus for separation of biological fluids |
US6821790B2 (en) | 1999-03-02 | 2004-11-23 | Vijay Mahant | Methods and apparatus for separation of biological fluids |
KR100968164B1 (en) | 1999-03-10 | 2010-07-06 | 더 리전츠 오브 더 유니버시티 오브 캘리포니아 | Adipose-derived stem cells and lattices |
US6777231B1 (en) | 1999-03-10 | 2004-08-17 | The Regents Of The University Of California | Adipose-derived stem cells and lattices |
WO2000054651A2 (en) | 1999-03-15 | 2000-09-21 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like genes |
AU3766700A (en) | 1999-03-22 | 2000-10-09 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like 2 |
US6662805B2 (en) | 1999-03-24 | 2003-12-16 | The Johns Hopkins University | Method for composite cell-based implants |
GB9907243D0 (en) | 1999-03-29 | 1999-05-26 | Reneuron Ltd | Therapy |
US20040131601A1 (en) | 2000-03-30 | 2004-07-08 | Foundry Networks, Inc., A Delaward Corporation | Injection of bone marrow-derived cells and medium for angiogenesis |
AU4329300A (en) | 1999-04-01 | 2000-10-23 | Osiris Therapeutics, Inc. | Human mesenchymal dnas and expression products |
US20030007954A1 (en) | 1999-04-12 | 2003-01-09 | Gail K. Naughton | Methods for using a three-dimensional stromal tissue to promote angiogenesis |
US7759113B2 (en) | 1999-04-30 | 2010-07-20 | The General Hospital Corporation | Fabrication of tissue lamina using microfabricated two-dimensional molds |
US6423681B1 (en) | 1999-05-04 | 2002-07-23 | The Trustees Of Columbia University In The City Of New York | Method of inducing formation of kidney epithelia from mesenchymal precursors |
JP2002544486A (en) | 1999-05-10 | 2002-12-24 | プロリンクス・インコーポレイテッド | Cell separation device and use thereof |
US6372494B1 (en) | 1999-05-14 | 2002-04-16 | Advanced Tissue Sciences, Inc. | Methods of making conditioned cell culture medium compositions |
US6339141B1 (en) | 1999-05-20 | 2002-01-15 | Hycey Inc. | Interleukin-1 Hy2 materials and methods |
WO2000073417A1 (en) | 1999-05-27 | 2000-12-07 | The Research Foundation Of State University Of New York | In vitro cell culture device including cartilage and methods of using the same |
US7135335B2 (en) | 1999-05-28 | 2006-11-14 | Stemcell Technologies Inc. | Method for separating cells using immunorosettes |
DE60013277T2 (en) | 1999-06-03 | 2005-08-11 | The University Of North Carolina At Chapel Hill | DESIGN OF A BIOREACTOR AND METHOD FOR MANIPULATING CELL TISSUE |
US6979308B1 (en) | 1999-06-03 | 2005-12-27 | University Of North Carolina At Chapel Hill | Bioreactor design and process for engineering tissue from cells |
GB9913185D0 (en) | 1999-06-07 | 1999-08-04 | Nat Power Plc | Sulfur precipitation detector |
GB2350895B (en) | 1999-06-07 | 2001-08-29 | Nat Power Plc | Methods for monitoting sulfonyl halide functional group content of materials |
JP2003509012A (en) | 1999-06-15 | 2003-03-11 | ジーントロール バイオセラピューティクス, インコーポレイテッド | Methods for enhancing cytokine production in cell culture |
MXPA01013423A (en) | 1999-06-21 | 2002-12-05 | Gen Hospital Corp | Cell culture systems and methods for organ assist devices. |
US6562616B1 (en) | 1999-06-21 | 2003-05-13 | The General Hospital Corporation | Methods and devices for cell culturing and organ assist systems |
US6821513B1 (en) | 1999-06-23 | 2004-11-23 | Oregon Health & Science University | Method for enhancing hematopoiesis |
WO2001000783A2 (en) | 1999-06-25 | 2001-01-04 | Advanced Tissue Sciences, Inc. | Monitorable three-dimensional scaffolds and tissue culture systems |
AU774876B2 (en) | 1999-06-29 | 2004-07-08 | Board Of Trustees Of The Leland Stanford Junior University | Mammalian myeloid progenitor cell subsets |
US6761883B2 (en) | 1999-06-29 | 2004-07-13 | The Board Of Trustees Of The Leland Stanford Junior University | Mammalian myeloid progenitor cell subsets |
US6333029B1 (en) | 1999-06-30 | 2001-12-25 | Ethicon, Inc. | Porous tissue scaffoldings for the repair of regeneration of tissue |
US7621606B2 (en) | 2001-08-27 | 2009-11-24 | Advanced Cell Technology, Inc. | Trans-differentiation and re-differentiation of somatic cells and production of cells for cell therapies |
US6306424B1 (en) | 1999-06-30 | 2001-10-23 | Ethicon, Inc. | Foam composite for the repair or regeneration of tissue |
GB9915413D0 (en) | 1999-07-01 | 1999-09-01 | Glaxo Group Ltd | Propagation method |
MY124198A (en) | 1999-07-02 | 2006-06-30 | Regenesys Tech Limited | Electrolyte rebalancing system |
US7670628B2 (en) | 1999-07-07 | 2010-03-02 | Angioblast Systems, Inc. | Mesenchymal precursor cell |
US20050158289A1 (en) | 1999-07-07 | 2005-07-21 | Simmons Paul J. | Mesenchymal precursor cell and use thereof in the repair of bone defects and fractures in mammals |
AU2003901668A0 (en) | 2003-03-28 | 2003-05-01 | Medvet Science Pty. Ltd. | Non-haemopoietic precursor cells |
AUPQ147799A0 (en) | 1999-07-07 | 1999-07-29 | Medvet Science Pty. Ltd. | Mesenchymal precursor cell |
US6872389B1 (en) | 1999-07-08 | 2005-03-29 | Rhode Island Hospital | Liver stem cell |
DE19932439C2 (en) | 1999-07-12 | 2002-06-13 | Sefar Ag Rueschlikon | bioreactor |
US6951738B2 (en) | 1999-07-16 | 2005-10-04 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptors TR13 and TR14 |
NZ516738A (en) | 1999-07-20 | 2004-01-30 | Univ Southern California | Identification of pluripotent pre-mesenchymal, pre-hematopoietic progenitor cells expressing a unique molecular marker |
US6394812B1 (en) | 1999-07-22 | 2002-05-28 | Organogenesis Inc. | Vivo induction for enhanced function of isolated hepatocytes |
BR0012787A (en) | 1999-07-28 | 2002-07-30 | Univ Leland Stanford Junior | Nicotine receptor agonists in stem cell and progenitor cell recruitment |
AU781084B2 (en) | 1999-07-28 | 2005-05-05 | Board Of Trustees Of The Leland Stanford Junior University | Nicotine in therapeutic angiogenesis and vasculogenesis |
US7927587B2 (en) | 1999-08-05 | 2011-04-19 | Regents Of The University Of Minnesota | MAPC administration for the treatment of lysosomal storage disorders |
EP2348104A1 (en) | 1999-08-05 | 2011-07-27 | Mcl Llc | Multipotent adult stem cells and methods for isolation |
US8075881B2 (en) | 1999-08-05 | 2011-12-13 | Regents Of The University Of Minnesota | Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure |
US7015037B1 (en) | 1999-08-05 | 2006-03-21 | Regents Of The University Of Minnesota | Multiponent adult stem cells and methods for isolation |
US8147824B2 (en) | 1999-08-05 | 2012-04-03 | Athersys, Inc. | Immunomodulatory properties of multipotent adult progenitor cells and uses thereof |
US10638734B2 (en) | 2004-01-05 | 2020-05-05 | Abt Holding Company | Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof |
US8252280B1 (en) | 1999-08-05 | 2012-08-28 | Regents Of The University Of Minnesota | MAPC generation of muscle |
US6719969B1 (en) | 1999-08-09 | 2004-04-13 | The Regents Of The University Of Michigan | Treatment of liver disease and injury with CXC chemokines |
US6555374B1 (en) | 1999-08-19 | 2003-04-29 | Artecel Sciences, Inc. | Multiple mesodermal lineage differentiation potentials for adipose tissue-derived stromal cells and uses thereof |
US6429013B1 (en) | 1999-08-19 | 2002-08-06 | Artecel Science, Inc. | Use of adipose tissue-derived stromal cells for chondrocyte differentiation and cartilage repair |
US6482411B1 (en) | 1999-08-27 | 2002-11-19 | Board Of Regents, The University Of Texas System | Methods of reducing bone loss with CD40 ligand |
ATE346911T1 (en) | 1999-09-07 | 2006-12-15 | Tyco Healthcare | SUPPORT MATERIAL FOR GROWING CELLS |
EP1087010B1 (en) | 1999-09-08 | 2011-11-09 | Levitronix LLC | Bioreactor with single-use pump |
US6239157B1 (en) | 1999-09-10 | 2001-05-29 | Osiris Therapeutics, Inc. | Inhibition of osteoclastogenesis |
WO2001021766A2 (en) | 1999-09-23 | 2001-03-29 | Cell Science Therapeutics | Methods and devices for obtaining non-hematopoietic lineage cells from hematopoietic progenitor cells |
US20030161817A1 (en) | 2001-03-28 | 2003-08-28 | Young Henry E. | Pluripotent embryonic-like stem cells, compositions, methods and uses thereof |
EP1218489B1 (en) | 1999-09-24 | 2009-03-18 | Cybios LLC | Pluripotent embryonic-like stem cells, compositions, methods and uses thereof |
WO2001022810A2 (en) | 1999-09-28 | 2001-04-05 | Us Transgenics, Inc. | Transgenic animals expressing von willebrand factor (vwf) and vwf-related polypeptides |
AUPQ319199A0 (en) | 1999-09-30 | 1999-10-28 | Unisearch Limited | Method and apparatus for culturing cells |
US6528052B1 (en) | 2000-09-29 | 2003-03-04 | The Board Of Trustees Of The Leland Stanford Junior University | Method for in vivo ex vivo and in vitro repair and regeneration of cartilage and collagen and bone remodeling |
DE19948184C2 (en) | 1999-10-06 | 2001-08-09 | Fraunhofer Ges Forschung | Electrochemical production of peroxodisulfuric acid using diamond coated electrodes |
ES2230157T3 (en) | 1999-10-06 | 2005-05-01 | Tigenix N.V. | INSULATION OF PRECURSOR CELLS AND ITS USE FOR REPAIR OF FABRICS. |
US6685936B2 (en) | 1999-10-12 | 2004-02-03 | Osiris Therapeutics, Inc. | Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation |
US6599520B2 (en) | 1999-10-14 | 2003-07-29 | Osteotech, Inc. | Method of inducing new bone growth in porous bone sites |
WO2001029189A2 (en) | 1999-10-15 | 2001-04-26 | Mount Sinai Hospital | Synthetic substrate for tissue formation |
CA2389488A1 (en) | 1999-10-29 | 2001-05-17 | Philadelphia Health & Education Corporation | Isolation and expansion of human marrow stromal cells |
US20040033599A1 (en) | 1999-10-29 | 2004-02-19 | Lawrence Rosenberg | Medium for preparing dedifferentiated cells |
US20050037490A1 (en) | 1999-10-29 | 2005-02-17 | Lawrence Rosenberg | Medium for preparing dedifferentiated cells |
US6280718B1 (en) | 1999-11-08 | 2001-08-28 | Wisconsin Alumni Reasearch Foundation | Hematopoietic differentiation of human pluripotent embryonic stem cells |
US20010044413A1 (en) | 1999-12-01 | 2001-11-22 | Glenn Pierce | In situ bioreactors and methods of use thereof |
IL149933A0 (en) | 1999-12-06 | 2002-11-10 | Gen Hospital Corp | Pancreatic stem cells and their use in transplantation |
US6541249B2 (en) | 1999-12-22 | 2003-04-01 | Human Genome Sciences, Inc. | Immortalized human stromal cell lines |
US20020142457A1 (en) | 1999-12-28 | 2002-10-03 | Akihiro Umezawa | Cell having the potentiality of differentiation into cardiomyocytes |
US6811776B2 (en) | 2000-12-27 | 2004-11-02 | The Regents Of The University Of Michigan | Process for ex vivo formation of mammalian bone and uses thereof |
WO2001048147A1 (en) | 1999-12-28 | 2001-07-05 | Iso Tis N.V. | Cell culture medium containing growth factors and l-glutamine |
US6479064B1 (en) | 1999-12-29 | 2002-11-12 | Children's Medical Center Corporation | Culturing different cell populations on a decellularized natural biostructure for organ reconstruction |
US6368859B1 (en) | 1999-12-29 | 2002-04-09 | Children's Medical Center Corporation | Methods and compositions for producing a fascial sling |
US20020063763A1 (en) | 2000-11-29 | 2002-05-30 | Mantell David Allen | Apparatus and method for removing air bubbles from an ink jet printhead |
US6428802B1 (en) | 1999-12-29 | 2002-08-06 | Children's Medical Center Corp. | Preparing artificial organs by forming polylayers of different cell populations on a substrate |
AU784361C (en) | 1999-12-30 | 2007-03-15 | Imclone Systems Incorporated | Progenitor cell preservation factors and related methods and products |
US6544506B2 (en) | 2000-01-05 | 2003-04-08 | Yeda Research & Development Co. Ltd. | Veto cells effective in preventing graft rejection and devoid of graft versus host potential |
US7455983B2 (en) | 2000-01-11 | 2008-11-25 | Geron Corporation | Medium for growing human embryonic stem cells |
WO2001052649A1 (en) | 2000-01-18 | 2001-07-26 | The Board Of Trustees Of The Leland Stanford Junior University | Expansion of stem and progenitor cells by beta-catenin |
EP1218002A4 (en) | 2000-01-24 | 2004-09-22 | Jozef S Mruk | Use of flavone 8-acetic acid in vascular and cardiovascular interventions and acute coronary syndromes |
ATE481111T1 (en) | 2000-01-31 | 2010-10-15 | Rothenpieler Uwe Waldemar | PAX2 FOR THE TREATMENT OF KIDNEY DISEASE |
US6610535B1 (en) | 2000-02-10 | 2003-08-26 | Es Cell International Pte Ltd. | Progenitor cells and methods and uses related thereto |
US6770478B2 (en) | 2000-02-10 | 2004-08-03 | The Regents Of The University Of California | Erythrocytic cells and method for preserving cells |
US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
PT1261694E (en) | 2000-02-26 | 2008-04-03 | Artecel Inc | Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof |
AU2001239947A1 (en) | 2000-02-29 | 2001-09-12 | Curis, Inc. | Methods and compositions for regulating adipocytes |
US6630153B2 (en) | 2001-02-23 | 2003-10-07 | Smith & Nephew, Inc. | Manufacture of bone graft substitutes |
US6849454B2 (en) | 2000-03-07 | 2005-02-01 | St. Jude Children's Research Hospital | Highly efficient gene transfer into human repopulating stem cells by RD114 pseudotyped retroviral vector particles |
US7160724B2 (en) | 2000-03-09 | 2007-01-09 | University Of South Florida | Human cord blood as a source of neural tissue for repair of the brain and spinal cord |
US6607522B1 (en) | 2000-03-16 | 2003-08-19 | General Hospital Corporation | Methods for tissue welding using laser-activated protein solders |
JP2001261587A (en) | 2000-03-21 | 2001-09-26 | Shimadzu Corp | Communication system for automatic synthesis device |
US20010049139A1 (en) | 2000-03-23 | 2001-12-06 | Eric Lagasse | Hepatic regeneration from hematopoietic stem cells |
GB2362752B (en) | 2000-03-24 | 2002-06-05 | Innogy Ltd | Method of operating a fuel cell |
GB2365964B (en) | 2000-03-24 | 2002-07-10 | Innogy Ltd | Membrane moisture measurement |
AU2001250865A1 (en) | 2000-03-29 | 2001-10-08 | Bioaccess, Inc. | System and method for processing bone marrow |
US6683192B2 (en) | 2000-03-30 | 2004-01-27 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
GB2360789A (en) | 2000-03-30 | 2001-10-03 | Christopher Mason | Method of producing tissue structures |
US6613798B1 (en) | 2000-03-30 | 2003-09-02 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
US6673606B1 (en) | 2000-04-12 | 2004-01-06 | The Children's Hospital Of Philadelphia | Therapeutic uses for mesenchymal stromal cells |
US7585412B2 (en) | 2000-04-13 | 2009-09-08 | Transvivo, Inc. | Specialized hollow fiber membranes for plasmapheresis and ultrafiltration |
US7195711B2 (en) | 2000-04-13 | 2007-03-27 | Transvivo Inc. | Specialized hollow fiber membranes for in-vivo plasmapheresis and ultrafiltration |
US6802820B1 (en) | 2000-04-13 | 2004-10-12 | Transvivo, Inc. | Specialized hollow fiber membranes for in-vivo plasmapheresis and ultrafiltration |
US7572374B2 (en) | 2000-04-13 | 2009-08-11 | Transvivo, Inc. | Anticoagulant and thrombo-resistant hollow fiber membranes for in-vivo plasmapheresis and ultrafiltration |
GB0009506D0 (en) | 2000-04-17 | 2000-06-07 | Innogy Ltd | Ion exchange membrane |
US6458589B1 (en) | 2000-04-27 | 2002-10-01 | Geron Corporation | Hepatocyte lineage cells derived from pluripotent stem cells |
US7473555B2 (en) | 2000-04-27 | 2009-01-06 | Geron Corporation | Protocols for making hepatocytes from embryonic stem cells |
AU5743601A (en) | 2000-04-28 | 2001-11-12 | Childrens Medical Center | Isolation of mesenchymal stem cells and use thereof |
US6690981B1 (en) | 2000-05-04 | 2004-02-10 | National Instruments Corporation | System and method for encapsulating user interface code for a graphical program |
US6828145B2 (en) | 2000-05-10 | 2004-12-07 | Cedars-Sinai Medical Center | Method for the isolation of stem cells by immuno-labeling with HLA/MHC gene product marker |
US20040087016A1 (en) | 2000-05-12 | 2004-05-06 | University Of Utah Research Foundation | Compositions and methods for cell dedifferentiation and tissue regeneration |
US8273570B2 (en) | 2000-05-16 | 2012-09-25 | Riken | Process of inducing differentiation of embryonic cell to cell expressing neural surface marker using OP9 or PA6 cells |
US6988004B2 (en) | 2000-05-16 | 2006-01-17 | Bioheart, Inc. | Method for inducing angiogenesis by electrical stimulation of muscles |
US20020009743A1 (en) | 2000-05-17 | 2002-01-24 | Carpenter Melissa K. | Neural progenitor cell populations |
US6645727B2 (en) | 2000-05-26 | 2003-11-11 | Stemcell Technologies Inc. | Antibody compositions for preparing enriched mesenchymal progenitor preparations |
DE10026482A1 (en) | 2000-05-29 | 2001-12-13 | Augustinus Bader | Process for the production of a bioartificial graft |
ES2312447T3 (en) | 2000-05-31 | 2009-03-01 | Novartis Vaccines And Diagnostics, Inc. | PROCEDURE FOR PURIFICATION OF ALFAVIRUS REPLICATION PARTICLES. |
AU2001264763A1 (en) | 2000-06-05 | 2001-12-17 | University Of South Florida | Human mesenchymal progenitor cell |
US7049072B2 (en) | 2000-06-05 | 2006-05-23 | University Of South Florida | Gene expression analysis of pluri-differentiated mesenchymal progenitor cells and methods for diagnosing a leukemic disease state |
WO2001094413A2 (en) | 2000-06-06 | 2001-12-13 | Bristol-Myers Squibb Company | B7-related nucleic acids and polypeptides and their uses for immunomodulation |
WO2001097872A1 (en) | 2000-06-22 | 2001-12-27 | Austin Sam L | Bioadhesive compositions and methods of preparation and use |
US6632620B1 (en) | 2000-06-22 | 2003-10-14 | Andrew N. Makarovskiy | Compositions for identification and isolation of stem cells |
WO2002000849A1 (en) | 2000-06-26 | 2002-01-03 | Renomedix Institute Inc. | Cell fraction containing cells capable of differentiating into nervous system cells |
BR0111948A (en) | 2000-06-26 | 2004-08-24 | Rxkinetix Inc | Composition for delivery of hematopoietic growth factor |
US6759039B2 (en) | 2000-06-30 | 2004-07-06 | Amcyte, Inc. | Culturing pancreatic stem cells having a specified, intermediate stage of development |
EP3020804A1 (en) | 2000-07-06 | 2016-05-18 | Sarepta Therapeutics, Inc. | Transforming growth factor beta (tgf- ) blocking agent-treated stem cell composition and method |
US6719970B1 (en) | 2000-07-10 | 2004-04-13 | Alkermes Controlled Therapeutics, Inc. | Method of generating cartilage |
DE20012003U1 (en) | 2000-07-11 | 2000-10-12 | Geis John S | Device for introducing particles into a body tissue, in particular muscle tissue |
US7686799B2 (en) | 2000-07-13 | 2010-03-30 | Abbott Cardiovascular Systems Inc. | Deployment system for myocardial cellular material |
US20030032143A1 (en) | 2000-07-24 | 2003-02-13 | Neff Thomas B. | Collagen type I and type III compositions for use as an adhesive and sealant |
WO2002008389A2 (en) | 2000-07-26 | 2002-01-31 | Scimed Life Systems, Inc. | Therapeutic angiogenesis by bone marrow-derived cell transplantation in myocardial ischemic tissue and skeletal muscle ischemic tissue |
JP2004504834A (en) | 2000-08-01 | 2004-02-19 | イスム リサーチ ディベロップメント カンパニー | Directed differentiation of embryonic cells |
US6984522B2 (en) | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
US6604555B2 (en) | 2000-08-04 | 2003-08-12 | Arch Specialty Chemicals, Inc. | Automatic refill system for ultra pure or contamination sensitive chemicals |
US6593123B1 (en) | 2000-08-07 | 2003-07-15 | Avigen, Inc. | Large-scale recombinant adeno-associated virus (rAAV) production and purification |
EP1309719B2 (en) | 2000-08-14 | 2022-09-07 | University of Maryland at Baltimore County | Bioreactor and bioprocessing technique |
CA2456008A1 (en) | 2000-08-19 | 2002-02-28 | Axordia Limited | Stem cell differentiation |
US20040023324A1 (en) | 2000-08-25 | 2004-02-05 | Seiji Sakano | Stem cell culture medium and culture method by using the same |
DE10042484A1 (en) | 2000-08-29 | 2002-03-28 | Merck Patent Gmbh | Preparing human cartilage implants, useful for repairing damaged joints, comprises culturing autologous chondrocytes in alginate gel at reduced oxygen partial pressure |
US6673603B2 (en) | 2000-09-01 | 2004-01-06 | Modex Therapeutiques, S.A. | Cell paste comprising keratinocytes and fibroblasts |
AU2001286202A1 (en) | 2000-09-12 | 2002-03-26 | Yukio Kato | Method of culturing mesenchymal stem cells |
US7597712B2 (en) | 2000-09-18 | 2009-10-06 | Organogenesis, Inc. | Method for treating a patient using a cultured connective tissue construct |
US6660523B2 (en) | 2000-09-21 | 2003-12-09 | Schering Corporation | Dendritic cells; methods |
US20070122904A1 (en) | 2000-09-29 | 2007-05-31 | Unisearch Limited | Method and apparatus for culturing cells |
US7270996B2 (en) | 2000-10-02 | 2007-09-18 | Cannon Thomas F | Automated bioculture and bioculture experiments system |
US20020146817A1 (en) | 2000-10-02 | 2002-10-10 | Cannon Thomas F. | Automated bioculture and bioculture experiments system |
EP1326968B1 (en) | 2000-10-12 | 2007-04-18 | Agency for Science, Technology and Research | Non-disruptive three-dimensional culture and harvest system for anchorage-dependent cells |
US6734000B2 (en) | 2000-10-12 | 2004-05-11 | Regents Of The University Of California | Nanoporous silicon support containing macropores for use as a bioreactor |
US20020045260A1 (en) | 2000-10-17 | 2002-04-18 | Shih-Chieh Hung | Method of isolating mesenchymal stem cells |
US8383806B2 (en) | 2000-10-20 | 2013-02-26 | University Of Medicine And Dentistry Of New Jersey | Method of reversing carboplatin resistance by inhibition of HGFIN |
US20030202938A1 (en) | 2000-10-20 | 2003-10-30 | Pranela Rameshwar | Hematopoietic growth factor inducible neurokinin-1 gene |
AU2002255458A1 (en) | 2000-10-20 | 2002-08-19 | University Of Medicine And Dentistry New Jersey Medical School | Hematopoietic growth factor inducible neurokinin-1 gene |
US7052517B2 (en) | 2000-10-24 | 2006-05-30 | Vita Special Purpose Corporation | Delivery device for biological composites and method of preparation thereof |
WO2002055095A2 (en) | 2000-11-06 | 2002-07-18 | Vi Technologies Inc | Use of aziridino-compounds in the treatment of immune dysfunctions |
AU2002239336A1 (en) | 2000-11-10 | 2002-06-03 | Arbor Vita Corporation | Molecular interactions in hematopoietic cells |
US6642019B1 (en) | 2000-11-22 | 2003-11-04 | Synthecan, Inc. | Vessel, preferably spherical or oblate spherical for growing or culturing cells, cellular aggregates, tissues and organoids and methods for using same |
US6576464B2 (en) | 2000-11-27 | 2003-06-10 | Geron Corporation | Methods for providing differentiated stem cells |
US20030027331A1 (en) | 2000-11-30 | 2003-02-06 | Yan Wen Liang | Isolated homozygous stem cells, differentiated cells derived therefrom, and materials and methods for making and using same |
US20040072259A1 (en) | 2001-11-29 | 2004-04-15 | Scadden David T. | Methods and products for manipulating hematopoietic stem cells |
US20020136709A1 (en) | 2000-12-12 | 2002-09-26 | Nucleus Remodeling, Inc. | In vitro-derived adult pluripotent stem cells and uses therefor |
US20020077687A1 (en) | 2000-12-14 | 2002-06-20 | Ahn Samuel S. | Catheter assembly for treating ischemic tissue |
WO2002053193A2 (en) | 2001-01-02 | 2002-07-11 | The Charles Stark Draper Laboratory, Inc. | Tissue engineering of three-dimensional vascularized using microfabricated polymer assembly technology |
EP1349614A2 (en) | 2001-01-03 | 2003-10-08 | President And Fellows Of Harvard College | Compounds regulating cell proliferation and differentiation |
US6616912B2 (en) | 2001-01-05 | 2003-09-09 | Spectrum Laboratories, Inc. | Bi-component microporous hollow fiber membrane structure for in vivo propagation of cells |
US20040079248A1 (en) | 2001-01-10 | 2004-04-29 | Yaron Mayer | Printer capable of printing simultaneously on both sides of the page |
EP1370642A2 (en) | 2001-01-20 | 2003-12-17 | Cardion AG | Pluripotent adult stem cells derived from regenerative tissue |
US7487182B2 (en) | 2001-01-23 | 2009-02-03 | Conformia Software, Inc. | Systems and methods for managing the development and manufacturing of a drug |
US20040077079A1 (en) | 2001-01-31 | 2004-04-22 | Peter Storgaard | Improved in vitro method of culturing mammalian cells for autologous cell implantation/transplantation methods |
US7045098B2 (en) | 2001-02-02 | 2006-05-16 | James Matthew Stephens | Apparatus and method for removing interfering substances from a urine sample using a chemical oxidant |
EP2316919B1 (en) | 2001-02-14 | 2015-10-07 | Anthrogenesis Corporation | Post-partum mammalian placenta, its use and placental stem cells therefrom |
WO2002063962A1 (en) | 2001-02-14 | 2002-08-22 | Hariri Robert J | Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells |
EP1367899A4 (en) | 2001-02-14 | 2004-07-28 | Leo T Furcht | Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof |
US7326564B2 (en) | 2001-02-20 | 2008-02-05 | St. Jude Medical, Inc. | Flow system for medical device evaluation and production |
GB2372875B (en) | 2001-03-02 | 2003-04-16 | Innogy Ltd | Process for operating a regenerative fuel cell |
US6808503B2 (en) | 2001-03-06 | 2004-10-26 | Baxter International Inc. | Automated system and method for pre-surgical blood donation and fluid replacement |
US6706008B2 (en) | 2001-03-06 | 2004-03-16 | Baxter International Inc. | Automated system and method for withdrawing compounds from blood |
US6582386B2 (en) | 2001-03-06 | 2003-06-24 | Baxter International Inc. | Multi-purpose, automated blood and fluid processing systems and methods |
US6884228B2 (en) | 2001-03-06 | 2005-04-26 | Baxter International Inc. | Automated system adaptable for use with different fluid circuits |
WO2002070506A2 (en) | 2001-03-07 | 2002-09-12 | Websar Innovations Inc. | Conversion of cbd to δ8-thc and δ9-thc |
US7341062B2 (en) | 2001-03-12 | 2008-03-11 | Bioheart, Inc. | Method of providing a dynamic cellular cardiac support |
US20020132343A1 (en) | 2001-03-19 | 2002-09-19 | Clark Lum | System and method for delivering umbilical cord-derived tissue-matched stem cells for transplantation |
AU2002306763A1 (en) | 2001-03-20 | 2002-10-03 | University Of Virginian Patent Foundation | Methods for identifying and purifying smooth muscle progenitor cells |
EP2522304B1 (en) | 2001-03-23 | 2014-01-08 | Histogenics Corporation | Composition and methods for the production of biological tissues and tissue constructs |
US7056738B2 (en) | 2001-03-23 | 2006-06-06 | Tulane University | Early stage multipotential stem cells in colonies of bone marrow stromal cells |
US6696575B2 (en) | 2001-03-27 | 2004-02-24 | Board Of Regents, The University Of Texas System | Biodegradable, electrically conducting polymer for tissue engineering applications |
US6629612B2 (en) | 2001-03-30 | 2003-10-07 | Carl H. Critz | Biological filtration station |
US20030027330A1 (en) | 2001-04-02 | 2003-02-06 | Robert Lanza | Method for facilitating the production of differentiated cell types and tissues from embryonic and adult pluripotent and multipotent cells |
JP2004536794A (en) | 2001-04-09 | 2004-12-09 | メドトロニック、インコーポレイテッド | Method for separating blood components using microcentrifuge and method for using the same |
US6841386B2 (en) | 2001-04-10 | 2005-01-11 | Viacell, Inc. | Modulation of primary stem cell differentiation using an insulin-like growth factor binding protein |
CA2367636C (en) | 2001-04-12 | 2010-05-04 | Lisa Mckerracher | Fusion proteins |
KR100449141B1 (en) | 2001-04-19 | 2004-09-21 | (주)라이프코드 | Method for differentiating a mesenchymal stem cell into neural cells |
GB2374722B (en) | 2001-04-20 | 2003-05-28 | Innogy Technology Ventures Ltd | Regenerative fuel cell with pH control |
DE60232585D1 (en) | 2001-04-24 | 2009-07-23 | Dolores Baksh | Precursor cell populations, their expansion, and the development of non-haematopoietic cell types |
JP2003284570A (en) | 2001-04-25 | 2003-10-07 | Chemo Sero Therapeut Res Inst | VON WILLEBRAND FACTOR (vWF) BREAKING ENZYME |
CA2445458C (en) | 2001-04-25 | 2016-12-13 | Cornell Research Foundation, Inc. | Devices and methods for pharmacokinetic-based cell culture system |
US20050130297A1 (en) | 2001-04-26 | 2005-06-16 | Societe Nouvelle Cell Tissue Progress | Cell and tissue culture device with temperature regulation |
WO2002090489A1 (en) | 2001-05-09 | 2002-11-14 | Bayer Pharmaceuticals Corporation | A cryopreservation bag assembly for mammalian cell lines |
US6582955B2 (en) | 2001-05-11 | 2003-06-24 | Spectrum Laboratories, Inc. | Bioreactor with application as blood therapy device |
US6814961B1 (en) | 2001-05-14 | 2004-11-09 | Gitte S. Jensen | Method for enhancing stem cell trafficking |
US20020197240A1 (en) | 2001-05-15 | 2002-12-26 | Chiu Ray C. | Marrow stem cell (MSC) transplantation for use in tissue and/or organ repair |
AU2002309330A1 (en) | 2001-05-17 | 2002-11-25 | Isotis N.V. | Isolation method of mesenchymal cells |
US6461853B1 (en) | 2001-05-17 | 2002-10-08 | Hong Zhu | Method for surface culture of microorganisms and cells in flexible culture bags |
GB2392116A (en) | 2001-05-31 | 2004-02-25 | Asahi Chemical Ind | Method of separating and concentrating cells for kidney regeneration |
AUPR540301A0 (en) | 2001-06-01 | 2001-06-28 | Walter And Eliza Hall Institute Of Medical Research, The | A method of purification of cells |
AU2002345691C1 (en) | 2001-06-13 | 2008-07-24 | Massachusetts Institute Of Technology | In vivo bioreactors |
US6566126B2 (en) | 2001-06-22 | 2003-05-20 | Fibercell Systems, Inc. | Apparatus and method for growing cells |
DE10130512B4 (en) | 2001-06-25 | 2007-08-16 | Bionethos Holding Gmbh | Device for pressure perfusion for growing and / or treating cells |
DE10130657A1 (en) | 2001-06-27 | 2003-01-16 | Axaron Bioscience Ag | New endothetially expressed protein and its use |
US6685971B2 (en) | 2001-06-28 | 2004-02-03 | Rongxiang Xu | Method and composition for repairing and promoting regeneration of mucosal tissue in the gastrointestinal tract |
US6626950B2 (en) | 2001-06-28 | 2003-09-30 | Ethicon, Inc. | Composite scaffold with post anchor for the repair and regeneration of tissue |
CN1827766B (en) | 2001-06-28 | 2010-08-25 | 徐荣祥 | In vitro cell cultivation method |
US6972195B2 (en) | 2002-09-27 | 2005-12-06 | Rongxiang Xu | Composition and method for culturing potentially regenerative cells and functional tissue-organs in vitro |
CA2453381A1 (en) | 2001-07-10 | 2003-01-23 | Massachusetts Institute Of Technology | Methods for ex vivo propagation of somatic stem cells |
CA2453804A1 (en) | 2001-07-17 | 2003-04-10 | Massachusetts Institute Of Technology | Unique properties of stem cells |
US20030017587A1 (en) | 2001-07-18 | 2003-01-23 | Rader William C. | Embryonic stem cells, clinical applications and methods for expanding in vitro |
DE10134667A1 (en) | 2001-07-20 | 2003-02-06 | Neuroprogen Gmbh Leipzig | Process for the production of isolated cell cultures, culture medium for the cultivation of cell cultures and cell culture |
US7452529B2 (en) | 2001-07-23 | 2008-11-18 | Viacell, Inc. | Treatment of muscular dystrophy with cord blood cells |
CA2452256A1 (en) | 2001-07-24 | 2003-02-06 | Es Cell International Pte Ltd | Methods of inducing differentiation of stem cells |
US20030049236A1 (en) | 2001-07-27 | 2003-03-13 | Arhus Amt | Immortalized stem cells |
WO2003013336A2 (en) | 2001-08-03 | 2003-02-20 | Stemsource Llc | Devices and method for extraction of bone marrow |
CA2456981C (en) | 2001-08-06 | 2012-02-28 | Bresagen, Inc. | Alternative compositions and methods for the culture of stem cells |
US20040235160A1 (en) | 2001-08-07 | 2004-11-25 | Mitsuo Nishikawa | Process for preparing hematopoietic stem cells |
JP2004537999A (en) | 2001-08-09 | 2004-12-24 | プロキュア・セラピューティクス・リミテッド | Cell culture method for obtaining prostate-like glands |
US20030211603A1 (en) | 2001-08-14 | 2003-11-13 | Earp David J. | Reprogramming cells for enhanced differentiation capacity using pluripotent stem cells |
AUPR703601A0 (en) | 2001-08-15 | 2001-09-06 | Peter Maccallum Cancer Institute, The | Identification and isolation of somatic stem cells and uses thereof |
JP2003052360A (en) | 2001-08-20 | 2003-02-25 | Japan Science & Technology Corp | Method for culturing mesenchymal stem cell using extracellular substrate of basement membrane cell |
US6617152B2 (en) | 2001-09-04 | 2003-09-09 | Corning Inc | Method for creating a cell growth surface on a polymeric substrate |
JP2003070464A (en) | 2001-09-04 | 2003-03-11 | Mitsubishi Heavy Ind Ltd | Method for culturing cell, method for producing artificial organ and the resultant artificial organ |
US20030104997A1 (en) | 2001-09-05 | 2003-06-05 | Black Ira B. | Multi-lineage directed induction of bone marrow stromal cell differentiation |
WO2003023019A1 (en) | 2001-09-07 | 2003-03-20 | Fox Chase Cancer Center | Methods and cell cultures for promoting organogenesis and tissue development |
US20050032207A1 (en) | 2001-09-12 | 2005-02-10 | Anna Wobus | Method for isolating, culturing and differentiating intestinal stem cells for therapeutic use |
US20030054331A1 (en) | 2001-09-14 | 2003-03-20 | Stemsource, Inc. | Preservation of non embryonic cells from non hematopoietic tissues |
US6790455B2 (en) | 2001-09-14 | 2004-09-14 | The Research Foundation At State University Of New York | Cell delivery system comprising a fibrous matrix and cells |
DE10147463B4 (en) | 2001-09-20 | 2009-03-19 | Hemoteq Ag | Process for the preparation of an absorber, absorber and its use |
US20050053587A1 (en) | 2001-09-20 | 2005-03-10 | Jacques Galipeau | Cultured stromal cells and uses thereof |
KR20040039382A (en) | 2001-09-20 | 2004-05-10 | 교와 핫꼬 고교 가부시끼가이샤 | Pluripotent stem cells originating in skeletal muscle intestinal tissue |
JP2004248505A (en) | 2001-09-21 | 2004-09-09 | Norio Nakatsuji | Undifferentiated fusion cell of somatic cell derived from es cell deficient in part or all of transplantation antigen and method for producing the same |
US6805860B1 (en) | 2001-09-30 | 2004-10-19 | Eckhard Alt | Method of transluminal application of myogenic cells for repair or replacement of heart tissue |
US6767740B2 (en) | 2001-10-09 | 2004-07-27 | Roger Anton Sramek | Stem cell and dental pulp harvesting method and apparatus |
AU2002341992A1 (en) | 2001-10-09 | 2003-04-22 | Millipore Corporation | Chemical process machine programming system |
US6645763B2 (en) | 2001-10-12 | 2003-11-11 | Naoya Kobayashi | Immortalized bone marrow mesenchymal stem cell |
US20030124091A1 (en) | 2001-10-26 | 2003-07-03 | Large Scale Biology Corporation | Endothelial cell derived hematopoietic growth factor |
WO2003038048A2 (en) | 2001-10-30 | 2003-05-08 | The United States Of America As Represented By The Secretary Of The Navy | Ex-vivo rescue of transplantable hematopoietic stem cells following myeloablative injury |
AUPR856501A0 (en) | 2001-10-30 | 2001-11-29 | Peter Maccallum Cancer Institute, The | Detection of haematopoietic stem cells and progeny and uses thereof |
CA2465653C (en) | 2001-10-30 | 2013-10-08 | Renomedix Institute Inc. | Method for inducing differentiation of mesodermal stem cells, es cells, or immortalized mesodermal stem cells into neural cells |
US20050084959A1 (en) | 2001-10-31 | 2005-04-21 | Hirofumi Hamada | Immortalized mesenchymal cells and utilization thereof |
US20040214314A1 (en) | 2001-11-02 | 2004-10-28 | Friedrich Srienc | High throughput bioreactor |
AU2002361601A1 (en) | 2001-11-06 | 2003-05-19 | Mark C. Fishman | Stem and progenitor cell capture for tissue regeneration |
IL161862A0 (en) | 2001-11-08 | 2005-11-20 | Univ California | Methods and compositions for correction of cardiac conduction disturbances |
AU2002350139A1 (en) | 2001-11-09 | 2003-05-26 | Viacell, Inc. | Production of cell suspensions |
KR20050044393A (en) | 2001-11-09 | 2005-05-12 | 아르테셀 사이언스, 인크. | Endocrine pancreas differentiation of adipose tissue-derived stromal cells and uses thereof |
US20030152558A1 (en) | 2001-11-09 | 2003-08-14 | Christopher Luft | Methods and compositions for the use of stromal cells to support embryonic and adult stem cells |
DE10156201C1 (en) | 2001-11-15 | 2002-10-17 | Voith Paper Patent Gmbh | To process high consistency paper fiber materials, an initial high consistency volume is held in a stack for a dwell time, to be taken off at the bottom by a circulation flow for dilution and delivery as a suspension |
CA2467258A1 (en) | 2001-11-15 | 2003-05-22 | Kyowa Hakko Kogyo Co., Ltd. | Agent for inducing embryonic stem cell to ectodermal cell, method for obtaining the same and use of the same. |
US20030113813A1 (en) | 2001-11-15 | 2003-06-19 | Heidaran Mohammad A. | Methods and devices for the integrated discovery of cell culture environments |
DE60233248D1 (en) | 2001-11-15 | 2009-09-17 | Childrens Medical Center | PROCESS FOR THE ISOLATION, EXPANSION AND DIFFERENTIATION OF FEDERAL STRAIN CELLS FROM CHORION ZOTTE, FRUIT WATER AND PLAZENTA AND THERAPEUTIC USES THEREOF |
DE10158680B4 (en) | 2001-11-30 | 2004-04-08 | Universitätsklinikum Hamburg-Eppendorf | Process for ex vivo expansion and differentiation of multipotent stem cells |
US6712850B2 (en) | 2001-11-30 | 2004-03-30 | Ethicon, Inc. | Porous tissue scaffolds for the repair and regeneration of dermal tissue |
US20050008626A1 (en) | 2001-12-07 | 2005-01-13 | Fraser John K. | Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions |
US7514075B2 (en) | 2001-12-07 | 2009-04-07 | Cytori Therapeutics, Inc. | Systems and methods for separating and concentrating adipose derived stem cells from tissue |
US9597395B2 (en) | 2001-12-07 | 2017-03-21 | Cytori Therapeutics, Inc. | Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions |
US20040224403A1 (en) | 2001-12-07 | 2004-11-11 | Robarts Research Institute | Reconstituting hematopoietic cell function using human embryonic stem cells |
US6951752B2 (en) | 2001-12-10 | 2005-10-04 | Bexter Healthcare S.A. | Method for large scale production of virus antigen |
US7504258B2 (en) | 2001-12-11 | 2009-03-17 | Cytograft Tissue Engineering, Inc. | Tissue engineered cellular sheets, methods of making and use thereof |
WO2003050273A1 (en) | 2001-12-13 | 2003-06-19 | Japan Science And Technology Agency | Human cell culture medium and culture method |
US20030113910A1 (en) | 2001-12-18 | 2003-06-19 | Mike Levanduski | Pluripotent stem cells derived without the use of embryos or fetal tissue |
US20030180296A1 (en) | 2001-12-20 | 2003-09-25 | Theodora Salcedo | Antibodies that immunospecifically bind to trail receptors |
CA2470707C (en) | 2001-12-21 | 2014-07-08 | Mount Sinai Hospital | Cellular compositions and methods of making and using them |
US6855542B2 (en) | 2001-12-21 | 2005-02-15 | Organogenesis Inc. | Chamber with adjustable volume for cell culture and organ assist |
US6695791B2 (en) | 2002-01-04 | 2004-02-24 | Spiration, Inc. | System and method for capturing body tissue samples |
US6777227B2 (en) | 2002-01-09 | 2004-08-17 | John L. Ricci | Bio-reactor and cell culture surface with microgeometric surfaces |
US7687505B2 (en) | 2002-01-14 | 2010-03-30 | Board Of Trustees Of The University Of Illinois | Use of modified pyrimidine compounds to promote stem cell migration and proliferation |
FR2834898B1 (en) | 2002-01-18 | 2005-06-10 | Didier Pourquier | NEW THERAPEUTIC APPLICATION OF G-CSF, GM-CSF AND SCF |
FR2834899B1 (en) | 2002-01-18 | 2005-06-10 | Didier Pourquier | NEW THERAPEUTIC APPLICATION OF G-CSF, GM-CSF AND SCF FACTORS |
US20040014209A1 (en) | 2002-01-23 | 2004-01-22 | Lassar Andrew B. | Compositions and methods for modulating cell differentiation |
IL152904A0 (en) | 2002-01-24 | 2003-06-24 | Gamida Cell Ltd | Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations |
US7033823B2 (en) | 2002-01-31 | 2006-04-25 | Cesco Bioengineering, Inc. | Cell-cultivating device |
JP4741189B2 (en) | 2002-02-08 | 2011-08-03 | ユニヴァーシティ オブ サウス フロリダ | Expanded cell lines and methods of use |
WO2003068961A2 (en) | 2002-02-13 | 2003-08-21 | Axordia Limited | Method to modify differentiation of pluripotential stem cells |
US7736892B2 (en) | 2002-02-25 | 2010-06-15 | Kansas State University Research Foundation | Cultures, products and methods using umbilical cord matrix cells |
US7378246B2 (en) | 2002-02-28 | 2008-05-27 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for regulating adipogenesis |
US20060057657A1 (en) | 2002-03-12 | 2006-03-16 | Oregon Health & Science University Technology & Research Collaborations | Stem cell selection and differentiation |
AUPS112802A0 (en) | 2002-03-15 | 2002-04-18 | Monash University | Methods of inducing differentiation of stem cells into a specific cell lineage |
EP1485479A2 (en) | 2002-03-19 | 2004-12-15 | The University Of Sheffield | Stem cell culture |
US20040009589A1 (en) | 2002-03-26 | 2004-01-15 | Shulamit Levenberg | Endothelial cells derived from human embryonic stem cells |
GB0207214D0 (en) | 2002-03-27 | 2002-05-08 | Univ Loughborough | A catalyst for lowering the reduction overpotential of polysulfide species |
CA2503681A1 (en) | 2002-04-05 | 2003-10-23 | Marc K. Hellerstein | Method for isolating and measuring proliferation of long-term label retaining cells and stem cells |
AU2003218572B2 (en) | 2002-04-08 | 2009-08-20 | Octane Biotech, Inc. | Automated tissue engineering system |
US7060494B2 (en) | 2002-04-09 | 2006-06-13 | Reliance Life Sciences Pvt. Ltd. | Growth of human Mesenchymal Stem Cells (hMSC) using umbilical cord blood serum and the method for the preparation thereof |
ITTO20020311A1 (en) | 2002-04-10 | 2003-10-10 | Medestea Int Spa | PROCEDURE FOR THE PREPARATION OF STEM CELLS FROM MUSCLE FABRIC AND HUMAN FAT FABRIC AND STEM CELLS OBTAINABLE BY T |
US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
AU2003231358A1 (en) | 2002-04-17 | 2003-10-27 | Otsuka Pharmaceutical Co., Ltd. | METHOD OF FORMING PANCREATIC Beta CELLS FROM MESENCHYMAL CELLS |
US20040161419A1 (en) | 2002-04-19 | 2004-08-19 | Strom Stephen C. | Placental stem cells and uses thereof |
AUPS187202A0 (en) | 2002-04-22 | 2002-05-30 | Griffith University | Method for culturing stem cells |
US7576186B2 (en) | 2002-04-23 | 2009-08-18 | Roger Williams Hospital | Compositions and methods for stem cell delivery |
CA2483441A1 (en) | 2002-04-24 | 2003-11-06 | The Council Of The Queensland Institute Of Medical Research | Mannose binding lectin and uses thereof |
US7271234B2 (en) | 2002-04-24 | 2007-09-18 | Rutgers, The State University Of New Jersey | Polyarylates for drug delivery and tissue engineering |
ITMI20021008A1 (en) | 2002-05-13 | 2003-11-13 | San Raffaele Centro Fond | METHOD FOR ESTABLISHING AND EXPANDING MULTIANGIOBLASTIC MULTI-ANGULAR STEM CELLS |
US20040242469A1 (en) | 2002-05-13 | 2004-12-02 | Lee Richard T. | Angiogenesis and cardiac tissue engineering with peptide hydrogels and related compositions and methods of use thereof |
JP2003332274A (en) | 2002-05-17 | 2003-11-21 | Tokyo Seimitsu Co Ltd | Chemical mechanical polishing method and chemical mechanical polishing apparatus |
US7119071B2 (en) | 2002-05-21 | 2006-10-10 | University Of Medicine And Dentistry Of New Jersey | Amino terminal substance P compositions and methods for using the same |
US20040091936A1 (en) | 2002-05-24 | 2004-05-13 | Michael West | Bank of stem cells for producing cells for transplantation having HLA antigens matching those of transplant recipients, and methods for making and using such a stem cell bank |
EP1367119B1 (en) | 2002-05-28 | 2008-09-17 | Toyo Boseki Kabushiki Kaisha | Methods of culturing, storing, and inducing differentiation in cells, instrument for use in the methods and method of using the instrument. |
US7048922B2 (en) | 2002-05-29 | 2006-05-23 | Demao Yang | Stimulation of hematopoiesis by ex vivo activated immune cells |
US20030022390A1 (en) | 2002-05-30 | 2003-01-30 | Stephens James Matthew | Method and kit for making interfering substances in urine undetectable |
US7491367B2 (en) | 2002-06-04 | 2009-02-17 | Applera Corporation | System and method for providing a standardized state interface for instrumentation |
WO2003104789A1 (en) | 2002-06-06 | 2003-12-18 | Rutgers, The State University Of New Jersey | MULTIFUNCTIONAL BIOSENSOR BASED ON ZnO NANOSTRUCTURES |
US8377683B2 (en) | 2002-06-06 | 2013-02-19 | Rutgers, The State University Of New Jersey | Zinc oxide-based nanostructure modified QCM for dynamic monitoring of cell adhesion and proliferation |
US7989851B2 (en) | 2002-06-06 | 2011-08-02 | Rutgers, The State University Of New Jersey | Multifunctional biosensor based on ZnO nanostructures |
US7160719B2 (en) | 2002-06-07 | 2007-01-09 | Mayo Foundation For Medical Education And Research | Bioartificial liver system |
AU2003275991A1 (en) | 2002-06-13 | 2003-12-31 | Sonya H. Murray | Liver assist system based on hollow fiber cartridges or rotating bioreactor |
FI113099B (en) | 2002-06-25 | 2004-02-27 | Ensto Electric Oy | Arrangements in connection with a system for functional control |
US20050282733A1 (en) | 2002-06-27 | 2005-12-22 | Prins Johannes B | Differentiation modulating agents and uses therefor |
WO2005014775A2 (en) | 2002-06-28 | 2005-02-17 | University Of Florida Research Foundation, Inc. | Raav compositions and methods for delivery of human factor vii polypeptides and treatment of hemophilia a |
US6730510B2 (en) | 2002-07-02 | 2004-05-04 | Organogenesis, Inc. | Culture dish and bioreactor system |
US20050136093A1 (en) | 2002-07-05 | 2005-06-23 | Polyzenix Gmbh | Implant for transport and release for pharmacologically active agents as well as a process for producing the same |
US7754943B2 (en) | 2002-07-11 | 2010-07-13 | Bses Limited | Transgenic plants used as a bioreactor system |
US20040009158A1 (en) | 2002-07-11 | 2004-01-15 | Washington University | Promotion of neovascularization using bone marrow-derived endothelial-progenitor cells |
CA2493871A1 (en) | 2002-07-16 | 2004-01-22 | Hadi Aslan | Methods of implanting mesenchymal stem cells for tissue repair and formation |
AU2003251992A1 (en) | 2002-07-17 | 2004-02-02 | Rutgers, The State University | Therapeutic devices for patterned cell growth |
AU2003259152A1 (en) | 2002-07-23 | 2004-02-09 | Boston Scientific Limited | Cell therapy for regeneration |
FR2842943B1 (en) | 2002-07-24 | 2005-07-01 | Commissariat Energie Atomique | METHOD FOR MANUFACTURING ANISOTROPIC CONDUCTIVE POLYMER FILM ON SEMICONDUCTOR WAFER |
US7422736B2 (en) | 2002-07-26 | 2008-09-09 | Food Industry Research And Development Institute | Somatic pluripotent cells |
WO2004013275A2 (en) | 2002-07-31 | 2004-02-12 | Yves Saint-Laurent Parfums | Stem cells derived from adipous tissue and differentiated cells derived from said cells |
AU2003252559A1 (en) | 2002-08-17 | 2004-03-03 | Hae-Young Suh | A method for transdifferentiating mesenchymal stem cells into neuronal cells |
US6943008B1 (en) | 2002-08-21 | 2005-09-13 | Florida State University Research Foundation, Inc. | Bioreactor for cell culture |
GB2393726A (en) | 2002-08-21 | 2004-04-07 | Regenesys Tech Ltd | Ion exchange membranes formed from hydrolysed polymers |
US20050271639A1 (en) | 2002-08-22 | 2005-12-08 | Penn Marc S | Genetically engineered cells for therapeutic applications |
US20040161412A1 (en) | 2002-08-22 | 2004-08-19 | The Cleveland Clinic Foundation | Cell-based VEGF delivery |
US20040037811A1 (en) | 2002-08-22 | 2004-02-26 | The Cleveland Clinic Foundation | Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy |
US20060128014A1 (en) | 2002-08-26 | 2006-06-15 | Johan Haggblad | Compositions and methods for culturing stem cells |
DE10244859B4 (en) | 2002-09-20 | 2007-01-11 | Leibniz-Institut Für Polymerforschung Dresden E.V. | Bioreactor with modular structure, in particular for ex-vivo cell proliferation |
AU2003275140A1 (en) | 2002-09-23 | 2004-04-08 | Massachusetts Institute Of Technology | Theree-dimensional construct for the design and fabrication of physiological fluidic networks |
AU2002348947A1 (en) | 2002-09-26 | 2004-04-19 | Institut National De La Sante Et De La Recherche Medicale | Compositions and methods for amplification of human stem cells |
US20040062753A1 (en) | 2002-09-27 | 2004-04-01 | Alireza Rezania | Composite scaffolds seeded with mammalian cells |
US20040121464A1 (en) | 2002-09-30 | 2004-06-24 | Rathjen Peter David | Method for the preparation of cells of mesodermal lineage |
US20050031587A1 (en) | 2002-10-04 | 2005-02-10 | Yamanouchi Pharmaceutical Co., Ltd. | Immune response induction method |
JP2006501848A (en) | 2002-10-04 | 2006-01-19 | ティシュテク,インク. | Culture and transplantation of retinal pigment epithelial cells in amniotic membrane |
US20040067585A1 (en) | 2002-10-07 | 2004-04-08 | Yu-Chi Wang | Cell cultivation surface and method of making the same |
US7776594B2 (en) | 2002-10-10 | 2010-08-17 | Wright Medical Technology, Inc. | Bone marrow infusion chamber and method |
AU2003286442A1 (en) | 2002-10-16 | 2004-05-04 | Advanced Cell Technology, Inc. | Methods using gene trapped stem cells for marking pathways of stem cell differentiation and making and isolating differentiated cells |
WO2004034890A2 (en) | 2002-10-17 | 2004-04-29 | Vacanti, Joseph, P. | Biological scaffolding material |
US20040151729A1 (en) | 2002-10-28 | 2004-08-05 | George Michalopoulos | Novel long-term three-dimensional culture system |
AU2003287429A1 (en) | 2002-11-01 | 2004-06-07 | Five Prime Therapeutics, Inc. | Stem cell libraries |
WO2004042033A2 (en) | 2002-11-01 | 2004-05-21 | The Board Of Trustees Of The Leland Stanford Junior University | Circulating stem cells and uses related thereto |
CA2505251A1 (en) | 2002-11-05 | 2004-05-27 | Brigham And Women's Hospital, Inc. | Mesenchymal stem cells and methods of use thereof |
US20050003534A1 (en) | 2002-11-07 | 2005-01-06 | Eliezer Huberman | Human stem cell materials and methods |
AU2003285172A1 (en) | 2002-11-08 | 2004-06-03 | The Johns Hopkins University | Human embryonic stem cell cultures, and compositions and methods for growing same |
WO2004044127A2 (en) | 2002-11-08 | 2004-05-27 | Viacell, Inc. | Stem cell populations |
WO2004042040A1 (en) | 2002-11-08 | 2004-05-21 | Reprocell Inc. | Expansion agents for stem cells |
KR100452403B1 (en) | 2002-11-19 | 2004-10-12 | 한국과학기술연구원 | Hybrid bioreactor for cell culture |
US20040101959A1 (en) | 2002-11-21 | 2004-05-27 | Olga Marko | Treatment of tissue with undifferentiated mesenchymal cells |
US20050112762A1 (en) | 2002-11-26 | 2005-05-26 | The Corporation Of The Trustees Of The Sisters Of Mercy In Queensland | Method for culturing dendritic cells |
AU2003298016A1 (en) | 2002-11-27 | 2004-06-23 | Regents Of The University Of Minnesota | Homologous recombination in multipotent adult progenitor cells |
US7947499B2 (en) | 2002-11-29 | 2011-05-24 | Technion Research & Development Foundation Ltd. | Method of dynamically culturing embryonic stem cells |
US20040110286A1 (en) | 2002-12-06 | 2004-06-10 | The John P. Robarts Research Institute | Method for making hematopoietic cells |
US20050031598A1 (en) | 2002-12-10 | 2005-02-10 | Shulamit Levenberg | Engineering three-dimensional tissue structures using differentiating embryonic stem cells |
US7252995B2 (en) | 2002-12-13 | 2007-08-07 | Yu-Show Fu | Method of generating neurons from stem cells and medium for culturing stem cells |
US20040115804A1 (en) | 2002-12-13 | 2004-06-17 | Yu-Show Fu | Cell system for generating somatic cells |
CN100549163C (en) | 2002-12-16 | 2009-10-14 | 技术研究及发展基金有限公司 | The stem cell culture for preparing the method for no feeder cell, no allogenic human embryo stem cell and use this method preparation |
DE10327988B4 (en) | 2002-12-18 | 2009-05-14 | Alpha Plan Gmbh | Filter module for the treatment of liquids |
US20040128077A1 (en) | 2002-12-27 | 2004-07-01 | Automated Cell, Inc. | Method and apparatus for following cells |
US20040126405A1 (en) | 2002-12-30 | 2004-07-01 | Scimed Life Systems, Inc. | Engineered scaffolds for promoting growth of cells |
US7071001B2 (en) | 2003-01-10 | 2006-07-04 | Dnk Associates, Inc. | System and method for in vitro bleeding time testing |
US20040143863A1 (en) | 2003-01-10 | 2004-07-22 | Linheng Li | Hematopoietic stem cell niche cells |
US20050002914A1 (en) | 2003-01-15 | 2005-01-06 | Rosen Michael R. | Mesenchymal stem cells as a vehicle for ion channel transfer in syncytial structures |
DE602004022508D1 (en) | 2003-01-16 | 2009-09-24 | Gen Hospital Corp | USE OF THREE-DIMENSIONAL, MICRO-MANUFACTURED SYSTEMS FOR PHARMACOLOGICAL APPLICATIONS MANUFACTURED BY TISSUE TECHNOLOGY |
US20040151706A1 (en) | 2003-01-27 | 2004-08-05 | Alex Shakhov | Collection and storage of biological specimens containing stem cells from healthy individuals for future use in treatment of their own cytopathological illnesses or other medical conditions |
AU2004207261B2 (en) | 2003-01-27 | 2009-07-09 | Harvest Technologies Inc | Autologous or homologous coagulant produced from anticoagulated whole blood |
US7186554B2 (en) | 2003-01-28 | 2007-03-06 | Stanford University | Methods and compositions for human bladder epithelial cell culture |
WO2004069172A2 (en) | 2003-01-30 | 2004-08-19 | The Government of the United States of America as represented by the Department of Veterans Affairs | Multilineage-inducible cells and uses thereof |
CA2514474C (en) | 2003-01-30 | 2014-05-06 | Avner Yayon | Freeze-dried fibrin matrices and methods for preparation thereof |
JP2006519015A (en) | 2003-01-31 | 2006-08-24 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | Use of Islet1 as a marker for isolating or generating stem cells |
US20040197310A1 (en) | 2003-02-12 | 2004-10-07 | Sanberg Paul R. | Compositions and methods for using umbilical cord progenitor cells in the treatment of myocardial infarction |
WO2004072264A2 (en) | 2003-02-12 | 2004-08-26 | Johns Hopkins University School Of Medicine | Fate determination by hes 1 in hematopoietic stem-progenitor cells and uses thereof |
MXPA05008445A (en) | 2003-02-13 | 2005-10-18 | Anthrogenesis Corp | Use of umbilical cord blood to treat individuals having a disease, disorder or condition. |
US7300571B2 (en) | 2003-02-13 | 2007-11-27 | Zenon Technology Partnership | Supported biofilm apparatus |
US7175763B2 (en) | 2003-02-13 | 2007-02-13 | Zenon Technology Partnership | Membrane supported biofilm process for autotrophic reduction |
CN100361907C (en) | 2003-02-13 | 2008-01-16 | 泽农技术合伙公司 | Supported biofilm apparatus and process |
US7294259B2 (en) | 2003-02-13 | 2007-11-13 | Zenon Technology Partnership | Membrane module for gas transfer |
KR20050102115A (en) | 2003-02-13 | 2005-10-25 | 제논 인바이런멘탈 인코포레이티드 | Supported biofilm apparatus and process |
US7303676B2 (en) | 2003-02-13 | 2007-12-04 | Zenon Technology Partnership | Supported biofilm apparatus and process |
US20070155661A1 (en) | 2003-02-14 | 2007-07-05 | The Board Of Trustees Of The Leland Standord Junior University | Methods and compositions for modulating the development of stem cells |
GB0304030D0 (en) | 2003-02-21 | 2003-03-26 | King S College London | Teeth |
WO2004076608A2 (en) | 2003-02-26 | 2004-09-10 | Georgia Tech Research Corporation | Bioreactor and methods for tissue growth and conditioning |
WO2004076642A2 (en) | 2003-02-27 | 2004-09-10 | The Rockefeller University | Method for modulating epithelial stem cell lineage |
AU2003900944A0 (en) | 2003-02-28 | 2003-03-13 | The University Of Queensland | Cell isolation & enrichment |
AU2004219820B2 (en) | 2003-03-10 | 2008-06-12 | Japan Science And Technology Agency | Marker for detecting mesenchymal stem cell and method of distinguishing mesenchymal stem cell using the marker |
US7153650B2 (en) | 2003-03-13 | 2006-12-26 | Geron Corporation | Marker system for preparing and characterizing high-quality human embryonic stem cells |
WO2004087870A2 (en) | 2003-03-25 | 2004-10-14 | The Johns Hopkins University | Neuronal cell lineages and methods of production thereof |
WO2004087896A2 (en) | 2003-03-31 | 2004-10-14 | Pfizer Products Inc. | Hepatocyte differentiation of stem cells |
US8603462B2 (en) | 2003-04-01 | 2013-12-10 | University Of Utah Research Foundation | Stem-cell, precursor cell, or target cell-based treatment of multi-organ failure and renal dysfunction |
US20040197375A1 (en) | 2003-04-02 | 2004-10-07 | Alireza Rezania | Composite scaffolds seeded with mammalian cells |
WO2004094588A2 (en) | 2003-04-19 | 2004-11-04 | Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health | Postnatal stem cells and uses thereof |
US7494811B2 (en) | 2003-05-01 | 2009-02-24 | Lifenet Health | In vitro growth of tissues suitable to the formation of bone and bone forming tissue formed thereby |
EP1641911A2 (en) | 2003-05-02 | 2006-04-05 | Insception Bioscience, Inc. | Apparatus and methods for amplification of blood stem cell numbers |
AU2004242091C1 (en) | 2003-05-07 | 2009-12-24 | La Jolla Institute For Molecular Medicine | Administration of hyaluronic acid to enhance the function of transplanted stem cells |
US7485460B2 (en) | 2003-05-21 | 2009-02-03 | Tulane University Health Sciences Center | Enhanced growth of adult stem cells with Dkk-1 |
WO2005001033A2 (en) | 2003-05-22 | 2005-01-06 | The Cleveland Clinic Foundation | Tolerance induction and maintenance in hematopoietic stem cell allografts |
JP2006525855A (en) | 2003-05-23 | 2006-11-16 | アンジオテック インターナショナル アクツィエン ゲゼルシャフト | Anastomosis joining device |
US20050014255A1 (en) | 2003-05-29 | 2005-01-20 | Board Of Regents, The University Of Texas System | Stem cells for clinical and commercial uses |
AU2003902776A0 (en) | 2003-06-03 | 2003-06-19 | Monash University | Method for expanding cells |
US20050019801A1 (en) | 2003-06-04 | 2005-01-27 | Curis, Inc. | Stem cell-based methods for identifying and characterizing agents |
CA2528134C (en) | 2003-06-04 | 2015-05-12 | University Of South Carolina | Tissue scaffold having aligned fibrils, apparatus and method for producing the same, and artificial tissue and methods of use thereof |
US7425440B2 (en) | 2003-06-10 | 2008-09-16 | The Automation Partnership (Cambridge) Limited | Culture flask |
DE10326750B4 (en) | 2003-06-13 | 2006-07-27 | Gerlach, Jörg, Dr.med. | Process for the preparation of a cell preparation and cell preparations prepared in this way |
DE10326764A1 (en) | 2003-06-13 | 2004-12-30 | Biotest Ag | Endothelium-protective perfusion solution, an apparatus and method for preserving the endothelium in isolated hollow organs and biological vessels |
DE10362002B4 (en) | 2003-06-23 | 2006-10-12 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Adult pluripotent stem cells |
AU2004249812B8 (en) | 2003-06-25 | 2011-09-15 | Ottawa Hospital Research Institute | Methods and compositions for modulating stem cell growth and differentiation |
EP1648999A4 (en) | 2003-06-25 | 2006-09-06 | Macropore Biosurgery Inc | Systems and methods for separating and concentrating regenerative cells from tissue |
CA2529718C (en) | 2003-06-27 | 2012-10-23 | Universite Laval | Method of isolating cells from umbilical cord |
CA2530533C (en) | 2003-06-27 | 2015-02-10 | Ethicon, Incorporated | Postpartum cells derived from umbilical cord tissue, and methods of making and using the same |
WO2005003320A2 (en) | 2003-07-02 | 2005-01-13 | Regents Of The University Of Minnesota | Neuronal differentiation of stem cells |
WO2005010172A2 (en) | 2003-07-16 | 2005-02-03 | Boston Scientific Limited | Aligned scaffolds for improved myocardial regeneration |
WO2005007799A2 (en) | 2003-07-17 | 2005-01-27 | Gamida-Cell Ltd. | Methods for ex-vivo expanding stem/progenitor cells |
EP1646715B1 (en) | 2003-07-22 | 2010-05-12 | Vivalis | Production of poxviruses with adherent or non adherent avian cell lines |
ITRM20030376A1 (en) | 2003-07-31 | 2005-02-01 | Univ Roma | PROCEDURE FOR THE ISOLATION AND EXPANSION OF CARDIOC STAMIN CELLS FROM BIOPSIA. |
JP4522994B2 (en) | 2003-08-01 | 2010-08-11 | 憲正 中村 | Scaffold-free self-organized 3D synthetic tissue (scaffold-freeSelf-Organized 3D synthetic tissue) |
EP2266500B1 (en) | 2003-08-01 | 2015-04-01 | CellSeed Inc. | Three-dimensional tissue structure |
US20050032122A1 (en) | 2003-08-06 | 2005-02-10 | Shiaw-Min Hwang | Optimizing culture medium for CD34<+> hematopoietic cell expansion |
DE10336152B4 (en) | 2003-08-06 | 2007-02-15 | Nephrogen LLC, Salt Lake City | Purification method for human mesenchymal stem cells |
US7074615B2 (en) | 2003-08-15 | 2006-07-11 | Becton, Dickinson And Company | Peptides for enhanced cell attachment and cell growth |
WO2005029224A2 (en) | 2003-09-12 | 2005-03-31 | Arkados, Inc. | Method and system for distributed content management and delivery |
EP1670511B1 (en) | 2003-09-15 | 2009-07-29 | Research Development Foundation | Cripto antagonism of activin and tgf-b signaling |
JP5186109B2 (en) | 2003-09-25 | 2013-04-17 | ラトガース,ザ ステート ユニバーシティ | Polymer products that are essentially radiopaque for embolization treatment |
WO2005044972A2 (en) | 2003-11-06 | 2005-05-19 | Nunc A/S | A three-dimensional carrier for culturing microbiological material |
US20050148512A1 (en) | 2003-11-10 | 2005-07-07 | Angiotech International Ag | Medical implants and fibrosis-inducing agents |
WO2005051452A2 (en) | 2003-11-20 | 2005-06-09 | Angiotech International Ag | Polymer compositions and methods for their use |
CA2536188A1 (en) | 2003-11-20 | 2005-06-09 | Angiotech International Ag | Electrical devices and anti-scarring agents |
US20050208095A1 (en) | 2003-11-20 | 2005-09-22 | Angiotech International Ag | Polymer compositions and methods for their use |
US7368169B2 (en) | 2003-12-01 | 2008-05-06 | Rutgers, The State University Of New Jersey | Hydrazide compounds with angiogenic activity |
TWI338714B (en) | 2003-12-02 | 2011-03-11 | Cathay General Hospital | Method of isolation and enrichment of mesenchymal stem cells from amniotic fluid |
EP1694345A1 (en) | 2003-12-04 | 2006-08-30 | Regents Of The University Of Minnesota | Compositions and methods for the treatment of lysosomal storage disorders |
US7608447B2 (en) | 2003-12-09 | 2009-10-27 | Ben Gurion University Of The Negev Research And Development Authority | Pulse-medium perfusion bioreactor with improved mass transport for multiple-3-D cell constructs |
CA2550326A1 (en) | 2003-12-19 | 2005-07-14 | Viacell, Inc. | Use of human cord blood-derived pluripotent cells for the treatment of disease |
US20050137517A1 (en) | 2003-12-19 | 2005-06-23 | Baxter International Inc. | Processing systems and methods for providing leukocyte-reduced blood components conditioned for pathogen inactivation |
GB0329449D0 (en) | 2003-12-19 | 2004-01-28 | Omnicyte Ltd | Stem cells |
US7172696B1 (en) | 2004-01-02 | 2007-02-06 | Spectrum Laboratories, Inc. | Radial dispersion mass transfer device having a semi-permeable tubular hollow fiber membrane wound around a porous core |
US20050180957A1 (en) | 2004-01-16 | 2005-08-18 | Scharp David W. | Method of using fibrin-bound angiogenic factors to stimulate vascularization of transplant site of encapsulated cells |
US7192776B2 (en) | 2004-01-28 | 2007-03-20 | James Matthew Stephens | Synthetic urine and method of manufacturing same |
WO2005076843A2 (en) | 2004-02-06 | 2005-08-25 | Elan Pharmaceuticals, Inc. | Methods and compositions for treating tumors and metastatic disease |
WO2005075636A1 (en) | 2004-02-09 | 2005-08-18 | The University Of Queensland | Molecular markers associated with metanephric development and renal progenitors |
WO2005087915A2 (en) | 2004-03-08 | 2005-09-22 | Biovest International, Inc. | Use of ethanolamine for enhancing cell growth in membrane systems |
JP2005278564A (en) | 2004-03-30 | 2005-10-13 | Hitachi Medical Corp | Cell culture apparatus |
RU2252252C1 (en) | 2004-04-09 | 2005-05-20 | Тепляшин Александр Сергеевич | Method for isolation of mesenchymal stem cells |
US7785883B2 (en) | 2004-04-28 | 2010-08-31 | Vax Design Corp. | Automatable artificial immune system (AIS) |
US20070298015A1 (en) | 2004-04-28 | 2007-12-27 | Viacell, Inc. | Treatment of Muscular Dystrophy with Mobilized Peripheral Blood Pluripotent Cells |
US7855074B2 (en) | 2004-04-28 | 2010-12-21 | Vaxdesign Corp. | Artificial immune system: methods for making and use |
WO2005107760A1 (en) | 2004-04-30 | 2005-11-17 | Irm Llc | Compounds and compositions as inducers of keratinocyte differentiation |
US20090214382A1 (en) | 2004-05-05 | 2009-08-27 | Wilson Burgess | Methods of sterilizing biological mixtures using alpha-keto acids |
US7658738B2 (en) | 2004-05-14 | 2010-02-09 | Ethicon Endo-Surgery, Inc. | Medical devices for use with endoscope |
AU2005247967B2 (en) | 2004-05-26 | 2011-09-01 | Octane Biotech, Inc. | Advanced tissue engineering system |
US7361493B1 (en) | 2004-05-26 | 2008-04-22 | The United States Of America As Represented By The Secretary Of The Department Of Veterans Affairs | Production of urokinase in a three-dimensional cell culture |
US7531351B2 (en) | 2004-06-14 | 2009-05-12 | Probiogen Ag | Liquid-gas-phase exposure reactor for cell culturing |
US7335508B2 (en) | 2004-07-22 | 2008-02-26 | Prochon Biotech Ltd. | Porous plasma protein matrices and methods for preparation thereof |
JP4831687B2 (en) | 2004-07-23 | 2011-12-07 | 株式会社カネカ | Method for inducing differentiation from mesenchymal stem cells to odontoblasts |
CH697191A5 (en) | 2004-07-29 | 2008-06-25 | Biospectra Ag | Multiple bio-reactor device. |
US7588938B2 (en) | 2004-08-04 | 2009-09-15 | The United States Of America As Represented By The Secretary Of The Navy | Neural stem cell-collagen-bioreactor system to construct a functional embryonic brain-like tissue |
WO2006019043A1 (en) | 2004-08-17 | 2006-02-23 | Kyushu Institute Of Technology | Porous sheet member for cell culture and, utilizing the same, bioreactor and culturing method |
US20080268538A1 (en) | 2004-09-10 | 2008-10-30 | Robert Nordon | Device and Method to Prevent Culture Media Degradation |
DE102004044429B4 (en) | 2004-09-14 | 2009-04-30 | Biotest Ag | Process for the preparation of a composition containing von Willebrand factor |
ES2710099T3 (en) | 2004-09-24 | 2019-04-23 | Mesoblast Inc | Progeny of multipotential expanded mesenchymal precursor cells (MEMP) and their uses |
AU2005287855B2 (en) | 2004-09-24 | 2011-06-16 | Mesoblast, Inc. | Method of enhancing proliferation and/or survival of mesenchymal precursor cells (MPC) |
EP2302388A1 (en) | 2004-10-14 | 2011-03-30 | Genentech, Inc. | COP1 molecules and uses thereof |
JP2008518603A (en) | 2004-11-01 | 2008-06-05 | ウイスコンシン アラムニ リサーチ ファンデーション | Stem cell-derived platelets |
US7439057B2 (en) | 2004-11-16 | 2008-10-21 | La Jolla Bioengineering Institute | Convective flow tissue assembly |
DK1819230T3 (en) | 2004-12-07 | 2012-08-20 | Univ Miami | ERYTROCYTA FLATED MICROPARTICLES AS HEMOSTATIC AGENTS FOR THE CONTROL OF HEMORAGY AND FOR THE TREATMENT OF BLEEDING DISORDERS |
US20060166364A1 (en) | 2004-12-22 | 2006-07-27 | Introgen, Inc. | Use of flexible bag containers for viral production |
US9163208B2 (en) | 2005-01-04 | 2015-10-20 | Larry Runyon | Method and system for bioreaction |
US7682823B1 (en) | 2005-01-04 | 2010-03-23 | Larry Runyon | Bioreactor systems |
CA2937005A1 (en) | 2005-03-22 | 2006-09-28 | President And Fellows Of Harvard College | Treatment of protein degradation disorders |
EP1890820A4 (en) | 2005-03-22 | 2012-04-11 | Cascade Medical Entpr Llc | Systems and methods of producing membranes |
JP5462483B2 (en) | 2005-04-12 | 2014-04-02 | メゾブラスト,インコーポレーテッド | Isolation of adult pluripotent cells by tissue non-specific alkaline phosphatase |
EP1874922A4 (en) | 2005-04-19 | 2009-10-28 | Univ Johns Hopkins | Method of using stroma cells from cord blood to expand and engraft nucleated cells from cord blood |
WO2006116381A2 (en) | 2005-04-22 | 2006-11-02 | Imquest Biosciences, Inc. | Plasma or serum fraction for treatment or prevention of abnormal cell proliferation |
US20070011752A1 (en) | 2005-05-06 | 2007-01-11 | American Integrated Biologics, Inc. | Production of human proteins in transgenic animal saliva |
US20060258586A1 (en) | 2005-05-06 | 2006-11-16 | Sheppard Paul O | Compositions and uses of secreted polypeptide, Zsig98 |
EP1882030B1 (en) | 2005-05-09 | 2014-08-06 | ALPHA PLAN GmbH | Apparatus for providing media to cell culture modules |
US7831293B2 (en) | 2005-05-10 | 2010-11-09 | Advanced Clinical Solutions, Inc. | Method of defining a biological target for treatment |
WO2006121445A2 (en) | 2005-05-10 | 2006-11-16 | United States Of America Department Of Veteran's Affairs | Therapy of kidney diseases and multiorgan failure with mesenchymal stem cells and mesenchymal stem cell conditioned media |
WO2006121518A2 (en) | 2005-05-10 | 2006-11-16 | Angiotech International Ag | Electrical devices, anti-scarring agents, and therapeutic compositions |
WO2006124021A1 (en) | 2005-05-12 | 2006-11-23 | Angiotech International Ag | Compositions and methods for treating diverticular disease |
EP1888741B1 (en) | 2005-05-27 | 2013-04-17 | Viacell, Inc. | Treatment of ischemia using stem cells |
JP2008545427A (en) | 2005-06-02 | 2008-12-18 | インモーション インベストメント,リミティド | Automatic cell therapy system |
US8058060B2 (en) | 2005-06-10 | 2011-11-15 | Nunc A/S | Culture insert carrier, culture insert and culture insert system |
JP2007000038A (en) | 2005-06-22 | 2007-01-11 | Toray Ind Inc | Closed-system circulatory circuit-type culturing device |
EP1739165A1 (en) | 2005-06-29 | 2007-01-03 | Cellution Biotech B.V. | Method and apparatus for cultivating cells utilizing wave motion |
WO2007015782A1 (en) | 2005-07-29 | 2007-02-08 | Ecole Polytechnique Federale De Lausanne | Molecular variant fibrinogen fusion proteins |
US8486621B2 (en) | 2005-08-11 | 2013-07-16 | Cornell Research Foundation, Inc. | Nucleic acid-based matrixes |
US7943374B2 (en) | 2005-08-21 | 2011-05-17 | Markus Hildinger | Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb |
US20070198063A1 (en) | 2005-10-03 | 2007-08-23 | Hunter William L | Electrical devices and anti-scarring drug combinations |
US20070196421A1 (en) | 2005-10-03 | 2007-08-23 | Hunter William L | Soft tissue implants and drug combination compositions, and use thereof |
US20070197957A1 (en) | 2005-10-03 | 2007-08-23 | Hunter William L | Implantable sensors, implantable pumps and anti-scarring drug combinations |
WO2007041593A2 (en) | 2005-10-03 | 2007-04-12 | Combinatorx, Incorporated | Anti-scarring drug combinations and use thereof |
US7888119B2 (en) | 2005-10-14 | 2011-02-15 | University Of Central Florida Research Foundation, Inc. | Tissue substitutes comprising stem cells and reduced ceria |
US20070116612A1 (en) | 2005-11-02 | 2007-05-24 | Biopath Automation, L.L.C. | Prefix tissue cassette |
WO2007071072A1 (en) | 2005-12-22 | 2007-06-28 | Corporation De L'ecole Polytechnique De Montreal | High-rate perfusion bioreactor |
MX2008008774A (en) | 2006-01-13 | 2008-09-26 | Osiris Therapeutics Inc | Mesenchymal stem cells expressing tnf-î± receptor. |
JP5167150B2 (en) | 2006-02-03 | 2013-03-21 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | Designed cell growth on polymer thin film and its biotechnological application |
SG170761A1 (en) | 2006-03-23 | 2011-05-30 | Pluristem Ltd | Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy |
US20110293583A1 (en) | 2006-03-23 | 2011-12-01 | Pluristem Ltd. | Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy |
US20110171182A1 (en) | 2006-03-23 | 2011-07-14 | Pluristem Ltd. | Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy |
US7682822B2 (en) | 2006-03-31 | 2010-03-23 | Aastrom Biosciences, Inc. | Ex vivo generated tissue system |
US8222308B2 (en) | 2006-04-07 | 2012-07-17 | The University Of Queensland | Porous polymer structures |
AU2007236549B2 (en) | 2006-04-07 | 2011-11-03 | The University Of Melbourne | Porous polymer blend structures |
US20100021990A1 (en) | 2006-04-12 | 2010-01-28 | Wade Edwards | High throughput bioprocess apparatus |
WO2007127848A1 (en) | 2006-04-26 | 2007-11-08 | University Of Louisville Research Foundation, Inc | Isolation of membrane vesicles from biological fluids and methods of using same |
DK2029722T3 (en) | 2006-05-22 | 2020-01-02 | Biovest Int Inc | METHOD AND CELL PRODUCTION PROCEDURE |
US8642307B2 (en) | 2006-05-25 | 2014-02-04 | Nalge Nunc International Corporation | Cell culture surface chemistries |
CA2654376A1 (en) | 2006-06-06 | 2007-12-13 | Rutgers, The State University Of New Jersey | Iodinated polymers |
US20080153077A1 (en) | 2006-06-12 | 2008-06-26 | David Henry | Substrates for immobilizing cells and tissues and methods of use thereof |
US20070295651A1 (en) | 2006-06-26 | 2007-12-27 | Martinez F Jesus | Dialysis bag system |
AU2007265147B2 (en) | 2006-06-26 | 2013-11-07 | Terumo Bct, Inc. | Method of culturing mesenchymal stem cells |
US8497126B2 (en) | 2006-06-30 | 2013-07-30 | Corning Incorporated | Method of making enhanced cell growth surface |
US20100086481A1 (en) | 2006-07-11 | 2010-04-08 | Baird Alison E | Differential expression of molecules associated with intra-cerebral hemorrhage |
WO2008006168A1 (en) | 2006-07-12 | 2008-01-17 | Angioblast Systems, Inc. | Treatment of excessive neovascularization |
US8715718B2 (en) | 2006-07-14 | 2014-05-06 | Rutgers, The State University Of New Jersey | Extracellular matrix production from nanoscale substrate |
AU2007278748B2 (en) | 2006-07-24 | 2013-08-15 | The University Of Queensland | Method of producing a population of cells |
HU3285U (en) | 2006-07-24 | 2007-05-29 | Tamas Dr Molnar | Tissue sample container |
EP2049159A4 (en) | 2006-08-11 | 2011-08-17 | Univ Queensland | Scaffold treatment - device and method |
WO2008028241A1 (en) | 2006-09-06 | 2008-03-13 | The University Of Queensland | Microbioreactor |
PT2086418E (en) | 2006-10-06 | 2011-03-29 | Bard Peripheral Vascular Inc | Tissue handling system with reduced operator exposure |
US20080113440A1 (en) | 2006-10-06 | 2008-05-15 | Leica Biosystems Melbourne Pty Ltd | Method and Apparatus for Tissue Sample Processing |
WO2010033640A1 (en) | 2008-09-16 | 2010-03-25 | Rutgers, The State University Of New Jersey | Bioresorbable polymers synthesized from monomer analogs of natural metabolites |
CN101541355B (en) | 2006-10-17 | 2012-08-08 | 雷瓦医药公司 | N-substituted monomers and polymers |
WO2008049056A2 (en) | 2006-10-18 | 2008-04-24 | Baylor College Of Medicine | Treatment of medical condition with a2 domain of von willebrand factor |
US20080095690A1 (en) | 2006-10-24 | 2008-04-24 | Wei Liu | Nano-sized needle crystal mullite film and method of making |
US20080103412A1 (en) | 2006-11-01 | 2008-05-01 | Yem Chin | Removing Tissue |
EP1935429A1 (en) | 2006-12-22 | 2008-06-25 | CSL Behring GmbH | Synergistic therapeutic use of prothrombin complex concentrates with FVIII concentrates |
JP2010516703A (en) | 2007-01-18 | 2010-05-20 | バクスター・インターナショナル・インコーポレイテッド | Fibrin gel for controlled release of TGF-β and use thereof |
WO2008103744A1 (en) | 2007-02-20 | 2008-08-28 | Rutgers, The State University Of New Jersey | Nerve guidance tubes |
EP2064324B1 (en) | 2007-02-22 | 2011-04-06 | Corning Incorporated | Substrates useful for cell culture and methods for making and using same |
US7718430B2 (en) | 2007-03-01 | 2010-05-18 | Caridianbct, Inc. | Disposable tubing set for use with a cell expansion apparatus and method for sterile sampling |
CA2678893C (en) | 2007-03-05 | 2015-12-29 | Caridianbct, Inc. | Methods to control cell movement in hollow fiber bioreactors |
US20080221444A1 (en) | 2007-03-07 | 2008-09-11 | Ritchie Paul G | Integrated Imaging and Biopsy System with Integrated Surgical, Therapy, and Diagnostic Devices |
JP2010520766A (en) | 2007-03-09 | 2010-06-17 | コーニング インコーポレイテッド | Three-dimensional gum matrix for cell culture, production method and method of use |
US20080220526A1 (en) | 2007-03-09 | 2008-09-11 | Ellison Adam J | Gum coatings for cell culture, methods of manufacture and methods of use |
WO2008112845A2 (en) | 2007-03-14 | 2008-09-18 | Caridianbct, Inc. | Cell expansion apparatus with plate bioreactor |
US8983570B2 (en) | 2007-03-27 | 2015-03-17 | Cardiovascular Biotherapeutics, Inc. | Therapeutic angiogenesis for treatment of the spine |
WO2008116261A1 (en) | 2007-03-27 | 2008-10-02 | The University Of Queensland | Production of particles |
AU2008236529B2 (en) | 2007-04-06 | 2013-09-05 | Terumo Bct, Inc. | Improved bioreactor surfaces |
US8906688B2 (en) | 2007-04-13 | 2014-12-09 | Terumo Bct, Inc. | Cell expansion system and methods of use |
MX2009010997A (en) | 2007-04-13 | 2009-11-02 | Catalyst Biosciences Inc | Modified factor vii polypetides and uses thereof. |
US20080268165A1 (en) | 2007-04-26 | 2008-10-30 | Curtis Robert Fekety | Process for making a porous substrate of glass powder formed through flame spray pyrolysis |
CA2689121A1 (en) | 2007-05-31 | 2008-12-11 | The Children's Hospital Of Philadelphia | Compositions and methods for modulation of adamts13 activity |
US8367078B2 (en) | 2007-06-06 | 2013-02-05 | University Of Florida Research Foundation, Inc. | Kinase inhibitor compounds |
TR201807554T4 (en) | 2007-06-07 | 2018-06-21 | Bayer Animal Health Gmbh | Control of ectoparasites. |
WO2008149129A1 (en) | 2007-06-08 | 2008-12-11 | Nova Thera Limited | Cell expansion |
US8377864B2 (en) | 2007-06-19 | 2013-02-19 | Baxter International Inc. | Fibrin gel for controlled release of PDGF and uses thereof |
US7906076B2 (en) | 2007-07-02 | 2011-03-15 | University Of Massachusetts | Method and apparatus for biopsy sample processing |
US9109193B2 (en) | 2007-07-30 | 2015-08-18 | Ge Healthcare Bio-Sciences Corp. | Continuous perfusion bioreactor system |
TWI603736B (en) | 2007-08-06 | 2017-11-01 | 安吉歐公司 | Method for generating, repairing and/or maintaining connective tissue in vivo |
EP2034010A1 (en) | 2007-08-30 | 2009-03-11 | Omrix Biopharmaceuticals Ltd. | Compositions suitable for repair and/or treatment of injured spinal tissue |
WO2009032117A2 (en) | 2007-08-31 | 2009-03-12 | Corning Incorporated | Reactive surface on a polymeric substrate |
WO2009026635A1 (en) | 2007-08-31 | 2009-03-05 | The University Of Queensland | Production of hyaluronic acid |
WO2009037690A1 (en) | 2007-09-19 | 2009-03-26 | Pluristem Ltd. | Adherent cells from adipose or placenta tissues and use thereof in therapy |
US7923241B2 (en) | 2007-10-10 | 2011-04-12 | Corning Incorporated | Cell culture article and methods thereof |
US8105822B2 (en) | 2007-10-10 | 2012-01-31 | Corning Incorporated | Biosensor article and methods thereof |
US20100297234A1 (en) | 2007-10-19 | 2010-11-25 | Ilene Sugino | Method of using an extracellular matrix to enhance cell transplant survival and differentiation |
US20120219737A1 (en) | 2007-10-19 | 2012-08-30 | University Of Medicine And Dentistry Of New Jersey | Production of extracellular matrix, conditioned media and uses thereof |
EP2339322B1 (en) | 2007-10-23 | 2017-02-15 | Becton, Dickinson and Company | Container system for tissue stabilization |
ES2837748T3 (en) | 2007-10-23 | 2021-07-01 | Becton Dickinson Co | Multi-chamber tissue containment system for molecular and histological diagnosis |
CA2702790C (en) | 2007-10-23 | 2015-06-09 | Becton, Dickinson And Company | Tissue container for molecular and histology diagnostics incorporating a breakable membrane |
BRPI0818068B1 (en) | 2007-10-23 | 2019-06-25 | Becton, Dickinson And Company | TISSUE CONTAINER WITH FLUID DISPLACEMENT FOR MOLECULAR AND HISTOLOGICAL DIAGNOSIS |
US20090104653A1 (en) | 2007-10-23 | 2009-04-23 | Finesse Solutions, Llc. | Bio-process model predictions from optical loss measurements |
US20100021954A1 (en) | 2008-07-23 | 2010-01-28 | Sophie Deshayes | High capacity nanoparticulate immobilization surface |
WO2009058146A1 (en) | 2007-10-31 | 2009-05-07 | Celonova Bioscience, Inc. | Vasodilator eluting blood storage and administration devices with a specific polyphosphazene coating and methods for their manufacture and use |
WO2009080054A1 (en) | 2007-12-21 | 2009-07-02 | Ifxa A/S | Protease inhibitor |
US20100331254A1 (en) | 2007-12-26 | 2010-12-30 | Metamorefix | Pulverized fibrin clots and pharmaceutical compositions containing them |
WO2009099555A2 (en) | 2008-01-30 | 2009-08-13 | Corning Incorporated | Synthetic surfaces for culturing cells in chemically defined media |
US8329469B2 (en) | 2008-01-30 | 2012-12-11 | Geron Corporation | Swellable (meth)acrylate surfaces for culturing cells in chemically defined media |
WO2009099539A2 (en) | 2008-01-30 | 2009-08-13 | Corning Incorporated | (meth)acrylate surfaces for cell culture, methods of making and using the surfaces |
WO2009111022A1 (en) | 2008-03-07 | 2009-09-11 | Corning Incorporated | Hydrophobically modified cellulose ether derivatives for cell culture and release |
US20090227027A1 (en) | 2008-03-07 | 2009-09-10 | Baker Wendy A | Coated cell culture surfaces and methods thereof |
US20090233334A1 (en) | 2008-03-11 | 2009-09-17 | Excellgene Sa | Cell cultivation and production of recombinant proteins by means of an orbital shake bioreactor system with disposable bags at the 1,500 liter scale |
US9458431B2 (en) | 2008-03-17 | 2016-10-04 | Agency For Science, Technology And Research | Microcarriers for stem cell culture |
US20120219531A1 (en) | 2008-03-17 | 2012-08-30 | Agency For Science, Technology And Research | Microcarriers for Stem Cell Culture |
US20110143433A1 (en) | 2008-03-17 | 2011-06-16 | Agency For Science, Technology And Research | Microcarriers for Stem Cell Culture |
US20120028352A1 (en) | 2008-03-17 | 2012-02-02 | Agency For Science, Technology And Research | Microcarriers for Stem Cell Culture |
US8828720B2 (en) | 2008-03-17 | 2014-09-09 | Agency For Science, Technology And Research | Microcarriers for stem cell culture |
TWI465247B (en) | 2008-04-11 | 2014-12-21 | Catalyst Biosciences Inc | Factor vii polypeptides that are modified and uses thereof |
US8532748B2 (en) | 2008-04-23 | 2013-09-10 | Devicor Medical Products, Inc. | Devices useful in imaging |
CA2723276A1 (en) | 2008-05-02 | 2009-11-05 | University Of Western Ontario | Fgf-9 and its use relating to blood vessels |
US9921576B2 (en) | 2008-05-05 | 2018-03-20 | Finesse Solutions, Inc. | Virtual transmitter for bioreactor automation system |
US20110182866A1 (en) | 2008-05-15 | 2011-07-28 | University Of Miami | Isolation of stem cell precursors and expansion in non-adherent conditions |
CA2725637A1 (en) | 2008-05-27 | 2009-12-03 | Pluristem Ltd. | Methods of treating inflammatory colon diseases |
SG10201510586PA (en) | 2008-06-30 | 2016-01-28 | Mesoblast Inc | Treatment of Eye Diseases And Excessive Neovascularization Using A Combined Therapy |
US20100183561A1 (en) | 2008-07-07 | 2010-07-22 | Arteriocyte Medical Systems | Biological therapeutic compositions and methods thereof |
US20100028311A1 (en) | 2008-07-09 | 2010-02-04 | Baxter International Inc. | Using of scaffold comprising fibrin for delivery of stem cells |
WO2010014253A2 (en) | 2008-08-01 | 2010-02-04 | University Of Florida Research Foundation, Inc. | Ant4 inhibitor compounds and methods of use thereof |
AU2009282271B2 (en) | 2008-08-12 | 2015-05-28 | Terumo Bct, Inc. | A predictor of when to harvest cells grown in a bioreactor |
CA2733985C (en) | 2008-08-14 | 2016-07-12 | Osiris Therapeutics, Inc. | Purified mesenchymal stem cell compositions and methods of purifying mesenchymal stem cell compositions |
AU2009284692B2 (en) | 2008-08-18 | 2016-02-25 | Mesoblast, Inc. | Monoclonal antibody STRO-4 |
WO2010026573A1 (en) | 2008-09-02 | 2010-03-11 | Pluristem Ltd. | Methods of selection of cells for transplantation |
SG190659A1 (en) | 2008-09-02 | 2013-06-28 | Pluristem Ltd | Adherent cells from placenta tissue and use thereof in therapy |
US9096827B2 (en) | 2008-09-02 | 2015-08-04 | Pluristem Ltd. | Adherent cells from placenta tissue and use thereof in therapy |
US20100075410A1 (en) | 2008-09-20 | 2010-03-25 | Virendra Desai | Reusable Tissue Biopsy Kit with Padded Cassette |
KR20110074563A (en) | 2008-09-24 | 2011-06-30 | 메디뮨 엘엘씨 | Methods for purification of viruses |
CN102216450B (en) | 2008-09-24 | 2014-05-14 | 米迪缪尼有限公司 | Methods for cultivating cells, propagating and purifying viruses |
JP5694940B2 (en) | 2008-10-11 | 2015-04-01 | ラトガース,ザ ステート ユニバーシティ オブ ニュー ジャージー | Phase separated biocompatible polymer composition for medical use |
KR101503835B1 (en) | 2008-10-13 | 2015-03-18 | 삼성전자주식회사 | Apparatus and method for object management using multi-touch |
EP2346984A4 (en) | 2008-10-22 | 2013-10-30 | Biovest Int Inc | Perfusion bioreactors, cell culture systems, and methods for production of cells and cell-derived products |
US20100183585A1 (en) | 2008-10-30 | 2010-07-22 | University Of Kentucky Research Foundation | Methods and compositions for treating tumors and metastases through the modulation of latexin |
EP2362789A2 (en) | 2008-11-03 | 2011-09-07 | Metamorefix Ltd. | Tissue adhesive |
WO2010059902A2 (en) | 2008-11-24 | 2010-05-27 | Corning Incorporated | 3d cell-culture article and methods thereof |
CN102395557A (en) | 2008-12-09 | 2012-03-28 | 佛罗里达大学研究基金会公司 | Kinase inhibitor compounds |
US20120046246A1 (en) | 2008-12-19 | 2012-02-23 | University Of Florida Research Foundation | Methods for treating osteoclast-related disease, compounds and compositions thereof |
US8802702B2 (en) | 2009-01-15 | 2014-08-12 | The General Hospital Corporation | Compounds for reducing drug resistance and uses thereof |
WO2010123594A2 (en) | 2009-01-15 | 2010-10-28 | Children's Medical Center Corporation | Device for filtration of fluids there through and accompanying method |
US8399245B2 (en) | 2009-02-18 | 2013-03-19 | Terumo Bct, Inc. | Rotation system for cell growth chamber of a cell expansion system and method of use therefor |
US8051947B2 (en) | 2009-03-12 | 2011-11-08 | E.I. Du Pont De Nemours And Company | Energy absorbing thermoplastic elastomer |
WO2010111255A1 (en) | 2009-03-23 | 2010-09-30 | Hememics Biotechnologies, Inc. | Desiccated biologics and methods of preparing the same |
WO2010119036A1 (en) | 2009-04-14 | 2010-10-21 | Humagene Inc. | Novel post-translational fibrinogen variants |
USD620732S1 (en) | 2009-04-15 | 2010-08-03 | Spectrum Laboratories, Llc | Beverage container holder |
EP2435490A1 (en) | 2009-05-28 | 2012-04-04 | Corning Incorporated | Swellable synthetic microcarriers for culturing cells |
JP2012527896A (en) | 2009-05-29 | 2012-11-12 | コーニング インコーポレイテッド | Substrates for attaching, culturing and examining cells |
US9833784B2 (en) | 2009-07-24 | 2017-12-05 | Emd Millipore Corporation | Feed bag construction |
US9068182B2 (en) | 2009-07-28 | 2015-06-30 | Corning Incorporated | Synthetic polysaccharide microcarriers for culturing cells |
EP2361968B1 (en) | 2010-02-26 | 2014-11-19 | Corning Incorporated | Synthetic polysaccharide microcarriers for culturing cells |
EP2459617A4 (en) | 2009-07-31 | 2016-06-08 | Univ Rutgers | Bioresorbable polymers synthesized from monomer analogs of natural metabolites |
FR2949195B1 (en) | 2009-08-24 | 2011-10-14 | Lfb Biomedicaments | STORAGE POUCH OF THERAPEUTIC SOLUTION |
US20120156779A1 (en) | 2009-08-27 | 2012-06-21 | Ge Healthcare Bio-Sciences Ab | Method for cell expansion |
CA3029961C (en) | 2009-10-11 | 2021-06-22 | Rutgers, The State Of University Of New Jersey | Biocompatible polymers for medical devices |
EP2488632B1 (en) | 2009-10-16 | 2020-04-01 | Rutgers, the State University of New Jersey | Closed system separation of adherent bone marrow stem cells for regenerative medicine applications |
FR2952041B1 (en) | 2009-10-29 | 2012-02-03 | Sartorius Stedim Biotech Sa | SOLDERED POCKET WALL MULTILAYER FILM FOR BIOPHARMACEUTICAL PRODUCT. |
CN102639692B (en) | 2009-11-30 | 2015-02-04 | 普拉里斯坦有限公司 | Adherent cells from placenta and use of same in disease treatment |
WO2011090605A2 (en) | 2009-12-29 | 2011-07-28 | Caridianbct, Inc. | Method of loading and distributing cells in a bioreactor of a cell expansion system |
US20120315696A1 (en) | 2010-02-15 | 2012-12-13 | Alfred Luitjens | METHOD FOR THE PRODUCTION OF Ad26 ADENOVIRAL VECTORS |
KR101342154B1 (en) | 2010-03-09 | 2013-12-13 | 이엠디 밀리포어 코포레이션 | Process bag container with sensors |
EP2561066B1 (en) | 2010-04-23 | 2016-03-30 | Pluristem Ltd. | Adherent stromal cells derived from plancentas of multiple donors and uses thereof |
AU2011250989B2 (en) | 2010-05-12 | 2015-05-07 | Scinus Cell Expansion B.V. | Cell-culture-bag |
WO2011142667A1 (en) | 2010-05-12 | 2011-11-17 | Xpand Biotechnology B.V. | Cell - culture - bag |
EP2575831B1 (en) | 2010-05-27 | 2016-04-20 | Pluristem Ltd. | Skeletal muscle regeneration using mesenchymal stem cells |
EP3679939A1 (en) | 2010-10-08 | 2020-07-15 | Mesoblast International Sàrl | Enhanced msc preparations |
WO2012068263A2 (en) | 2010-11-17 | 2012-05-24 | Emd Millipore Corporation | Feed bag construction |
US20120237557A1 (en) | 2010-11-30 | 2012-09-20 | Rutgers, The State University Of New Jersey | Bioactive carbon-nanotube agarose composites for neural engineering |
FR2968197B1 (en) | 2010-12-01 | 2013-12-20 | Sartorius Stedim Biotech Sa | FLEXIBLE POUCH FOR BIOPHARMACEUTICAL USE HAVING A PLURALITY OF OUTPUT PORTS. |
WO2012079086A2 (en) | 2010-12-10 | 2012-06-14 | Florida State University Research Foundation, Inc. | Mesenchymal stem cells (msc) expansion methods and materials |
US8961948B2 (en) | 2011-01-17 | 2015-02-24 | Rutgers, The State University Of New Jersey | Molecular surface design of tyrosine-derived polycarbonates for attachment of biomolecules |
WO2012127320A1 (en) | 2011-03-22 | 2012-09-27 | Pluristem Ltd. | Methods for treating radiation or chemical injury |
US20140017209A1 (en) | 2011-03-22 | 2014-01-16 | Pluristem Ltd. | Methods for treating radiation or chemical injury |
EP2694639A1 (en) | 2011-04-08 | 2014-02-12 | The University of Akron | Thermoresponsive cell culture supports |
CN103476924A (en) | 2011-04-15 | 2013-12-25 | 普拉里斯坦有限公司 | Methods and systems for harvesting cells |
US8668886B2 (en) | 2011-04-24 | 2014-03-11 | Therapeutic Proteins International, LLC | Separative bioreactor |
US8841122B2 (en) | 2011-05-17 | 2014-09-23 | Terumo Bct, Inc. | Systems and methods for expanding high density non-adherent cells |
WO2012171030A2 (en) | 2011-06-10 | 2012-12-13 | Biovest International, Inc. | Method and apparatus for antibody production and purification |
WO2012171026A2 (en) | 2011-06-10 | 2012-12-13 | Biovest International, Inc. | Methods for high yield virus production |
DE102012200939B4 (en) | 2012-01-23 | 2016-05-12 | Alpha Plan Gmbh | Bioreactor for the cultivation of cells and tissue cultures as well as yeasts and bacteria as objects |
DE102012200938B4 (en) | 2012-01-23 | 2016-08-18 | Alpha Plan Gmbh | Biological and medical engineering modular system |
CN110172405A (en) * | 2012-08-20 | 2019-08-27 | 泰尔茂比司特公司 | The component of the fluid recycled across cell growth chamber is concentrated |
US9175259B2 (en) | 2012-08-20 | 2015-11-03 | Terumo Bct, Inc. | Method of loading and distributing cells in a bioreactor of a cell expansion system |
CA2920957A1 (en) | 2012-08-28 | 2014-03-06 | Biovest International, Inc. | Biomanufacturing suite and methods for large-scale production of cells, viruses, and biomolecules |
WO2014036488A1 (en) | 2012-08-31 | 2014-03-06 | Biovest International, Inc. | Methods for producing high-fidelity autologous idiotype vaccines |
CA2882687A1 (en) | 2012-09-04 | 2014-03-13 | Pluristem Ltd. | Methods for prevention and treatment of preeclampsia |
ME02052B (en) | 2012-09-06 | 2015-05-20 | Devices and methods for culture of cells | |
JP6506693B2 (en) | 2012-10-31 | 2019-04-24 | プルリステム リミテッド | Method and apparatus for thawing biological material |
WO2014128634A1 (en) | 2013-02-20 | 2014-08-28 | Pluristem Ltd. | Gene and protein expression properties of adherent stromal cells cultured in 3d |
DE102013203082B4 (en) | 2013-02-25 | 2014-10-09 | Alpha Plan Gmbh | Testing and drying device for functional testing of dialyzers |
DE102013203306B4 (en) | 2013-02-27 | 2015-10-22 | Alpha Plan Gmbh | Use for two-sided cultivation of a pore-containing membrane for cells and tissue cultures as well as yeasts and bacteria as objects |
WO2014141111A1 (en) | 2013-03-14 | 2014-09-18 | Pluristem Ltd. | Methods for prevention and treatment of graft-versus-host disease |
WO2015004609A2 (en) | 2013-07-09 | 2015-01-15 | Pluristem Ltd. | Adherent cells from placenta and use thereof in treatment of injured tendons |
CN105992816B (en) * | 2013-11-16 | 2018-04-17 | 泰尔茂比司特公司 | Cell amplification in bioreactor |
BE1022439B1 (en) | 2014-02-10 | 2016-03-30 | Univercells Sa | APPARATUS SYSTEM AND METHOD FOR PRODUCING BIOMOLECULES |
BE1023557B1 (en) | 2014-02-10 | 2017-05-03 | Univercells Sa | SYSTEM, APPARATUS AND METHOD FOR PRODUCING BIOMOLECULES |
BE1022441B1 (en) | 2014-02-10 | 2016-03-30 | Univercells Sa | SYSTEM, APPARATUS AND METHOD FOR PRODUCING BIOMOLECULES |
US20170081638A1 (en) | 2014-02-28 | 2017-03-23 | Florida State University Research Foundation, Inc. | Materials and methods for expansion of stem cells |
AU2016218037B2 (en) | 2015-02-09 | 2020-12-17 | Univercells Technologies S.A. | System, apparatus and method for the production of cells and/or cell products |
KR20180074775A (en) | 2015-10-26 | 2018-07-03 | 론자 리미티드 | Manufacturing facilities for the production of biopharmaceuticals |
US20180010082A1 (en) | 2016-06-03 | 2018-01-11 | Lonza Ltd | Bioreactor With Higher Agitation Rates |
JP2019532624A (en) | 2016-09-01 | 2019-11-14 | タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. | Method for producing virus for vaccine production |
-
2015
- 2015-09-25 CN CN201580051995.7A patent/CN106715676A/en active Pending
- 2015-09-25 JP JP2017516369A patent/JP6830059B2/en active Active
- 2015-09-25 WO PCT/US2015/052158 patent/WO2016049421A1/en active Application Filing
- 2015-09-25 US US14/865,222 patent/US20160090569A1/en not_active Abandoned
- 2015-09-25 EP EP15778480.2A patent/EP3198006B1/en active Active
-
2020
- 2020-07-28 US US16/941,057 patent/US11667881B2/en active Active
-
2023
- 2023-04-14 US US18/300,427 patent/US20230250387A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8309347B2 (en) * | 2007-03-05 | 2012-11-13 | Terumo Bct, Inc. | Cell expansion system and methods of use |
US20120086657A1 (en) * | 2010-10-08 | 2012-04-12 | Caridianbct, Inc. | Configurable Methods and Systems of Growing and Harvesting Cells in a Hollow Fiber Bioreactor System |
US9725689B2 (en) * | 2010-10-08 | 2017-08-08 | Terumo Bct, Inc. | Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system |
US20120308531A1 (en) * | 2011-06-06 | 2012-12-06 | ReGenesys BVBA | Expansion of Stem Cells in Hollow Fiber Bioreactors |
US20130244322A1 (en) * | 2012-03-15 | 2013-09-19 | Cellprothera | Automated apparatus and method of cell culture |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109153954A (en) * | 2016-05-05 | 2019-01-04 | 泰尔茂比司特公司 | Automated production and collection |
US20170349869A1 (en) * | 2016-06-07 | 2017-12-07 | Terumo Bct, Inc. | Methods and Systems for Coating a Cell Growth Surface |
US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
US11634677B2 (en) | 2016-06-07 | 2023-04-25 | Terumo Bct, Inc. | Coating a bioreactor in a cell expansion system |
US11685883B2 (en) * | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
Also Published As
Publication number | Publication date |
---|---|
JP6830059B2 (en) | 2021-02-17 |
CN106715676A (en) | 2017-05-24 |
JP2017529088A (en) | 2017-10-05 |
EP3198006A1 (en) | 2017-08-02 |
US20230250387A1 (en) | 2023-08-10 |
US11667881B2 (en) | 2023-06-06 |
EP3198006B1 (en) | 2021-03-24 |
US20200354669A1 (en) | 2020-11-12 |
WO2016049421A1 (en) | 2016-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230250387A1 (en) | Scheduled Feed | |
US9670451B2 (en) | Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions | |
US11795432B2 (en) | Passive replacement of media | |
US11634677B2 (en) | Coating a bioreactor in a cell expansion system | |
JP6986031B2 (en) | Automated manufacturing and collection | |
US20230174917A1 (en) | Cell Growth With Mechanical Stimuli | |
US20200239819A1 (en) | Methods and Systems for Coating a Cell Growth Surface | |
US10577575B2 (en) | Coating a bioreactor | |
JP2020531021A (en) | Cell proliferation | |
US20240060030A1 (en) | Cell expansion system | |
US20240101946A1 (en) | Expanding Cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: TERUMO BCT, INC., COLORADO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:VANG, BOAH;REEL/FRAME:036760/0260 Effective date: 20151007 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION |